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resumo 
 
 
A Doença de Parkinson, a segunda doença neurodegenerativa progressiva 
mais comum, é uma doença multifatorial causada conjuntamente por fatores 
genéticos e fatores ambientais. De entre os inúmeros genes associados à 
Doença de Parkinson, a DJ-1 é uma proteína multifuncional envolvida na 
resposta ao stress oxidativo e neuroproteção. Mutações na DJ-1, tais como 
L166P, M26I e E136K levam à perda de função da proteína causando a forma 
de Parkinson autossomal recessiva com desenvolvimento precoce. De 
salientar que o resíduo C106 é considerado crucial na função de sensor de 
stress oxidativo que a DJ-1 desempenha. Neste estudo, foram produzidas e 
caracterizadas duas mutações sintéticas no resíduo C106 (C106A e C106DD) 
e uma mutação natural (E163K) de modo a avaliar o efeito neuroprotetor de 
cada mutação bem como caracterizar o seu interactoma dinâmico.  
Análises estruturais confirmaram a produção de todos os mutantes na forma 
dimérica, apresentando um peso molecular de aproximadamente 43kDa. A 
estabilidade térmica das proteínas foi ainda avaliada por thermal shift e os 
resultados revelaram que o mutante E163K foi o menos estável enquanto que 
o mutante C106A foi o mais estável. Análise da estrutura secundária foi 
realizada por dicroísmo circular revelando elevada semelhança entre as 
estruturas secundárias da DJ-1 nativa e mutantes.  
Por fim, foi realizada uma análise de LC-MS/MS de modo a determinar os 
contaminantes das proteínas produzidas e verificou-se que a maioria dos 
contaminantes era proveniente do sistema de expressão e meio de cultura 
utilizados na produção das proteínas.  
Seguidamente, ensaios de neuroproteção revelaram que a DJ-1 nativa não 
exercia um efeito neuroprotetor nas células SH-SY5Y em condições de stress 
oxidativo. 
O interactoma dinâmico da DJ-1 nativa e mutantes C106DD, E163K e C106A 
foi caracterizado sob condições de stress oxidativo. Um elevado número de 
interactores foram identificados e para alguns deles foi possível obter uma 
quantificação nas diferentes condições. Os referidos interactores apresentam 
uma enorme variedade de funções, contudo a grande maioria está associada à 
resposta celular ao stress oxidativo. 
O estudo das mutações na DJ-1 é considerado muito relevante visto que 
fornece importantes elucidações relativamente às funções e mecanismos da 
DJ-1 nativa associados à doença. Neste sentido, os supostos interactores da 
DJ-1 nativa identificados ainda carecem de validação, mas da caracterização 
dos interactomas dinâmicos, elucidações podem ser obtidas sobre a patologia 
da Doença de Parkinson e identificação de novos potenciais alvos para 
prevenção e terapia desta doença, tal como a RNA helicase DDX3X 
dependente de ATP aqui identificada como novo interactor dinâmico da DJ-1. 
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abstract 
 
Parkinson´s disease (PD), the second most common progressive 
neurodegenerative disorder, is a multifactorial disease caused by both genetic 
and environmental factors. Among the genes associated with PD, DJ-1 is a 
multifunctional protein involved in oxidative stress response and 
neuroprotection. DJ-1 mutations, such as L166P, M26I and E163K lead to loss 
of protein function causing early onset autosomal recessive PD. Moreover, the 
residue C106 is considered crucial in DJ-1 function as a sensor of oxidative 
stress. In this study, one missense mutations (E163K) and two engineered 
mutations in the residue C106 (C106A and C106DD) were produced and 
characterized in order to evaluate the neuroprotective effect of each mutation 
and also characterize their dynamic interactome.  
Structural analysis confirmed the production of all the mutants in the dimeric 
form, with a molecular weight of approximately 43kDa. Moreover, protein´s 
thermal stability was assessed by thermal shift and the results showed that the 
mutant E163K was the less stable and the C106A the most stable. Secondary 
structure analysis was performed by circular dichroism and revealed similar 
secondary structures between DJ-1 WT and mutants.  
In addition, a LC-MS/MS was performed to determine proteins´ contaminants 
and the majority of the protein contaminants were coming from the expression 
system and culture medium used in proteins´ production.  
Moreover, neuroprotection assays revealed that DJ-1 WT did not protect SH-
SY5Y cells under oxidative stress conditions. 
The dynamic interactome of DJ-1 WT and mutants C106DD, E163K and 
C106A was characterized under oxidative stress conditions. A wide number of 
binding partners were identified and for some of them quantification in the 
different conditions was also determined. These interactors have a broad range 
of functions but the majority are associated with cellular response to oxidative 
stress.  
The study of DJ-1 mutations is very important, since it gives elucidations into 
DJ-1 WT functions and related disease mechanisms. In this way, the putative 
DJ-1 WT interactors identified still lack validation, but from these characterized 
dynamic interactomes further elucidations can be obtained into Parkinson’s 
Disease pathology and potential new targets for PD prevention and therapy, 
like ATP-dependent RNA helicase DDX3X herein identified as new dynamic 
interactor of DJ-1. 
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1.1. PARKINSON´S DISEASE  
Parkinson’s disease (PD) was first described in 1817 by James Parkinson in the 
classic ‘‘Essay on the Shaking Palsy’’ [1], and is the second most common 
neurodegenerative disorder, after Alzheimer’s disease [2]. 
Parkinson´s disease prevalence increases with age, affecting 1-2% of the 
population over the age of 65 years and reaching a prevalence of almost 4% in those 
aged above 85 years [3, 4]. Due to demographic changes and increased life expectancy 
the prevalence of PD is expected to double by the year 2030 as populations age, 
forecasting an impending burden on the healthcare systems of many countries [3, 5].  
 From the clinical point of view, PD is characterized by cardinal symptoms, 
usually described as “parkinsonism”, including resting tremor, rigidity, bradykinesia, 
and postural instability [2, 4]. Furthermore, many non-motor symptoms frequently 
appear in PD, such as cognitive impairment, behavioral abnormalities, autonomic 
insuﬃciency and sleep disorders [4]. 
The pathological hallmark of classical PD includes loss of nigrostriatal 
dopaminergic neurons in the substantia nigra pars compacta (SNpc) leading to loss of 
dopamine in the striatum, and the presence of Lewy bodies (LB) and Lewy neurites in 
the surviving neurons (Figure 1.1) [2-4]. LB are dense cytosolic inclusions that contain a 
variety of insoluble proteins being the main component fibrillar α-synuclein [6, 7]. PD 
diagnoses are typically based on the presence of LB, however some monogenic forms 
of PD lack this characteristic (LB) pathology [3]. In addition, the symptoms of PD can 
vary extensively between patients and many neurological insults can cause 
parkinsonism. Therefore, a post-mortem examination of the neural tissue must be 
done in order to obtain a deﬁnitive diagnosis of PD [5]. Symptoms appear when about 
50–60% of the nigral neurons and about 80–85% of the dopamine content of the 
striatum are lost [2]. Unfortunately, only some improvements of the symptoms are 
obtainable by current treatments, which are based on levodopa and dopaminergic 
therapy, however currently there is no available treatment to detain the progression of 
the disease [4]. 
PD can be considered mostly as sporadic (90-95%) and to a lesser extent as 
familial (5-10%) [8, 9]. The etiology of PD is considered complex and multifactorial, 
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resulting probably from an elaborated interplay of several factors, like genes, 
modifying effects by susceptibility alleles, environmental exposures and gene-
environment interactions (e.g., inﬂuence of environmental agents on gene expression), 
and their direct impact on the developing and aging brain [10]. Although the majority 
of cases appear sporadic in nature, the discovery of genes linked to rare familial forms 
of PD have conﬁrmed the role of genetics in development of PD, providing vital clues in 
understanding molecular pathogenesis of this disease [9, 11]. Even though knowledge 
has grown rapidly, the pathogenesis of PD is still unknown [2]. 
 
1.1.1. ETIOLOGY OF PD 
Environmental factors were long thought to be the predominant cause of 
Parkinson’s disease, but currently PD is thought to arise from a combination of 
environmental exposures, and complex gene-environment interactions superimposed 
on slow and sustained neuronal dysfunction due to aging (Figure 1.2) [4, 13]. 
The environmental hypothesis was supported by the identiﬁcation, in the early 
1980s, of an exogenic toxin that caused Parkinsonian symptoms. After intravenous 
application of a synthetic drug that contained 1-methyl-4-tetrahydropyridine (MPTP), 
 
Figure 1.1 | PATHOLOGY OF PARKINSON'S DISEASE. A simplified view of the main neuropathological 
events in PD is shown at three levels from left to right. In the brain, a major pathway is degeneration of 
the dopaminergic projections from the substantia nigra (in black) to the striatum (in purple). At the 
level of substantia nigra, the neurons are normally melanized and are easily identified by this pigment 
in control brains (upper panel). In contrast, the loss of neurons in this region is substantial leading to 
depigmentation in PD cases (lower panel). Of the few remaining cells, many show pathological changes, 
including the accumulation of proteins and lipids in LB (arrow, right panel) [12]. 
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some of the drug addicts developed an akinetic-rigidic syndrome that responded to 
levodopa therapy [14]. MPTP causes selective degeneration of the nigrostriatal 
pathway by inhibiting mitochondrial complex I leading to a parkinsonian syndrome in 
rodents, primates, and humans (Figure 1.3) [15]. Since the discovery that MPTP causes 
parkinsonism in humans and non-human primates, as well as in various other 
mammalian species, it has been extensively used as a model of PD [16].  
 
 
Figure 1.2 | KEY ENVIRONMENTAL AND GENETIC FACTORS THAT CONTRIBUTE TO THE DEVELOPMENT 
OF PARKINSONISM. The etiology of PD is thought to be multifactorial with contributions from 
environmental and genetic factors. Both factors are involved in several pathways, such as 
mitochondrial dysfunction, oxidative stress, proteasome inhibition, LB and ROS formation, which 
ultimately lead to cell death and neurodegeneration [17-21]. 
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Figure 1.3 | REPRESENTATION OF MPTP 
METABOLISM. MPTP can cross the blood–
brain barrier and is metabolized to MPP+ 
with the assistance of the enzyme 
monoamine oxidase B (MAO-B) in glial cells. 
MPP+ is then taken up into neuronal cells by 
dopamine transporter for which it has high 
affinity. Once inside neurons, MPP+ is 
concentrated within the mitochondria, 
where it impairs mitochondrial oxidative 
phosphorylation by inhibiting complex I of 
the respiratory chain [18]. 
 
Toxicological studies showed that subacute exposure to other toxins, like 
rotenone, paraquat and 6-hydroxydopamine (6-OHDA) also induces behavioral and 
pathological changes characteristic of PD in animal models [19]. Several 
epidemiological studies showed that additional environmental factors, like rural living, 
well-water drinking, prolonged pesticide/insecticide exposure, and metal exposure, 
also increase the risk of developing PD [22]. Furthermore, some studies showed that 
cigarette smoking and coffee or tea drinking could be protective against PD, but the 
physiologic mechanisms for these relations are poorly understood [23]. 
Although environmental factors may play an important role in PD etiology, in 
the past 15 years it has been witnessed a seed change in the etiologic basis of this 
disease. This change has been largely driven by genetics, progressing through the early 
recognition of familial forms of the disease, to include the identiﬁcation of gene 
mutations that cause rare familial forms of PD, ﬁnding moderate risk variants, and 
most recently the mapping of multiple low-risk conferring loci by genome-wide 
association studies (GWAS) [24]. 
The current view of PD etiology is that it is multifactorial in which 
environmental insults and genetic predisposition interact to cause the disease. Still, 
knowledge about the roles of individual pathogenic factors may lead to the useful 
insights into the disease process and further identification of targets responsive to 
therapy.  
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1.1.2. MONOGENIC FORMS OF PD 
It is currently believed that PD is largely sporadic, meaning that the disease 
arises in individuals without a family history of PD. However, some patients have 
monogenic PD, where the cause of the disease can be ascribed to mutations in single 
genes that have been convincingly demonstrated to be pathogenic [13]. Monogenic PD 
probably accounts for about 5–10% of the total population of PD patients and exhibit 
an autosomal dominant or recessive mode of inheritance [3]. 
During the past few years, 18 loci, also called PARK locus, and a few other genes 
have been assigned through linkage analysis or GWAS (Table 1.1) [10, 25]. 
Table 1.1 | GENE/LOCI UNDERLYING MONOGENIC PARKINSONISM [10, 25-27]. 
PARK 
Locus Gene 
Map 
Position Inheritance 
Mutations 
Identiﬁed 
(Pathogenic) 
Clinical Phenotype Pathology 
PARK 1/4 SNCA 4q21 AD;Rarely sporadic 27 (25) EOPD LB+ 
PARK 2 Parkin 6q25-q27 AR; Sporadic 214 (128) Juvenile and  EOPD LB- (most brains) 
PARK 3 Unknown 2p13 AD NA LOPD LB+ 
PARK 5 UCHL1 4p14 AD NA LOPD Unknown 
PARK 6 PINK1 1p35-p36 AR 138 (28) EOPD LB+ (only 1 brain 
 PARK 7 DJ-1 1p36 AR 28 (6) EOPD Unknown 
PARK 8 LRRK2 12q12 AD; Sporadic 128 (6) LOPD LB+ (most brains) 
PARK 9 ATP13A2 1p36 AR NA Kuffor-Rakeb syndrome Unknown 
PARK 10 Unknown 1p32 Unclear NA LOPD Unknown 
PARK 11 GIGYF2 2q36-q37 AD NA LOPD Unknown 
PARK 12 Unknown Xq21-q25 X-linked NA LOPD Unknown 
PARK 13 HTRA2 2p13 AD NA Not clear Unknown 
PARK 14 PLA2G6 22q12-q13 AR NA 
Juvenile levodopa-
responsive 
dystonia-
parkinsonism 
LB+ 
PARK 15 FBXO7 22q12-q13 AR NA EOPD pyramidal syndrome Unknown 
PARK 16 Unknown 1q32 Unclear NA LOPD Unknown 
PARK 17 VPS35 16q11.2 AD NA LOPD  
PARK 18 EIF4G1 3q27.1 AD NA LOPD  
FTDP-17 MAPT 17q21.1 - - Dementia (sometimes 
parkinsonism) 
Neurofibrillar
y tangles 
Gaucher’s 
locus GBA 1q21 
Recessive for 
Gaucher´s disease - LOPD LB+ 
SCA2 Ataxin 2 12q24.1 Ataxia (sometimes 
parkinsonism) - Not clear Unknown 
SCA3 Ataxin 3 14q21 Ataxia (sometimes 
parkinsonism) - Not clear Unknown 
Abbreviations: AD, Autosomal dominant; AR, autosomal recessive; EOPD, Early-onset Parkinson´s Disease; LOPD, 
Late-onset Parkinson Disease; LB+, Presence of LB pathology; NA, not available. 
Note: Well-validated monogenic forms are listed in bold. 
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Some follow-up genetic studies have been inconsistent for certain genes, nonetheless 
there is evidence that mutations in ﬁve of those genes (SNCA, parkin, PINK1,DJ-1 and 
LRRK2) cause typical PD [28], where SNCA and LRRK2 are conclusively associated with 
autosomal dominant PD, and parkin, PINK1 and DJ-1 with early-onset autosomal 
recessive PD [29]. Moreover, mutations in ATP13A2 gene cause Kufor-Rakeb disease, a 
neurodegenerative disease characterized by parkinsonism [30]. 
Polymorphic variants in SNCA and LRRK2 and in candidate genes such as 
microtubule-associated protein tau (MAPT), as well as rare mutations in the 
glucocerebrosidase gene (GBA) have also emerged as susceptibility factors in several 
populations [25]. 
 
1.1.2.1. SNCA 
α-synuclein is a 140 amino-acid protein encoded by the SNCA gene that is 
highly abundant in the mammalian brain particularly in presynaptic nerve terminals, 
and also present in other tissues, like red blood cells[4]. It was originally identiﬁed in 
association with synaptic vesicles in the presynaptic nerve terminal [31] and has been 
revealed to interact with membranes both in vitro and in vivo [10]. Fibrillar forms of α-
synuclein are the major structural component of LB, the pathogenomic hallmark of all 
forms of PD [32]. Currently, studies show that mutations in α-synuclein lead to an 
increased tendency of the protein to form oligomers and ﬁbrillar aggregates critical to 
LB formation, suggesting a link between α-synuclein aggregation and PD [33]. From the 
information given before, there are evidences that α-synuclein could lead to PD 
pathology through both toxic-gain of function of mutant protein and over-production 
of wild-type (WT) protein. 
In 1997 SNCA mutations were the first to be identified in monogenic PD [24], 
and patients with variants in this gene are usually associated to early-onset PD with a 
rapid progression (sometimes with atypical clinical features) [10].  
Three missense mutations (A53T, A30P and E64K), and duplications or 
triplications of the locus containing SNCA have been identified in families with 
autosomal dominant forms PD (Figure 1.4) [34]. Furthermore, clinical characteristics of 
patients with duplications presented typical late-onset PD phenotype while patients 
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with triplications had lower age at onset, rapid progression, and more often dementia 
[29]. Hence, the severity of clinical phenotype in SNCA multiplication seems to be gene 
dose dependent [34], where an increased number of SNCA copies, and therefore 
higher levels of the protein encoded by this gene, α-synuclein, is associated with a 
more severe phenotype, and faster disease progression [31]. Importantly, GWAS linked 
single nucleotide polymorphisms in the SNCA gene with increased susceptibility to 
sporadic PD [13]. 
The biological function of α-synuclein is still not fully understood, however 
several studies suggest that it is involved in modulating neuronal plasticity and 
synaptic transmission, as well as providing a stabilizing effect on complexes of SNARE 
proteins critical for neurotransmitter release, vesicle recycling, and synaptic integrity 
[21]. Furthermore, several studies associate the SNCA-expression levels with the 
appearance and possible mechanisms underlying PD [26, 32]. 
 
Figure 1.4 | SCHEMATIC REPRESENTATION OF Α-SYNUCLEIN PROTEIN. There are three pathogenic 
missense mutations represented above the protein organization and duplications or triplications of 
different genomic sizes below the protein (red lines). α-synuclein has seven imperfect repeats (KTKEGV) 
in the amino terminal, a central hydrophobic NAC (nonamyloid component) region, and an acidic 
carboxilic-terminal region [16]. 
 
1.1.2.2. LRRK2 
The leucine-rich repeat kinase 2 (LRRK2) gene encodes for a 2527 amino acid 
protein named dardarin, which has several predicted functional domains (e.g. Roc 
GTPase, Roc-COR tandem domain and protein kinase domains) (Figure 1.5) suggesting 
that this protein has multiple functions, including scaffold protein function, substrate 
binding, and protein phosphorylation [21]. However, how these domains interact in 
9 | 
| Introduction  
order to influence LRRK2 function under physiological and pathophysiological 
conditions remains to be fully characterized [33]. 
In cellular models, evidences show that overexpression of disease-causing 
LRRK2 mutants is toxic and that toxicity is associated with kinase activity, GTP-binding, 
and mitochondria-dependent apoptosis [21]. 
Mutations in the LRRK2 gene, the most common known cause of PD, are 
associated with late-onset autosomal dominant (accounting for an estimated 5–10% of 
occurrences) and sporadic forms of PD (an estimated 1–5% of occurrences) [13]. So far, 
over 100 variations in LRRK2 have been described 
(http://www.molgen.ua.ac.be/PDmutDB) [28] but only seven mutations have been 
proven to be pathogenic (N1437H, R1441G/C/H, Y1699C, G2019S, and I2020T) [3]. The 
G2019S mutation is the most common, found in a wide range of ethnic groups, and in 
1– 3% of sporadic and 4–8% of familial cases (Figure 1.5) [26, 29]. In addition to these 
mutations that alone are sufficient to cause the disease, two common non-
synonymous SNPs in LRRK2 (G2385R and R1628P) appear to be true risk variants for PD 
in the Asian population [16].  
 
Figure 1.5 | SCHEMATIC REPRESENTATION OF LRRK2 GENE AND PROTEIN. This gene has seven proven 
pathogenic mutations (in red) and the two Asian-speciﬁc risk factors (in blue) above the protein 
organization. LRRK2 contains several conserved domains: ARM (Armadillo), ANK (ankyrin repeat), LRR 
(leucine-rich repeat), Roc (Ras of complex proteins: GTPase), COR (carboxilic terminal of Roc), kinase 
domain, and WD40 [16]. 
 
One significant feature of pathogenic LRRK2 mutations is that they typically 
result in clinical phenotypes that resemble late-onset sporadic PD even though LB 
pathology is sometimes absent or lacking [26]. 
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PD-causative mutations have been localized in several different domains, and it 
is possible that these mutations could interfere with LRRK2 protein functions in 
different ways [13]. 
 
1.1.2.3. PARKIN 
 PARK2 gene codes for a 465 amino acid protein (Figure 1.6)- parkin which is 
expressed widely, but most prominently in muscle and brain  [35, 36]. Parkin contains 
an amino terminal ubiquitin-like (UBL) domain followed by three RING ﬁnger domains 
(RING 0–2) separated by a 51-residue IBR domain in the carboxylic terminal part [16]. 
Functionally, parkin protein is a member of a family of E3 ubiquitin ligases responsible 
for tagging proteins for proteasomal degradation mediated by the transfer of activated 
ubiquitin molecules to a protein substrate [16, 35]. Moreover, under physiological 
conditions, parkin is also involved in mitochondrial maintenance and clearance of 
dysfunctional mitochondria by autophagy (mitophagy) [21]. Most PD-causing 
mutations in Parkin abolish its E3 ubiquitin ligase activity causing a loss of parkin 
catalytic competency [16]. Furthermore, several studies refer that dopaminergic, 
oxidative, and nitrosative stress, key players in PD, can inactivate Parkin indicating that  
 
Figure 1.6 | SCHEMATIC REPRESENTATION OF PARKIN ON TRANSCRIPT LEVEL AND FUNCTIONAL 
DOMAINS. Exonic deletions above the transcript (red lines) and exonic duplications (green lines) 
or triplications (blue lines) below the transcript. Only homozygous or compound heterozygous 
mutations are listed [16]. 
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parkin dysfunction plays a role in both autosomal recessive parkinsonism (owing to 
parkin mutations) and sporadic PD [37]. Thus, accumulation of parkin substrates is 
thought to contribute to DA neurodegeneration owing to parkin inactivation in the 
pathogenesis of PD but there is the need of further clarification [26]. 
Mutations in PARK2 gene have been identified as the most common known 
cause of autosomal recessive juvenile parkinsonism (AR-JP) [36]. Currently it is thought 
that up to half of hereditary parkinsonism and 10% of all early-onset PD cases are 
associated with mutations in this gene [38]. Besides this, more than 100 putatively 
pathogenic mutations have been observed in PD families (Figure 1.6) [28]. Clinically, 
the disease is usually indistinguishable from early onset idiopathic PD, characterized by 
early onset and a marked response to levodopa treatment but generally there is no LB 
formation [24]. 
 
1.1.2.4. PINK1 
PINK1 protein is a kinase with 581 amino acids, containing an N-terminal 
mitochondrial targeting motif and a highly conserved serine/threonine kinase domain 
(Figure 1.7) [39]. It is widely expressed and mainly localizes in mitochondria, especially 
in the outer membrane [32]. Studies suggest that PINK1 may regulate mitochondrial 
response to cellular and oxidative stress, protecting cells from mitochondrial 
dysfunction [21, 39]. This protein has been reported to participate in multiple 
mitochondrial functions, such as calcium dynamics, mitochondrial trafﬁcking and 
respiration efﬁcacy, reactive oxygen species (ROS) formation, and opening of the 
mitochondrial permeability transition pore [21]. Interestingly, recent studies provided 
evidence that PINK1 and Parkin function in a common pathway in the maintenance of 
mitochondrial quality via autophagy (mitophagy) [10, 26, 40]. 
Mutations in the PINK1 (PTEN-induced putative kinase 1) gene are so far the 
second most common cause of autosomal recessive early-onset PD after mutations in 
the parkin gene [39]. To date, more than 50 pathogenic mutations have been reported 
in PINK1 (http://www.molgen.ua.ac.be/PDmutDB/) (Figure 1.7) [41]. It is thought that 
pathogenic mutations in PINK1 inﬂuences its kinase activity, stability and localization 
[21, 39]. Most of the mutations are observed in or near the serine/threonine 
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kinase domain, suggesting that the disruption of kinase activity plays a crucial part in 
the pathogenesis of PINK1-linked PD [40]. Clinically, patients usually present a later age 
at onset in between 30 and 50 years but otherwise are similar to parkin related disease 
[24].  
 
Figure 1.7 | SCHEMATIC REPRESENTATION OF PINK1 ON TRANSCRIPT LEVEL AND FUNCTIONAL 
DOMAINS. Rare deletions (above, red lines). Only homozygous or compound heterozygous mutations 
are listed. PINK1 has an amino terminal mitochondrial targeting signal (MTS) motif, a putative 
transmembrane (TM) region, and a serine-threonine kinase domain [16]. 
 
1.1.2.5. DJ-1 
PARK7/DJ-1 was the third gene associated with AR-PD, is located on 
chromosome 1p36.23, contains eight exons, the first two of which are noncoding and 
subject to alternative splicing, and codify a 189-amino acid protein of approximately 20 
kDa, the DJ-1 protein (Figure 1.8) [42, 43]. DJ-1 is a multifunctional protein that has 
been widely recognized as involved in the oxidative stress response pathways and this 
is believed to have an important role in the preservation of neuronal viability [2, 44]. 
However, the exact function and regulation of DJ-1 remains to be elucidated and this 
has been an active ﬁeld of study for over a decade [45].  
 Several mutations have been associated to this gene (Figure 1.8) leading to a 
form of parkinsonism characterized by an age of onset in the 20s or 30s with resting 
tremor, postural tremor, bradykinesia, loss of postural reﬂexes, an asymmetric onset 
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of symptoms, and slow progression with response to levodopa [24, 46]. A more 
detailed description of all the aspects related to DJ-1 and its mutations will be given in 
following topics of this chapter.  
 
Figure 1.8 | SCHEMATIC REPRESENTATION OF DJ-1 ON TRANSCRIPT LEVEL AND FUNCTIONAL 
DOMAINS. Pathogenic frameshift mutations above the transcript and protein organization and 
missense mutations below the protein. Rare deletions (red lines) and duplications (green lines) (above) 
are represented. Only homozygous or compound heterozygous mutations are listed [16]. 
 
1.1.2.6. ATP13A2 
 In recent years, another gene has been associated to autosomal recessive 
forms of parkinsonism, the ATP13A2 gene (PARK9) [32]. ATP13A2 encodes a P-type 
adenosine triphosphatase (ATPase) [47], which is localized to the lysosomal membrane 
with ten transmembrane domains [32]. Interestingly, truncating mutations promote 
the mislocalization of ATP13A2 to the endoplasmic reticulum (ER) where they are 
subsequently degraded by the proteasome [47]. This might indicate that lysosomal 
dysfunction could play an important role in the pathogenesis of parkinsionism and may 
provide crucial insights into the pathogenic mechanisms of PD [30]. The function of 
ATP13A2 protein is still largely unknown, although it seems to participate in protein 
degradation, like protecting against α-synuclein misfolding and toxicity, and lysosomal 
pathway, where loss of ATP13A2 function might lead to insufﬁcient lysosomal protein 
degradation [30]. Thus, ATP13A2 may represent the ﬁrst genetic link between 
lysosomal impairment and PD [32].  
Mutations in this gene have been identified as causative in Kufor-Rakeb 
Syndrome (KRS), a rare form of autosomal recessive juvenile or early-onset, levodopa-
responsive type of parkinsonism [47, 48]. Numerous mutations (homozygous or 
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compound heterozygous and truncating mutations) in ATP13A2 gene have been 
reported and considered pathogenic, leading to a loss-of-function of the ATP13A2 
protein [48]. 
 
1.1.3. PATHWAYS RELATED TO PD 
 The discovery of PD genes, together with the pathological and epidemiological 
investigation of sporadic PD cases, has provided some insights into the main pathways 
of PD pathogenesis [49].  
Even though the molecular mechanisms that can trigger degeneration of SNpc 
neurons are not fully understood, there are evidences indicating mitochondrial 
impairment, oxidative stress, accumulation of misfolded and aggregated proteins, and 
impairment of clearance systems such as ubiquitin-proteasome system (UPS) and the 
autophagy pathway as the main factors involved in the neurodegenerative process 
(Figure 1.9) [50, 51].  
 
Figure 1.9 | PATHWAYS LEADING TO OXIDATIVE STRESS IN PD AND THE MODULATION BY PD-RELATED 
GENES. Diﬀerent pathways contribute to high levels of oxidative stress in dopaminergic neurons, 
including impaired DA handling (1), mitochondrial dysfunction (2), and neuroinﬂammation (3). As 
further discussed in the text, alterations in PD genes can potentiate all these impairments and, 
therefore, lead to enhanced levels of oxidative stress. UPS dysfunction (4), another important 
pathogenic pathway in PD, can contribute to the damaging eﬀects of α-syn, due to improper 
degradation of α-syn mutants or oligomers [52]. 
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These cellular pathways are believed to be interconnected, since mitochondrial 
dysfunction leads to increased free radical generation, which further evokes deﬁcits in 
the respiratory chain. Importantly, the UPS is dependent on oxidative phosphorylation 
for energy production and oxidatively damaged proteins increase the bulk of 
substrates to be degraded by the UPS. Moreover, this leads to increased cell 
dysfunction and a lowered threshold to apoptosis [53]. However, the exact sequence 
in which these events act and which points of interaction between events are key to 
the demise of SNpc dopaminergic neurons are still unknown [19].  
Moreover, another unclear issue is whether the multiple cell death-related 
molecular pathways activated during PD neurodegeneration ultimately engage 
common downstream machinery, such as apoptosis, or remain highly divergent [19]. 
 
1.1.4. MITOCHONDRIAL DYSFUNCTION 
 It has been suggested that mitochondrial dysfunction may be an important 
player in loss of neurons and development of PD, and could be triggered by 
environmental factors alongside with certain gene variants and typical age-related loss 
of mitochondrial function [26]. This assumption is supported by several lines of 
evidence such as: (i) post mortem biochemical studies have demonstrated decreased 
complex I activity, a major component of the electron transport chain, in the SNpc of 
PD brains compared to controls; (ii) inhibition of complex I with rotenone, paraquat or 
MPTP reproduces the pathological degeneration of the SNpc in mammalian models; 
and (iii) the protein products of genes known to cause familial forms of parkinsonism 
have clear roles in the maintenance of functional mitochondria [44]. Furthermore, it 
was observed a 20-35% decrease in complex I activity in several cases of PD [5, 54]. 
Inhibition of complex I contribute to two main consequences to neuronal 
degeneration in PD through the decrease of ATP synthesis and consequently 
impairment of all ATP dependent cellular processes, and excess production of free 
radicals (ROS) that cause oxidative stress [55]. Inversely, higher oxidative stress can 
induce anomalies in mitochondrial function [54]. Moreover, mitochondria have also an 
important role in regulation and mediating cell death pathways and are involved in 
calcium homeostasis in cells [56].  
16 | 
Introduction | 
 
Interestingly, many of the genes associated with familial forms of PD are also 
associated to mitochondria in disease pathogenesis. From the several genes involved 
in the pathogenesis of PD, SNCA, parkin, DJ-1, PINK1, LRRK2 and high temperature 
requirement A2 (HTRA2) directly or indirectly impact mitochondrial function (Figure 
1.10) [57]. 
 
Figure 1.10 | PRODUCTS OF PD-ASSOCIATED GENES THAT AFFECT MITOCHONDRIAL FUNCTION AND 
OXIDATIVE STRESS. Acquired somatic mutations affect mitochondrial electron transport chain function, 
and such mutations are increased in the substantia nigra in patients with PD. Rare inherited mutations 
in genes encoding electron transport chain components have been associated with parkinsonism. 
Parkin, α-synuclein, PINK1, DJ-1, LRRK2 and HTRA2, are all encoded by nuclear genes, mutations in 
which can lead to PD, and all show a degree of localization to the mitochondria. Parkin is partially 
localized to the outer mitochondrial membrane, protects against oxidative stress, and has a 
hypothesized role in mitochondrial biogenesis. LRRK2 associates, at least in part, with the outer 
mitochondrial membrane; its precise function in that location is unclear, but it is thought to interact 
with Parkin. HTRA2 is a mitochondrial serine protease, the release of which might be involved in 
apoptotic cell death. PINK1 is a mitochondrial serine–threonine kinase that affords protection against 
oxidative stress and acts with Parkin to regulate the balance of mitochondrial fission and fusion. DJ-1 is 
relocated to mitochondria under conditions of oxidative stress and is thought to be neuroprotective 
under such conditions. The α-synuclein protein has an amino-terminal mitochondrial targeting 
sequence and, when overexpressed or under conditions of acidification, is at least partially associated 
with the inner mitochondrial membrane, where it might cause direct damage [56]. 
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The accumulation of point mutations and deletions in mitochondrial DNA 
(mtDNA) is another interesting possibility that could cause the mitochondrial defects 
and dysfunction observed in PD. Several studies have shown increased mtDNA 
deletions in brains of PD patients when compared to controls [7, 50]. The proteins 
encoded by mtDNA include subunits from all parts of the electron transport chain, 
therefore, point mutations or deletions in any of the genes that encode these proteins 
would alter complex I activity [5]. 
 
1.1.4.1. MITOPHAGY  
Recently, mitochondrial physiology and autophagy in the central nervous 
system has also captured additional attention, since it could give new insights in PD 
pathogenesis [58]. Mitophagy, a pathway for selective degradation of mitochondria by 
autophagy, is evolving as an important pathway in PD and has been linked to this 
disorder through the study of its recessively inherited forms, involving PINK1, parkin 
and DJ-1 [59]. Particularly, mitophagy is important in neurons because they are post-
mitotic and rely heavily and continuously on high levels of ATP production [59]. 
Therefore, neuronal activity and survival is believe to be severely dependent on 
mitochondrial integrity and functionality [58, 60].  
 It has been known that the process of mitophagy is greatly regulated and 
conserved from yeast to mammals, nonetheless much remains to be learned about 
this degradation process [60]. It appears that mitophagy shares key regulatory steps 
with the macroautophagy pathway, while displaying distinct steps specific for 
mitochondrial removal [60]. Recent ﬁndings indicate that parkin and PINK1 are 
involved in regulation of mitochondrial dynamics, and quality through the modulation 
of mitophagy [50, 61]. In the absence of PINK1 or Parkin, cells often develop 
fragmented mitochondria. Parkin is important in the repair of damaged and mutated 
mtDNA and mitochondrial biogenesis, among others, whereas PINK1 regulate the 
mitochondrial membrane potential, cristae structure and calcium homeostasis in order 
to maintain mitochondrial integrity. In the mitophagy pathway, parkin is speciﬁcally 
recruited by PINK1 that selectively targets the mitochondria promoting the 
degradation and removal of dysfunctional mitochondria [50, 61]. This has particularly 
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interest for cells that lack PINK1, where mitochondrial defects are rescued by parkin 
overexpression [61]. As expected, mutations in PINK1, parkin and also DJ-1 have been 
associated with mitochondrial dysfunction, likely leading to dopaminergic neuron 
degeneration in PD [59, 60].  
Concluding, excessive mitochondrial stress derived from exposure to 
environmental toxins, increased oxidative stress or defects in mtDNA, together with 
the incapability of the cell to remove damaged mitochondria through mitophagy, may 
contribute to PD pathogenesis [60]. 
 
1.1.5. OXIDATIVE STRESS 
Oxidative stress is characterized by a redox imbalance between the generation 
of free radicals or other reactive species and antioxidant defenses [62]. Many cellular 
reactions use molecular oxygen for catalysis and energy production. These reactions in 
turn produce ROS such as superoxide anions and hydrogen peroxide (H2O2) which in 
excessive production is detrimental to the cell and can lead to cell death. Cells have 
antioxidants such as glutathione (GSH) and vitamin E to manage this situation [63]. 
Moreover, dopamine metabolism can also be a source of ROS in dopaminergic neurons 
since dopamine autoxidation produces dopamine quinones (DAQ) that support ROS 
formation [57]. 
The detection of lipid peroxidation, increased iron, and proteins oxidation in 
autopsy tissue from the brains of individuals with PD support the evidence of an 
oxidative stress state in the SNpc. In addition, reduced levels of GSH in the midbrain 
are consistent with an increase of free radical levels [55, 57]. Oxidative stress in PD has 
been suggested to be a consequence of complex I dysfunction [62] and on the other 
hand the formation of ROS seems to impair mitochondrial proteins, further impairing 
mitochondrial function [64]. The linking of mitochondrial dysfunction and increased 
oxidative stress is also predicted to interfere with the UPS function, leading to the 
accumulation of misfolded or damaged proteins and formation of LB [56].  
The increase in oxidative stress together with the decline in endogenous 
antioxidants is an important underlying risk factors for older people to develop 
neurodegenerative diseases including Alzheimer’s and PD [63]. 
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1.1.6. MISFOLDING AND PROTEIN AGGREGATION 
The abnormal accumulation of misfolded or aggregated proteins within 
neurons has long been recognized a central pathogenetic mechanism associated with 
neurodegenerative disorders, including PD [50]. These aberrantly folded proteins were 
first thought to be pathogenic, affecting several cell functions. However, recent 
evidence has suggested that these aggregates may be a defensive measure by the cell 
to separate these aberrant proteins, therefore reducing the amount of toxic soluble 
misfolded proteins in cells. Indeed, reduction of toxicity is associated with increased 
accumulation of protein aggregates in healthy neurons, indicating that the appearance 
of such structures is a response to pathological stress [55, 65]. 
Specifically in PD, significant evidence came from the ﬁnding that LB are mainly 
constituted by aggregated α-synuclein, which in its native state is a soluble and 
unfolded protein [7, 50]. This protein is very sensitive to environmental stimuli and is a 
target of oxidative modiﬁcations induced by its interaction with ROS and reactive 
nitrogen species leading to a high propensity to aggregate [7]. 
Usually misfolded proteins are cytotoxic and there is a need to remove them 
from cells through cellular mechanisms for quality control, namely protein degradation 
systems, such as molecular chaperones, the UPS, and autophagy/lysosomal 
degradation [65]. As expected, under pathological conditions an impairment of these 
degradation systems can occur, resulting in the accumulation of aberrant and toxic 
proteins within or outside cells [55, 65]. Regarding the UPS system, parkin (an ubiquitin 
E3-ligase that ubiquitinates protein targets for UPS-mediated degradation) contributes 
to the removal of misfolded and damaging proteins, and the UCHL1 (a brain-speciﬁc 
ubiquitin C-terminal hydrolase) is involved precisely in α-synuclein degradation [7, 50]. 
The proteins LRRK2 and PINK1 are related to autophagy, the latter being known to 
directly activate autophagy and to interact with other autophagic proteins, and also 
ATP13A2 and GBA gene encode for lysosomal enzymes [50]. Several mutations (in 
molecular chaperones or UPS-associated enzymes), oxidative stress, mitochondrial 
dysfunction and ageing have been associated with the protein degradation systems 
dysfunction. Subsequently, dysfunction of protein degradation has arisen as an key 
contributor to nigral neuronal death and pathophysiology of PD [19, 64, 65]. 
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1.2. DJ-1 
DJ-1 is highly conserved throughout diverse species, and was initially identified 
as an oncogene whose transforming ability is enhanced by H-ras, with possible roles in 
sperm maturation and fertilization [46]. Furthermore, it was observed an increased DJ-
1 expression in several types of cancer and also DJ-1 as a circulating tumor antigen in 
breast cancer [46, 66]. 
DJ-1 belongs to the Thi/PfpI/GAT protein superfamily and is ubiquitously 
expressed in many cell types, including the brain. It mainly localizes in the cytosol, but 
it can also be found in the nucleus and in some specific conditions in the mitochondria 
[42, 66]. In the human brain DJ-1 is predominantly expressed in astrocytes and 
astrocytic processes, and in a much less extent in neurons, which can be explained by 
the restrict antibody access within neurons due to the presence of DJ-1 binding 
partners [67]. These evidences suggest that DJ-1 might be involved in the cross-talk 
between glia and neurons [67]. 
 
1.2.1. STRUCTURAL BIOLOGY 
The study and determination of DJ-1 crystal structure [68, 69] provided 
significant molecular insights regarding the function of this redox-reactive protein 
[46]. DJ-1 protein is a homodimer both in crystal and in solution that comprises 8 α-
helices (α1-α8) and 11 β-strands (β1-β11) [45, 66]. This protein has a ﬂavodoxin-like 
fold adopting a helix-strand-helix sandwich structure. The dimer interface is formed by 
close contact of several α-helices of each monomer. These interactions occur mainly 
through hydrophobic contacts, but hydrogen bonds and ionic interactions can also 
take part, forming a hydrophobic core between the two monomers (Figure 1.11) [66]. 
The superfamily to which DJ-1 belongs is characterized by the archetypical 
bacterial ThiJ and PfpI structures, but despite the remarkable structural similarities 
between DJ-1 and the bacterial PfpI/PH1704 proteases, there are two features that 
are not conserved: (i) DJ-1 possesses a distorted catalytical triad (Cys106-His126-
Glu18) which is vital for protease activity and (ii) the additional C-terminal helix that 
DJ-1 has blocks the putative active site of this protein. 
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Figure 1.11 | RIBBON DIAGRAM OF HUMAN DJ-1 DIMER. The structure is colored from blue (N-
terminal) to red (C-terminal) (PDB entry 1UCF, [68]). Image was created using PyMOL (DeLano 
Scientific; http://www.pymol.org). 
 
Nonetheless, upon removal of the C-terminal helix DJ-1 shows proteolytic activity [70]. 
Furthermore, DJ-1 quaternary structure differs from that of other members of this 
superfamily therefore DJ-1 lacks protease activity [46].  
 Despite the differences in the configuration of the catalytical triad residues E18, 
C106, and H126, DJ-1 retains the highly conserved cysteine residue 106 (C106) and in 
the close proximity there are also the side chains of Glu-18 and His-126 (Figure 1.12) 
[46, 66]. The C106 is the best conserved among the three cysteine residues that 
human DJ-1 contains (C46, C53 and C106) and resides at the sharp turn between a β-
strand and an α-helix called the “nucleophile elbow” [45].  
 
 
Figure 1.12 | RIBBON DIAGRAM OF HUMAN DJ-1 SHOWING THE LOCATION AND CONFIGURATION OF 
THE CATALYTIC TRIAD. The side chain of highly conserved C106 is located near the side chains of His-
126 and buried Glu-18. Residues Asp-24′ and Arg-28′ from the opposite subunit contribute to stabilizing 
interactions across the subunit-subunit interface in the dimer [66]. 
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This residue is high oxidizable and is believed to be involved in DJ-1 activation. In this 
process the side chain of Glu18 is thought to stabilize the oxidized C106 sulfinic acid, 
which is considered the active form of DJ-1 [46]. Nonetheless, the orientation that 
these residues display is not the appropriated for proton transfer which is 
characteristic of the cysteine protease catalysis [69]. 
It seems that most of the PD-causing mutations (L166P, M26I, E163K, D149A) 
form heterodimers with WT DJ-1. Furthermore, DJ-1 mutants are unstable, frequently 
not correctly folded and rapidly degraded in cells [10]. For instance, the L166P mutant 
displays severe structural disruption leading to an intense destabilization and thus loss 
of DJ-1 neuroprotective function [46]. Commonly, the others DJ-1 mutants also lead to 
loss of DJ-1 neuroprotective function but most of them present only slight structural 
perturbations compared to WT DJ-1. This suggest that even the slight structural 
defects in DJ-1 structure can cause DJ-1 loss of function, but the biophysical basis of 
the pathogenicity of these mutants and how this conformational changes affect the 
C106 oxidation and its cytoprotective effect remains unclear [45, 46]. 
 
1.2.2. CELLULAR FUNCTION 
DJ-1 is a multifunctional protein with several proposed biochemical and cellular 
activities. It is involved in cellular processes like oxidative stress, cellular 
transformation, androgen-receptor signaling, spermatogenesis and fertilization [71]. 
Among the multiple functions ascribed for this protein, it is important to highlight the 
function as transcriptional co-regulator, molecular chaperone, antioxidant, RNA-
binding, mitochondria protection against oxidative stress [67, 72] and recently discover 
glyoxalase activity [73]. A connection between DJ-1 and astrocytes has been reported 
that could lead to increase of neuronal susceptibility to oxidative stress. Studies 
indicate that astrocyte dysfunction can be triggered by DJ-1 deficiency thereby 
neuronal protection and secretion of soluble protective factors by astrocytes is 
impaired [74]. Furthermore, DJ-1 is involved in cell signaling pathways like the 
PTEN/Akt pathway and interacts with the apoptosis-implicated proteins Daxx, 
apoptosis signal regulating kinase 1 (ASK1) and p53 (Figure 1.13) [45]. Due to the 
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complexity and diverse roles that DJ-1 plays in cells the exact function of this protein is 
still to be determined despite the known neuronal cytoprotective effect. 
 
Figure 1.13 | MODEL OF DJ-1 AS A STRESS-RESPONSIVE, MULTIFUNCTIONAL PROTEIN. DJ-1 has 
multiple functions and some of the most important are chaperone activity, oxidative stress sensor, 
modulation of expression of genes (interacting with PIAS and cytosolic RNA-binding protein complexes, 
and other nuclear cofactor) and an association with GAPDH [43]. 
 
DJ-1 is a member of the ThiJ/PfpI family, as mentioned above, which is 
associated with functions like protease and chaperone activity. Additionally, the 
analogy between DJ-1 and Hsp31 (a molecular chaperone in Escherichia coli), and 
several observations that DJ-1 prevents aggregation of citrate synthase, luciferase and 
the PD-linked protein α-synuclein led to the identification of the DJ-1 
chaperone activity [66, 71]. DJ-1 chaperone activity is activated in an oxidative 
environment and is dependent on oxidation state of DJ-1 at residue C106. 
Furthermore, for robust chaperone activity the mildly oxidized form of DJ-1 (Cys106-
SO2-) is required [45, 75]. 
  In addition, several studies suggest that DJ-1 protects neurons through an 
antioxidant function [6, 9]. Upon oxidative stress conditions DJ-1 shifts its pI from 6.2 
to 5.8 and is converted to more acidic isoforms, specifically through the oxidation of 
C106 to cysteine sulfinic acid (Cys-SO2H). Also, DJ-1 has the capability to undergo self-
oxidation in order to eliminate H2O2. These evidences and the fact that C106 oxidation 
necessarily consumes ROS lead to the proposed role of DJ-1 acting as scavenger of ROS 
[6, 9, 45]. The DJ-1 antioxidant function can be dependent on its translocation to the 
mitochondria and the C106 oxidation seems to be part of an oxidative stress sensing 
mechanism that promotes the DJ-1 localization to mitochondria [6, 9].  
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Some studies also show that DJ-1 antioxidant action can be due to the 
regulation of antioxidant gene expression rather than by simply scavenging H2O2. In 
fact, it has been shown that DJ-1 stabilize the antioxidant transcriptional regulator Nrf2 
(nuclear factor erythroid 2-related factor) by preventing association with its inhibitor. 
DJ-1 also serves as scaffold protein attenuating the inﬂammatory responses of 
astrocytes and microglia [76]; modulates the expression of genes such as glutamate–
cysteine ligase, the rate-limiting enzyme of GSH biosynthesis; and regulates the 
expression of superoxide dismutase-1 and 3 [42, 72]. It was also reported that DJ-1 can 
modulate expression of several other genes such as androgen receptor reporter 
activity by interacting with PIASx; tyrosine hydroxylase and Bax [46, 72]. These studies 
and results propose that DJ-1 participates in numerous pathways in order to enhance 
cell survival in response to oxidative stress conditions.  
 Another area in which DJ-1 is involved is the mitochondria and its functions. 
Several lines of evidence suggest that DJ-1 is important in maintaining mitochondrial 
dynamics, integrity and fusion [26, 77]. Indeed, there are many studies that report 
partial localization of DJ-1 towards mitochondria and this re-localization is enhanced 
under oxidative stress stimuli [77]. The oxidative-induced modification of DJ-1 (at the 
C106) leads to DJ-1 mitochondrial translocation and it is believed that this step is 
necessary for the DJ-1 neuroprotective function which is abolished by certain 
mutations in the protein [26, 77]. Recent evidences suggest that DJ-1 is involved in the 
PINK1/parkin pathway in order to help maintain mitochondrial function, dynamics and 
integrity when an oxidative stimulus occurs [4].  
 Originally DJ-1 was described as a regulatory subunit (RS) which is a regulatory 
component of an RNA binding complex. Van der Brug and colleagues exposed the RNA 
binding function of DJ-1 that can associate with RNA targets in cells and the brain, such 
as mitochondrial genes, genes involved in GSH metabolism and members of the 
PTEN/PI3K cascade. They also discovered that this protein binds in an oxidation-
dependent manner to several RNA targets since after oxidative stress the interaction 
between DJ-1 and RNA is disrupted. Thus, the hypothesis was that the postulated 
pleiotropic effects of DJ-1 could be related to the single function of binding to multiple 
mRNA transcripts [78]. 
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1.2.3. ROLE IN NEUROPROTECTION 
As mentioned before, in normal human brain DJ-1 is expressed both in 
astrocytes, and neurons although in the later in lower proportions [46]. Moreover, it 
was found that DJ-1 does not accumulate in α-synuclein-positive LBs yet oxidized and 
reduced DJ-1 protein levels were observed in PD brains [42, 46].  
Several studies report the translocation of DJ-1 towards mitochondria after an 
oxidative stimulus, and this re-localization is believed to play a neuroprotective role in 
cells through mitochondrial autophagy regulation [51, 79]. Importantly, the C106 
residue is also involved in neuroprotection mediated by DJ-1, since it plays a crucial 
role in DJ-1 acidic pI shift in oxidative stress conditions [80].  
In model systems, DJ-1 confers protection to dopaminergic neurons against 
various insults, such as rotenone, mutant α-synuclein, H2O2 and 6-OHDA [42]. Several 
studies, including in Drosophila, C. elegans and mice that cells lacking DJ-1 are more 
sensitive to stress insults, which can be rescued by overexpression of DJ-1 WT but not 
by DJ-1 mutants [51, 81]. Interestingly, DJ-1 protects cells against low rotenone 
concentrations but at higher levels or prolonged stress the protective function of DJ-1 
is abolished and apoptotic pathways are activated [51]. These evidences seem to 
mimic the corresponding ones in PD pathogenesis, thus provide a very helpful way to 
study pathogenesis PD associated to DJ-1. 
Among the several functions attributed for DJ-1, the putative role in 
neuroprotection is the most relevant and it has been mainly linked to oxidative stress 
response. However, the mechanisms by which DJ-1 plays its neuroprotective roles are 
far from being elucidated and understood [81].  
 
1.2.4. DJ-1 MUTATIONS 
DJ-1 has been receiving more attention in the last years due to its involvement 
in familial early onset PD and also due to a large number of mutations identified in this 
gene [82, 83]. Mutations in DJ-1 are rare, varying between populations and ethnic 
groups and account for up to 1-2% of the sporadic cases with early-onset [83]. 
However, the study of these DJ-1 variations provides insights into the molecular and 
cellular mechanisms involved in the etiology of this disorder [46, 75]. PD-linked 
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mutations associated to DJ-1/PARK7 gene comprise CNVs (exonic deletions and 
truncations), homozygous (L10P, M26I, E64D, E163K and L166P) and heterozygous 
(A39S, A104T and D149A) missense mutations and also rare polymorphisms (R98Q, 
A171S), among others (Table 1.2) [84]. 
Table 1.2 | DJ-1 GENETIC VARIANTS. 
Mutation Inheritance Population Effect Ref. 
14-kbdeletion Homozygous Dutch Loss of protein [46] 
L166P Homozygous Italian Protein instability [46] 
M26I Homozygous Ashkenazi Jewish Decreased stability [46] 
D149A Heterozygous Afro Caribbean Unknown [46] 
IVS6-1G-C Heterozygous Hispanic Altered transcript [46] 
c.56delC Heterozygous Hispanic Frame shift [46] 
c.57G→A 
 
Both Global Polymorphism [46] 
A104T Heterozygous Latino Unknown [46] 
Ex5-7del Heterozygous Northern Italian Altered transcript [46] 
IVS5+2-12del Heterozygous Russian Altered transcript [46] 
R98Q Heterozygous Global Polymorphism [46] 
E64D Homozygous Turkish Unknown [46] 
E163K Compound Italian Altered activity [46] 
g.168_185dup Homozygous 
 
Unknown [46] 
P158del Homozygous Dutch Unknown [46] 
A179T Heterozygous Dutch Unknown [46] 
Ex1–5dup Heterozygous Dutch Unknown [46] 
A39S Heterozygous Chinese Protein instability [85] 
A167A Both Global Unknown [86] 
L10P Homozygous Chinese Unknown [87] 
A171S Heterozygous American Polymorphism [88] 
Both – homozygous and heterozygous; Compound –comprises two different mutations in the paternal 
and maternal alleles 
 
Due to the recessive inheritance of DJ-1 associated PD, it is assumed that 
disease development is due to loss of function and therefore point mutations are 
expected to trigger loss of function of the protein, the presumed cause of their 
pathogenicity [89]. Identification of novel disease-linked missense mutations would 
help the discovery and analysis of functionally important domains in the DJ-1 protein 
and furthermore in understanding the role and mechanisms of DJ-1 in PD [43]. 
In recent years, remarkable developments have been accomplished in the 
characterization of some pathological DJ-1 mutations, however structural explanations 
for the observed deleterious effects of these missense mutations is still missing [90].  
In the following sections three missense mutations that are believed to be the 
more studied and prominent will be analyzed and described: the L166P, M26I and 
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E163K mutations (Figure 1.14). Moreover, a topic related to the C106 engineered 
mutations will also be discussed.  
 
Figure 1.14 | RIBBON DIAGRAM OF HUMAN DJ-1 DIMER. The structure is colored from blue (N-
terminal) to red (C-terminal) (PDB entry 1UCF, [68]). The L166 residue is represented by green spheres, 
the M26 residue by red spheres and the E163 residue by magenta spheres. The L166P substitution is 
located between two helices that form part of the dimer interface. Image was created using PyMOL 
(DeLano Scientific; http://www.pymol.org). 
 
1.2.4.1. L166P 
 The substitution of the highly conserved leucine at position 166 for a proline 
(L166P) is one of the most extensively investigated and deleterious missense mutation 
in DJ-1 [66, 90]. This mutation was first reported for an Italian family and is located in 
the center of α-helix 7 (the second to last C-terminal helix), near the dimer interface, 
which together with the α-helix 8 mediates dimerization of DJ-1 (Figure 1.15) [91, 92].  
 
Figure 1.15 | RIBBON DIAGRAM OF HUMAN DJ-1 DIMER WITH THE L166 POSITION HIGHLIGHTED. The 
structure is colored from blue (N-terminal) to red (C-terminal) (PDB entry 1UCF, [68]). The L166 residue 
is represented by red spheres. The L166P substitution is located between two helices that form part of 
the dimer interface. Image was created using PyMOL (DeLano Scientific; http://www.pymol.org). 
28 | 
Introduction | 
 
It was proposed that this substitution to proline acts as a helix breaker, 
disturbing the packing interactions at the dimer interface and consequently, leading to 
the disruption of the dimer which is associated with an increase in the total 
hydrophobic surface area exposed to solvent, probably explaining the propensity of 
this mutant to aggregate (Figure 1.16) [66, 92, 93]. 
 
 
Figure 1.16 | STRUCTURAL PERTURBATIONS CAUSED BY L166P MUTANT REGARDING THE DIMERIC 
STRUCTURE AND HYDROPHOBIC SURFACE. A) Increase in hydrophobic solvent accessible surface areas 
(SASA) of L166P DJ-1 (right) relative to WT DJ-1 (left). Molecular surface is colored by residue from least 
hydrophobic (green) to most hydrophobic (blue). B) Perturbations in the DJ-1 dimer interface following 
L166P substitution in each subunit. Loss of intermolecular contacts that mediate DJ-1 dimerization after 
50 ns of L166P molecular dynamics simulations. The key hydrophobic interactions across the interface 
are represented by spheres in both subunits. Residue 166 positions are indicated by orange spheres[66]. 
 
The unfolded structure of L166P exhibits an impaired ability to form stable 
homodimer with itself or a heterodimer with DJ-1 WT however is capable of forming 
high molecular-weight complexes containing DJ-1 oligomers or aggregates with other 
proteins [66]. Due to the structural perturbations, the L166P mutant protein is 
significantly unstable in mammalian cells [93], probably due to direct proteasomal 
endoproteolytic cleavage not requiring prior ubiquitination for its degradation [84]. 
This lead to expression of L166P at lower steady-state protein levels compared to the 
WT protein and an accelerated turnover rate [92]. 
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As a consequence of impaired dimerization and reduced stability the L166P 
mutation abolish DJ-1 chaperone and protease activity of DJ-1 protein [90, 92]. 
Furthermore, this substitution also led to major perturbations in the region of the 
C106 residue, highly conserved, that is involved in dimerization and critical for the 
putative chaperone function of DJ-1, suggesting that the structural effects from this 
mutation are not conﬁned to the vicinity of the substitution, but spread quickly 
throughout the entire protein [66].  
Additionally, this mutant fail to protect cells from death induced by H2O2 and in 
removing it when in cells [75], and under stress conditions the L166P protein is only 
partially mislocalizes or sequestered to mitochondria [82, 91, 94]. 
 
1.2.4.2. M26I 
 The second most studied mutation in DJ-1 is the conservative amino acid 
substitution of the methionine in position 26 for an isoleucine (M26I)[95, 96]. This 
methionine residue is highly conserved throughout evolution, suggesting that it could 
be critical for the structure and function of DJ-1 and is located on the C-terminal end of 
α-helix A (or 1), causing packing defects in the core of the dimer (Figure 1.17) [6, 90]. 
This mutation was first identified in an Ashkenazi Jewish patient with early-onset PD 
[95].  
 
Figure 1.17 | RIBBON DIAGRAM OF HUMAN DJ-1 DIMER WITH THE M26 POSITION HIGHLIGHTED. The 
structure is colored from blue (N-terminal) to red (C-terminal) (PDB entry 1UCF, [68]). The M26 residue 
is represented by red spheres. The M26I substitution is located in the core of the DJ-1 dimer. Image 
was created using PyMOL (DeLano Scientific; http://www.pymol.org). 
 
Contradictory data is reported regarding the stability of this mutant. Some 
studies refer that M26I is stable in cells and not subjected to proteasomal degradation 
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[84, 89] where others claim that this mutant form of DJ-1 is unstable and produced in 
low steady state levels in cell cultures [6, 93]. On the other hand, several studies refer 
the ability of M26I mutant to adopt the dimeric DJ-1 WT fold as well as to form 
heterodimers with the WT protein [75, 93]. Furthermore, the M26I substitution leads 
to decreased thermal stability and an enhanced propensity to form high molecular 
weight oligomers [6]. This pathogenic mutation can localize in the cytoplasm or 
mitochondria in slightly varying degrees compared to the DJ-1 WT, but the localization 
in the latter compartment is enhanced by oxidative conditions [93]. 
Moreover, studies show that M26I mutant aberrantly bound to ASK1, failing to 
suppress ASK1 activity and nuclear export of the death domain-associated protein 
Daxx, thereby leading to loss of cytoprotective activity [97]. Also, some reported 
approaches can help to stabilize the M26I mutant protein. A previous study revealed 
that heterodimer formation between M26I mutant protein and DJ-1 WT could help to 
stabilize the mutant protein and this could play a central role in preserving DJ-1 
function in heterozygous individuals [6]. Another study shows that introduction of a 
disulfide linkage between residue Val 51 and Cys 53 stabilized the mutant M26I against 
thermal denaturation, improved their ability to scavenge ROS, and restored a 
chaperone-like function of blocking α-synuclein aggregation [79].  
 
1.2.4.3. E163K 
 The E163K missense mutation in exon 7 and is characterized by the substitution 
of the glutamic acid residue in the position 163 for a lysine residue. This is a very non-
conservative exchange of a strictly conserved acidic amino acid residue within the 
structurally essential helix G (or 7) (Figure 1.18) [46, 98]. This mutation was first 
reported for a family in southern Italy, resulting in a severe phenotype as early as 24 
years of age. Subjects homozygous for this E163K mutation develop symptoms that 
include parkinsonism, dementia, and amyotrophic lateral sclerosis [99]. 
The E163K pathogenic mutant retains similar properties to DJ-1 WT protein, 
under normal conditions, in terms of solubility and dimerization, and only subtle 
perturbations in the DJ-1 structure [90, 99]. Nonetheless, this mutant compromises the 
ability of DJ-1 to protect against oxidative stress while retaining the ability to protect 
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the cells against mitochondrial stress and proteasome inhibition [99]. This means that 
the effect of this mutation on impairing DJ-1 function is specific to oxidative stress, in 
contrast to the other mutations in DJ-1 [99]. Another important particularity of this 
mutant is that it causes the disruption of a structurally critical salt bridge with the 
arginine residue 145 (R145), which leads to an increased mobility of R145 and 
consequently interferes with a network of hydrogen bonds that involves L186 and 
spans the dimer interface [90]. 
 
Figure 1.18 | RIBBON DIAGRAM OF HUMAN DJ-1 DIMER WITH THE E163 POSITION HIGHLIGHTED. The 
structure is colored from blue (N-terminal) to red (C-terminal) (PDB entry 1UCF, [68]). The residue E163 
is represented by red spheres. The E163K substitution is located in the DJ-1 surface. Image was created 
using PyMOL (DeLano Scientific; http://www.pymol.org). 
 
 Under oxidative stress conditions the E163K mutant shows a lack of localization 
towards mitochondria. It is though that the change from a negatively to positively 
charged residue in addition to the subtle structural effects may prevent the interaction 
of DJ-1 with other proteins that may be involved in the redistribution of DJ-1 under 
conditions of oxidative stress [99].  
The features described above reveal that the loss of DJ-1 protective function 
can occur without evident biochemical changes on the protein and demonstrate that 
alterations to specific residues can affect precisely individual functions indicating that 
probably DJ-1 is involved in multiple cellular pathways [99].  
 
1.2.4.4. CYS 106 ENGINEERED MUTANTS 
There are specific residues that are very important and highly conserved and 
C106 is one of those residues. Cysteine 106 is crucial for DJ-1 activity in 
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neuroprotection and replacement of this residue by other amino acids blocks the 
neuroprotective DJ-1 function [100].  
Through direct oxygen addition, C106 forms 3 different species, specifically, 
cysteine-sulfenic acid (Cys-SOH), cysteine-sulfinic acid (Cys-SO2H), and cysteine-
sulfonic acid (Cys-SO3H). In cells exposed to oxidative stress the pI of DJ-1 shifts to a 
more acidic value and C106 is oxidized to Cys-SO2H or Cys-SO3H [101, 102]. Currently, 
existing data suggests that mild oxidation to Cys106-SO2- is associated with DJ-1 
cytoprotection whereas extensive oxidation of DJ-1 is associated with aging and 
neurodegenerative disease (Figure 1.19) [45].  
 
Figure 1.19 | ROLE OF MAJOR OXIDIZED DJ-1 FORMS. The question mark is used to indicate 
unresolved aspects of the current set of proposals for DJ-1 function [45]. 
 
 
Moreover, the partially oxidized DJ-1 isoform where C106 is converted to the 
sulfinic acid form is believed to trigger DJ-1 chaperone activity and suppress α-
synuclein fibrillization, while further oxidation of the protein is thought to lead to 
partial loss of protein structure and to abolish this chaperone function [6, 103]. 
Additionally, oxidation of C106 to Cys106-SO2- necessarily consumes ROS and therefore 
it has been suggested that DJ-1 acts as direct scavenger of ROS [45]. To validate this 
statement the engineered mutant C106DD (substitution of C106 for two aspartic acids) 
should be nonfunctional for a putative C106 dependent ROS scavenging role in DJ-1, 
but that is not the case. Hence, current data suggest that this effect is not the main 
contributor to the protective function of DJ-1, despite oxidation of C106 indeed results 
in some reduction of cellular ROS [45].   
Cysteine residue 106 was also identified as the functionally critical amino acid 
that promotes direct binding of DJ-1 to ASK1 and thus cytoprotection in oxidatively 
stressed cells [97]. DJ-1 forms a mixed disulfide bonds involving the central C106 with 
the N-terminus of ASK1, similar to a known negative regulator, Trx1 and this could be 
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recapitulated by the C106DD mutation [45, 97]. On the other hand, the substitution of 
C106 for an alanine specifically abolished binding to ASK1 and the cytoprotective 
activity of DJ-1 [97].  
Unlike C106A that impairs DJ-1 neuroprotective functions, C106DD mimics and 
activates the cytoprotective protein DJ-1 and consequently provides protection to cells 
against oxidative stress [45]. However, it is unknown whether the loss of DJ-1 
protective function in these mutants is due to the absence of C106 oxidation or the 
absence of the cysteine residue itself [104].  
 Some residues around C106 are responsible for the modulation of C106 
reactivity toward ROS. Among these residues the glutamate in position 18 (E18) is 
essential to the stabilization of Cys-106-SO2- residue through the formation of a 
hydrogen bond with it [104]. Thereby mutations in Glu-18 to other residues affected 
the ability of C106 to oxidize to sulfinic acid without changing the cysteine residue 
itself [104]. Furthermore, under oxidative conditions, DJ-1 WT translocates to 
mitochondria and this recruitment is closely related with its susceptibility for 
oxidation, thus C106A abrogate this feature of DJ-1 and is not relocated in this way 
[80].  
 
1.2.5. DJ-1 INTERACTOME  
Protein interaction networks are crucial to acquire knowledge about proteins´ 
functions and characterization, disease mechanisms, and in some cases it could lead to 
the discovery of novel targets for therapeutic drugs [105]. Proteins can interact with 
several types of molecules (other proteins, nucleic acids, carbohydrates, and lipids 
among others) in order to modulate biochemical reactions and/or mediate numerous 
stimuli towards signaling pathways [106]. Interactome can be referred as a network of 
all types of molecular interactions, but protein-protein interactions (PPI) have a 
fundamental role in cellular systems. In order to function properly these interactions 
need to occur at the right time and location, and proteins must bind specifically with 
appropriate interacting partners [106]. 
Following this perspective, several studies have been performed with the 
purpose of discovering DJ-1 interacting partners (Table 1.3).  
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Table 1.3 | EXAMPLES OF DJ-1 INTERACTING PARTNERS REFERRED IN THE LITERATURE AND 
DATABASES. 
Molecular Function Classification Protein Reference 
Ubiquitin-protein ligase activity Parkin [11, 107] 
TRAF6 [108] 
Dopamine release and transport α-synuclein [109, 110] 
SUMO ligase activity SUMO-1 [111, 112] 
SUMO- conjugating enzyme UBC9 (UBE2I) [112] 
PIAS1 [111] 
Protein binding polyubiquitin-C [113] 
Phosphatase activity PTEN [114] 
SHP-1 [76] 
Chromatin binding protein MTA1 [115] 
MTA2 [115] 
Kinase activity 
 
PINK1 [107] 
MAP3K5 [97] 
ERK1/2 [116] 
Chaperone Activity HSPA4 [11] 
HSP70 and 90 [117] 
BAG1 [118] 
Mortalin [119] 
grp94 [119] 
calnexin [119] 
Apoptosis regulator activity BCL2L1 [77] 
Tumor necrosis factor TRAF and TNF receptor-associated protein [108] 
Ubiquitin thiolesterase activity Cezanne/Za20d1 [120] 
Histone deacetylase activity HDAC1 [115] 
Histone-binding protein RBBP4 [115] 
Mi-2/NuRD complex [115] 
RNA binding Nucleolin [119] 
Monoamine transmembrane transporter 
activity VMAT2 [121] 
Structural molecule activity MAP1B [122] 
clathrin [119] 
Superoxide dismutase activity SOD1 [123] 
Protein Kinase 
 ASK1 [124] 
Transcriptional factor p53 [125] 
DAXX [112] 
C-myc [126] 
DJBP [127] 
Dehydrogenase and nitrosylase activities 
(phosphorylating activity) GAPDH [126] 
Proline biosynthesis activity PYCR 1 [128] 
 
Nowadays, there are already databases that aim to map protein-protein 
interaction networks, namely PPI networks associated with the human interactome. 
BioGRID, DIP, IntAct are some examples of PPI databases [129], where a list of 
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interactors of a target protein could be found and in some database a list of interactors 
of the target protein could be accessed.  
As mentioned before, the function and protein interactors vary with the time, 
conditions and location in cells. In this way, some studies are focused on studying the 
interactome changes when the time and conditions are modified. An example of that is 
the work done by Sandra Anjo during her master thesis project (unpublished data) in 
which the endogenous DJ-1 interactome was studied under normal and stress 
conditions for different time points of oxidative stress exposure. 
Genetic mutations associated with genetically inherited disorders doesn’t cause 
the disease only due to the malfunction of the mutated gene product, but rather 
through the perturbations in the interaction network in which that altered protein is 
inserted [129]. Thus, understanding and revealing the complex interaction network in 
which the disease-related proteins are linked is essential to understand the network 
perturbations associated with the disease phenotype [129, 130]. From this standpoint 
the study of DJ-1 mutations dynamic interactome may generate significant information 
about the modifications in the DJ-1 interaction network caused by these mutations 
and furthermore in understanding the PD molecular mechanisms and phenotype. For 
some mutations interesting interacting partners have been identified [11, 82, 96, 97, 
108], but a full interactome analysis under different conditions is still lacking. 
 
1.3. INTERACTOMICS 
 For several years, the genomic field has been generating a huge amount of data 
concerning genetic sequences with special highlight to the human genome project. 
However, currently the challenge has shifted to the study of the proteins´ functions 
encoded by genes identiﬁed in the human genome project [131]. The proteome has 
dynamic properties compared to the static nature of the genome. Therefore, the focus 
of proteomics is the study of protein structures, modiﬁcations and localization, and 
protein–protein interactions among them [131].  
Frequently, in several cellular processes proteins fulfill their functions within a 
complex network of interactions that could be stable or dynamic and where a single 
component can affect a wide range of other components [132, 133]. Thus, PPI are 
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crucial to biological processes and the characterization of PPI networks, called 
interactomes, are important to translate molecular mechanisms into cells functions 
and physiology [132, 134]. PPIs can also help to elucidate the functions of newly 
discovered interacting proteins or new functions of proteins already identified [132, 
133]. Importantly, PPIs are frequently regulated in response to a specific stimulus or 
cell condition, where different interactomes vary according to tissue, cell type, and 
biological state [132, 135].  
 It was observed that a single protein, under different conditions, can interact 
with several different partners leading to different biological outcomes. Therefore, PPI 
mapping is particularly important for many diseases helping to understand their 
molecular basis and pathogenesis that could lead to the identification of new disease 
markers [129, 136, 137]. Disruption of PPIs is also associated with disease 
development since many cellular processes are regulated by multimeric protein 
complexes. Hence, a new type of drugs that influence PPIs regulation by blocking the 
formation of functional protein complexes instead of affecting individual target 
proteins could be developed [132]. In fact, to date, some interaction studies related to 
PD-associated proteins have been made, particularly in α-synuclein and LRRK2 proteins 
[137, 138].  
Several methodologies can be used to map PPI, with major use of two 
approaches: the yeast two-hybrid system (Y2H) and the affinity purification coupled to 
tandem mass spectrometry (AP–MS/MS) [130, 139]. The Y2H system was used to 
obtain the first interactome maps and is based in a binary assay that captures direct 
PPI, whereas AP-MS identiﬁes and maps direct and indirect protein associations within 
protein complexes [129, 134]. In the first approach a transcription factor can be 
separated into two parts, a DNA binding domain (DBD) that is fused to a bait-protein 
(known protein used to capture other proteins) and an activation domain (AD) that is 
fused to a prey-protein (one or several proteins that interact with the bait-protein). 
The transcription factor is functional only when the bait and prey proteins interact 
physically which lead to the junction of DBD and AD. The functional transcription factor 
will induce transcriptional activation of a reporter gene and subsequently to a 
detectable and measurable outcome, which could be growth on selective conditions 
media or generation of a colorimetric or fluorescent signal [140, 141].  
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The advantages of Y2H system are the fact that is a scalable method and the 
speed in PPIs identification. However, this method has high false-positive and false-
negative rates due to numerous aspects, including the fact that yeast is a heterologous 
system. Thus, AP-MS/MS has been an alternative method widely used [131, 135].  
 
1.3.1. AP-MS/MS 
AP-MS/MS is a high-throughput and powerful technology, thus currently is the 
most common approach used to characterize protein complexes and analyze 
interactomes [142, 143] (Figure 1.20). In this methodology, the protein of interest 
(bait) is made by the fusion of the protein with a specific tag (recombinant tagged 
proteins) that is immobilized in a solid support (usually agarose) or it is purified using 
antibodies bound to agarose or magnetic beads [131]. The next step is separation of 
the protein (bait) and its binding partners (preys) that is accomplished through 
cleavage in specific sites (between the bait protein and support) by a specific enzyme 
or using a soluble substrate that will compete for binding sites [144]. Then, the purified 
protein complexes can be analyzed in a gel based approach using 1D or 2D gels and the 
desired bands can be proteolyticly digested into small peptides that are subsequently 
identified by mass spectrometry (MS). Alternatively, a gel free based approach using 
sample digestion and direct analysis by liquid chromatography coupled to tandem 
mass spectrometry (LC-MS/MS) can also be employed (Figure 1.20) [131, 145]. MS 
data generate a list of proteins that comprises the protein of interest (bait), its cellular 
binding partners and also some background contaminant proteins [135]. 
The biggest challenge of AP-MS method is to distinguish between true 
interaction partners and co-purifying contaminants (unspeciﬁc background of proteins) 
[143]. Two approaches to overcome this problem are tandem afﬁnity puriﬁcation (TAP) 
and quantitative AP-MS (q-AP-MS). In the former tagged bait proteins are puriﬁed by 
two-step puriﬁcation procedure, reducing the amount of contaminants, while the later 
uses quantitative proteomics providing evidence to differentiate real interactions from 
false positives [135, 143]. 
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Figure 1.20 | OVERVIEW OF AN AFFINITY PURIFICATION COUPLED TO MS APPROACH. (a) Specific bait 
protein (blue) is tagged by specific methods (a.1) or has affinity to a specific antibody (a.2).(b) The 
expressed bait proteins with the affinity tag are purified from a cell lysate of the bait protein and binding 
partners (orange and green) using affinity chromatography (b.1) or beads with the specific antibody for 
the bait protein are used to purify the bait protein and binding partners (orange and green) from a cell 
lysate (b.2). (c) Purified protein complex and contaminants (red) that can also be present. (d) In an 
optional step, proteins in the complex can be separated by SDS–PAGE. (e) Proteins are subject to 
proteolysis (usually with trypsin). (f) MS analysis of peptides, involving in most cases LC-MS/MS that 
yields a tandem MS (MS/MS) spectrum (simplified MS/MS scan is shown). (g) Interpretation of the MS 
data and protein identification using database searching and statistical software which generate a list of 
the tagged protein, its interacting partners and contaminant [139, 146]. 
  
The TAP method involves the expression of a dual tag fused to the bait protein 
and the original TAP tag was a sequence stretch containing a calmodulin-binding 
peptide (CBP), a tobacco etch virus (TEV) protease cleavage site and the 
immunoglobulin G (IgG)-binding domain of protein A from Staphylococcus aureus 
(SpA), but through the years many variations of this strategy have been developed 
[143, 147]. This strategy has been commonly and successfully used in numerous 
protein interaction studies, increasing the efficiency of isolation of protein complexes 
[143]. The main advantages are the mild washing conditions that prevent the 
destruction of protein complexes and the near physiological conditions of the method 
[132]. However it has limitations in identifying very weak or transient interactions due 
to the long purification protocol that preserves only stable interactions being too 
extensive for this type of associations [142, 147].  
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The other approach developed to eliminate nonspecific interactors without 
losing abundant and transiently interacting proteins is q-AP-MS [129]. In this method 
two or more afﬁnity puriﬁcations are made in parallel. In one of the affinity 
purifications, the bait protein is captured with an antibody or a speciﬁc/tagged ligand 
and the other one is planned in order to capture only background proteins or a 
different condition from the first one, therefore working as a negative control or as 
different experimental condition, respectively. After that the relative amount of each 
protein in those conditions must be determined and for that quantitative proteomics is 
employed. True interactors will appear only in one of the pull-downs and will have 
peaks with higher abundance compared to the false positives that should be equally 
present and appear in both pull-downs [143]. To help elucidating and validating the 
direct protein interactions bioinformatics tools will correlate MS data with other 
methods like Y2H, or interactive MS measurements in conjunction with chemical 
crosslinking [148]. 
Despite the limitations of AP-MS/MS, this technique has also many advantages 
such as the native cellular environment where the expression occurs, which allows the 
accurate regulation and post-translational modifications of the protein of interest in its 
cellular compartment [136, 139]. Moreover, when used in combination with 
quantitative proteomics techniques, this method can be used to prove dynamic 
changes in PPIs of protein complexes, providing information associated with cell 
signaling [135, 143].  
 
1.3.2. MS 
Mass spectrometry has revolutionized the proteomics field becoming the 
method of choice to analyze and identify large numbers of proteins in complex protein 
samples [131, 148]. This technique measures the mass to charge ratios (m/z) of gas-
phase ions from the sample [149]. In the last years, MS has played an increasingly 
significant role in the biological sciences and nowadays is used to characterize 
structurally several types of biomolecules [149]. It is characterized by extreme 
sensitive, speed, allows the identification of peptides present at femtomole levels, is 
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compatible with high-throughput strategies, is able to characterize peptide 
modifications, and can also quantitatively measure peptide abundance [139].  
 A mass spectrometer consists of an inlet device to introduce the analyte into 
the ion source (usually a separation technique such as liquid chromatograph or just a 
direct injection), an ion source to produce ions from the sample, one or more mass 
analyzers, to separate the ions according to their m/z ratios, a detector that registers 
the number of ions at each m/z value and a computer, to process the data and 
produce the mass spectrum [148, 149].  
Analysis of proteins and peptides by MS was only possible with the 
development of soft ionization methods, like electrospray ionization (ESI) and matrix-
assisted laser desorption ionization (MALDI) that allow the transfer of large, polar, 
thermally labile biomolecules (like peptides and proteins) into the gaseous phase for 
mass analysis [131]. ESI ionizes the analytes out of a solution phase sample generating 
gaseous ions and therefore can be easily coupled to liquid-based separation 
technologies such as LC and capillary electrophoresis. MALDI sublimates and ionizes 
the samples out of a dry, crystalline matrix via laser pulses and is normally used to 
analyze simple peptide mixtures, while for the analysis of complex samples liquid-
chromatography ESI-MS methods (LC-MS) are preferred [148, 149].  
 These advances led to the development of new mass analyzers and complex 
multistage devices in order to resolve the challenges of protein and proteome analysis. 
In some cases when additional information is needed, after the initial mass 
determination, specific ions are selected and subjected to fragmentation through 
collision in a methodology called tandem mass spectrometry (MS/MS) [150]. In the 
past few years, tandem MS has been widely used for high-throughput analysis of 
complex protein samples [151]. This method combines sequence and mass 
information in order to identify proteins (MS/MS). The first step is to measure the 
peptides masses, then isolate single peptides in the mass spectrometer and promote 
their collision with inert gas molecules (collision-induced dissociation (CID)), which will 
lead to fragmentation of the peptide backbone. Each MS–MS spectrum is associated 
with an amino acid sequence and in a second phase the data obtained is compared 
against one or more databases to infer the identity of the proteins in the sample [129, 
151]. 
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 Files with thousands of MS and MS/MS spectra are generated when tandem MS 
is performed and there is the need to analyze all the information for further use in 
protein identification and characterization [151]. Usually, peptides are identified by the 
submission of the data to selected protein sequence databases [151]. In this 
methodology, each acquired MS/MS spectrum is compared with theoretical spectra 
obtained from a sequence database and each acquired MS/MS spectrum is thereby 
assigned the best matching database peptide [151]. According to the degree of 
similarity between the experimental measured data and the theoretical data there is a 
score that indicates the reliability of peptide identification [151].  
 Protein identification and characterization by itself does not give information 
regarding proteome dynamics that include significant cellular events such as protein 
synthesis and degradation, or the formation of protein assemblies [152]. Quantitative 
proteomics is based in MS quantification in the changes in protein abundances and is 
an important tool used to study protein interactions´ dynamics [153]. Thus, protein 
quantification in LC-MS methods is centered on the peak height or area of the 
proteolytic peptide peaks in the mass spectrum and/or chromatogram [152]. Different 
approaches have been developed to perform quantitative proteomics experiments and 
can be broadly divided into labeling with stable isotopes and label-free methods [153]. 
The former can be divided into metabolic labeling (SILAC) and chemical/enzymatic 
(ICAT, ICPL, and iTRAQ) whereas the latter in spectral counting and peptide ion 
chromatogram extraction [153, 154]. Labeling methods involve the incorporation of 
stable isotopes (artificial labeling of peptides or proteins) into one or more samples 
being studied while in label free methods the samples native isotope composition is 
maintained and identical peptides between samples can be compared [154].  
 In general terms, an MS-based proteomics analysis uses site-specific enzymatic 
proteases to digest proteins into peptides that are subsequently fragmented in the 
mass spectrometer, giving MS/MS spectra which are used to identify the peptides 
sequences through databases and moreover quantify through quantitative MS (Figure 
1.21) [155].  
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Figure 1.21 | GENERIC MS-BASED PROTEOMICS APPROACH. A classic proteomics approach comprises 
five stages. In stage 1, the proteins to be analyzed are isolated from cell lysate or tissues. This often 
includes a final step of one-dimensional gel electrophoresis. Proteins are degraded enzymatically to 
peptides in stage 2, usually by trypsin. In stage 3, the peptides are separated by high-pressure liquid 
chromatography and eluted into an electrospray ion source. In stage 4, a mass spectrum of the peptides 
eluting at this time point is taken (MS1 spectrum). The computer generates a prioritized list of these 
peptides for fragmentation and a series of tandem mass spectrometric or “MS/MS” experiments ensues 
(stage 5). The MS and MS/MS spectra are acquired and stored for matching against protein sequence 
databases. The outcome of the experiment is the identity of the peptides and therefore the proteins 
making up the purified protein population (stage 6) [148]. 
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1.4. OBJECTIVES 
The exact functions and mechanisms of DJ-1 remain largely unknown, however 
the involvement of this protein in PD and its fundamental role in neuroprotection is 
indisputable. DJ-1 neuroprotection in cells is believed to be associated with an 
oxidative stress response, with DJ-1 playing diverse functions.  
Mutations associated to this gene lead to structural defects and loss of DJ-1 
function which will cause an inherited form of PD. Identifying and clarifying the 
mechanisms of DJ-1 related disease has already provided insight into pathophysiology 
of PD and may promote the understanding of many other mechanisms of brain 
neuronal maintenance. Additionally, the identification and study of PD associated 
genes has a fundamental contribution in understanding and unravel the 
pathophysiologic mechanisms of common sporadic forms of this disease. Following 
these perceptions, this study aims to characterize the dynamic interactome of WT DJ-1 
with the interactome of certain DJ-1 mutants, particularly E163K, C106A and C106DD 
mutants, under normal and stress conditions. These approaches will help to identify 
the changes in protein-protein interactions that DJ-1 undergoes when mutated and 
later on in understanding how this changes compromise DJ-1 functions and 
neuroprotection. 
 
 
 
 
 
 
 
 
 
44 | 
  
 
 
 
 
 
 
 
 
 
2. EXPERIMENTAL PROCEDURES 
  
 
   
 
Experimental Procedures | 
2.1. DJ-1 CONSTRUCTS AND SITE-DIRECTED MUTAGENESIS  
A previously designed pET28a plasmid construct was used, the DJ-1_pSKB-3 
(Figure 2.1) that contains the cDNA sequence of wild-type DJ-1 fused to an N-terminal 
hexahistidine tag.  
 
Figure 2.1 | MAP OF DJ-1_PSKB-3 CONSTRUCT. Representation of the DJ-1_pSKB-3 construct that 
contains: lac I – lac repressor gene; His Tag – hexahistidine tag; TEV – tobaco etch virus protease 
recognition site; kan – kanamycin resistance gene; the DJ-1 cDNA (optimized for E. coli expression) 
cloned between Nhe I and Xho I restriction endonuclease sites. The vector pSKB-3 corresponds to 
pET28a where thrombin recognition site was modified to TEV recognition site. 
 
The QuickChange® Site Directed Mutagenesis Kit from Stratagene was used in 
the DJ-1_pSKB-3 construct in order to generate constructs with the E163K, C106A and 
C106DD mutants´ forms of human DJ-1. The primers containing the pathogenic 
mutations were designed according to the manufacturer’s recommendations, with 
codons optimized for expression in Escherichia coli (Table 1.1). 
DJ-1 mutants´ constructs were used to transform E. coli XL1 blue competent 
cells (Agilent), grown at 37oC in Luria Broth Base (Miller's LB Broth Base) 
(Invitrogen/agar plates supplemented with kanamycin (50µg/mL)). Colonies were 
picked and grown in liquid LB supplemented with kanamycin (50μg/mL), the DNA was 
isolated using PureLink® Quick Plasmid Miniprep Kit (Invitrogen) and the DNA 
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sequence of all DJ-1 mutants´ constructs were confirmed by Sanger DNA Sequencing at 
STAB Vida.  
Table 1.1 | DJ-1 MUTATIONS WITH RESPECTIVE CODON SUBSTITUTIONS AND PRIMERS. 
Mutation Codon substitution Primer 
   
E163K GAA  AAA 
Forward: 5´- GTC CGG GTA CAA GCT TTA AAT TTG CAC 
TGG CAA TTG -3´ 
Reverse: 5´- CAA TTG CCA GTG CAA ATT TAA AGC TTG 
TAC CCG GAC -3´ 
   
C106A TGT  GCG 
Forward: 5´- CTG ATT GCA GCA ATT GCG GCA GGT CCG 
ACC GCA CTG -3´ 
Reverse: 5´- CAG TGC GGT CGG ACC TGC CGC AAT TGC 
TGC AAT CAG -3´ 
   
C106DD TGT  GAT GAT 
Forward: 5´- CGC AAA GGT CTG ATT GCA GCA ATT GAT 
GAT GCA GGT CCG ACC GCA CTG C -3´ 
Reverse: 5´- GCA GTG CGG TCG GAC CTG CAT CAT CAA 
TTG CTG CAA TCA GAC CTT TGC G -3´ 
 
2.2. DJ-1 MUTANTS PRODUCTION AND PURIFICATION 
The DJ-1 mutants´ constructs were transformed into competent E. coli BL21star 
(DE3) strain and plated into LB/agar supplemented with 50μg/mL kanamycin. One 
colony was used to inoculate 50mL of LB supplemented with 50μg/mL kanamycin that 
was grown overnight at 37oC. To inoculate 1L of LB, supplemented with 50μg/mL 
kanamycin, 25mL of the previous cell culture were used. The cells were allowed to 
grow at 37oC with shaking. When the optical density at 600nm reached 0.5, the 
temperature of the incubator was decreased to 18oC and after one hour IPTG was 
added to a final concentration of 1mM to induce protein expression. This was allowed 
to occur for 16 hours. 
The cell suspension was centrifuged (20 min, 4 000g, 4oC), the cellular pellet 
was resuspended in 60mL of 20mM sodium phosphate, 500mM NaCl, 20mM 
Imidazole, pH 7.5, and disrupted through a high pressure homogenizer EmulsiFlex-C3 
(Avestin), by 3 passages at 1 000 bar. The cellular extract obtained was clarified by 
centrifugation (20 min, 18 900g, 4oC) and the supernatant was loaded into a 5mL 
HisTrap HP column (GE Healthcare) using the peristaltic pump EP-1 Econo Pump (Bio-
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Rad). After column loading, the column was extensively washed with loading buffer 
(20mM sodium phosphate, 500mM NaCl, 20mM Imidazole, pH 7.2) and subsequent 
protein elution was obtained by stepwise increasing of imidazole concentration up to 
500mM (50, 100, 300 and 500mM). The fractions containing the DJ-1 mutants were 
combined, loaded into a HiLoad 26/60 Superdex 200 prep grade and protein elution 
was obtained using a solution of PBS (8mM K2HPO4, 2mM NaH2PO4·H2O, 150mM 
NaCl). The fraction containing the dimeric form of the DJ-1 mutants was concentrated 
using 10kDa molecular weight cut-off (MWCO) centrifugal concentration (Millipore) 
and then protein concentration was determined by Nanodrop ND-1000 
Spectrophotometer (Thermo FisherScientific) measuring the absorption at 280nm, 
and stored in PBS with 10% glycerol at -80oC. These fractions were also analyzed by 
silver stained SDS-PAGE [4-20% polyacrylamide gel (Bio-Rad)]. The other fractions 
recovered were quantified using the BCA protein determination assay (Thermo Fisher 
Scientific) and analyzed by Coomassie Brilliant Blue G-250. 
 
2.3. GEL SEPARATION, GEL BAND PROCESSING AND PEPTIDE EXTRACTION 
Samples from DJ-1 WT and mutants were electrophoretically separated in a 
pre-cast 4-20% SDS-polyacrylamide gel (Bio-Rad) using a Mini-PROTEAN Tetra 
Electrophoresis System (Bio-Rad). Sample preparation involved protein denaturation 
with Laemmli Sample Buffer 2x (65.8mM Tris-HCl, pH 6.8, 2.1% SDS, 26.3% (w/v) 
glycerol, 0.01% bromophenol blue) (Bio-Rad) and boiling at 95oC for 5 minutes. After 
cooling at room temperature, 4µL of acrilamide/bis-acrilamide solution for each 30µL 
of sample was added to promote the cysteine alkylation. After protein separation, the 
gel was stained with Colloidal Coomassie Blue. The entire gel lanes were sliced into 
small pieces and transfered to microcentrifuge tubes with 1mL of deionized water to 
prevent gel bands dehydration. To destain the gel bands the water was remove, 1mL 
of destaining solution (50mM ammonium bicarbonate and 30% acetonitrile) was 
added and the tubes were placed in a thermomixer (Comfort, Eppendorf) at 850 rpm 
for 15 minutes. The previous procedure was repeated if the gel pieces that remained 
blue, otherwise 1mL of water was added and tubes were placed in a thermomixer for 
10 minutes at 850 rpm. After this, the water was removed and 100µL of acetonitrile 
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(ACN) was added to promote faster gel dehydration. The ACN was removed and the 
gel bands were dehydrated on the Concentrador Plus (Eppendorf) for 1 hour at 60oC. 
Adequate volume of trypsin (15ng/µL in 10mM ammonium bicarbonate) was added to 
cover the dried gel bands and tubes were incubated for 10 minutes on ice to rehydrate 
the gel. After this time, sufficient volume of 10mM ammonium bicarbonate (final 
concentration of trypsin 10ng/µL) was added to cover gel bands and samples were 
incubated overnight at room temperature in the dark to perform the in-gel digestion. 
The tryptic solution (containing trypsin and peptides) was collected to low binding 
microcentrifuge tubes (Eppendorf) and the remaining peptides were extracted by 
sequential addition of 50µL of 30%, 50%, and 98% of ACN in 1% formic acid (FA). After 
the addition of each solution, the tubes were agitated in a thermomixer at 1 050 rpm 
for 15 minutes and the solution was collected to the tube containing the initial tryptic 
solution. Samples containing the peptides were concentrated on the Concentrador 
Plus (Eppendorf) at 60oC, resuspended to a final volume of 100µL in a solution of 2% 
ACN and 1% FA, and sonicated on a Sonics 750W using a cup-horn (2 min with 1 sec on 
1 sec off cycles at 20% of amplitude). The next step was desalting the peptides using 
C18 Bond Elut OMIX solid phase extraction pipette tips (Agilent technology). Briefly, tip 
columns were hydrated with 100µL of 50% ACN and equilibrated with 100µL of 2% 
ACN and 1% FA. Peptides were loaded to the columns and this step was repeated five 
times, followed by a washing step with 100µL of 2% ACN and 1% FA solution and 
elution to new protein LoBind tubes with 100µL of 70% ACN and 0.1% FA. Eluates were 
concentrated using the Concentrator Plus at 60oC until approximately 10µL of solution 
remained. Sample volume was adjusted to 15 or 30µL in a solution with final 
concentration of 2% ACN and 0.1 % FA. Finally, samples were sonicated on a Sonics 
750W using a cup-horn (2 min with 1 sec on 1 sec off cycles at 20% of amplitude), 
centrifuged 5 minutes at 14 100g and the supernatant was transferred into vials for 
subsequent LC-MS/MS analysis. 
 
2.3.1. POLYACRYLAMIDE GEL STAINING METHODS 
To evaluate the SDS-PAGE profile of the fractions recovered from the proteins´ 
production and purification homemade gels with 12.5% of polyacrylamide and 1.5mm 
thickness were used. For gel band digestion and protein identification, pre-cast gels 
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with 4 to 20% polyacrylamide and 0.75mm (Bio-Rad) were used. Samples were 
electrophoretically separated using a Mini-PROTEAN Tetra Electrophoresis System 
(BioRad) and gels were stained with Coomasie Brilliant Blue G-250 (Bio-Rad) or Silver 
(Sigma-Aldrich). 
 
2.3.1.1. COLLOIDAL COOMASSIE STAINING 
The Coomassie staining was adapted from the work described by Candiano and 
co-workers [156] with some adjustments. Briefly, after electrophoresis, the gel was 
washed with distilled water and immersed in staining solution [10% (v/v) of 85% 
solution of phosphoric acid, 10% (w/v) ammonium sulphate, 20% (v/v) methanol]. The 
Coomassie powder was added to the solution with a filter to allow the formation of 
colloidal particles under agitation and allowed to stain overnight. After that, successive 
washes with distilled water were made and the gel was maintained in water to use in 
further analysis. 
 
2.3.1.2. SILVER STAINING  
Silver staining was used to allow the detection of low level proteins separated 
by electrophoresis. Therefore, the method used by O’Connell and Stults [157] was 
adapted in which the gel was washed with distilled water and immersed in the fixation 
solution [25% (v/v) methanol and 5% (v/v) acetic acid] for 30 minutes with agitation 
(all steps were performed under agitation). Subsequently, the gel was dehydrated by 
consecutive immersion in two alcoholic solutions of gradually decreasing 
concentrations [50% (v/v) ethanol followed by 30% (v/v) ethanol] for 10 minutes each. 
Then, the gel was submersed in a solution with 0.2g/L of sodium thiosulfate for 1 
minute followed by 3 washes with de-ionized water and immersion in the solution of 
silver nitrate with a final concentration of 2g/L for 20 minutes. Finally, it was added the 
developing solution [0.7mL/L of a solution of 37% of formaldehyde, 30g/L of sodium 
carbonate anhydrous and 10mg/L of sodium thiosulfate]. Once the desired staining 
was reached, a stop solution [50g/L of Tris and 2.5% of acetic acid] was added for 1 
minute. Until further use the gel was stored in distilled water. 
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2.4. PROTEIN IDENTIFICATION BY LC-MS/MS 
Protein identification experiments were carried out on a hybrid quadrupole 
time-of-flight mass spectrometer (Triple TOF™ 5600 System; ABSciex) after both gel 
and liquid digestions. Peptides separation was performed using liquid chromatography 
(nanoLC Ultra 2D, Eksigent) on a ChromXP™ C18 reverse phase column (300µm ID × 
15cm length, 3µm particles, 120Å pore size, Eksigent) at 5µL/min. Peptides were 
eluted into the mass spectrometer with an acetonitrile gradient in 0.1% FA (2% to 35% 
ACN, in a multiple step gradient for 25 min for gel digested samples and 5% to 35% 
ACN, in a multiple step gradient for 25 min for liquid digested samples), using an 
electrospray ionization source (DuoSpray™ Source, ABSciex). The mass spectrometer 
was set for information dependent acquisition (IDA) scanning full spectra (350-1250 
m/z), followed by 20 MS/MS on multiple charged ions (+2 to +5) and performed one 
MS/MS before adding those ions to the exclusion list for 15s (mass 
spectrometer operated by Analyst® TF 1.6, ABSciex).  
Protein identification was accomplished using Protein Pilot software (v4.5, 
ABSciex) with the following search parameters: SwissProt database, against E. coli and 
all species, SwissProt database with DJ-1 mutants in study, against all species; trypsin 
digestion; acrylamide as cysteine alkylating reagent; thorough ID search effort, and 
0.05 unused ProtScore (10% confidence score) as detected protein threshold. Data 
analysis was based on an independent False Discovery Rate analysis (FDR) using the 
target-decoy approach (5% critical FDR). When the analysis based on FDR was not 
possible to perform, the criteria used in positive identification were proteins 
presenting at least 95% confidence and unused score of 1.3 or more. Proteins with a 
single peptide hit were considered if the individual confidence was above 95% and a 
minimum sequence tag of 3 amino acids (4 consecutive peaks in the MS/MS 
spectrum). 
 
2.5. INTACT PROTEIN ANALYSIS BY LC-MS  
To analyze the intact DJ-1 WT and mutants, 400pmols of each protein were 
mixed with 6 volumes of acetone at -20oC and incubated at -20oC for 20 minutes. After 
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that time the samples were centrifuged at 20 000g (Eppendorf Centrifuge 5417R), 4oC 
for 20 minutes. The pellet was resuspended in 15µl of 2% ACN and 0.1% FA and 
transferred into vials for further LC-MS analysis. Protein analysis was carried out on a 
hybrid quadrupole time-of-flight mass spectrometer (Triple TOF™ 5600 System; 
ABSciex). Proteins separation was performed using liquid chromatography (nanoLC 
Ultra 2D, Eksigent) on a ChromXP™ C18 reverse phase trap-column (300 µm ID × 
0.5mm length, 3µm particles, 120Å pore size, Eksigent) at 7µL/min. Proteins were 
eluted into the mass spectrometer with an acetonitrile gradient in 0.1% FA (2% to 50% 
ACN, in a multiple step gradient for 10min), using an electrospray ionization source 
(DuoSpray™ Source, ABSciex) with the Intact Protein mode activated. The mass 
spectrometer was set for full spectra scanning (600-1250 m/z, operated by Analyst® TF 
1.6, ABSciex). Intact mass was determined using BioAnalyst™ Software (ABSciex). 
Briefly, the deconvolution of the spectra was obtained by Baesian Protein Reconstruct 
of the average of the spectra, with the following parameters: mass range from 15 to 
30kDa (defined according with the expected protein molecular weight), spectrum limit 
range from 620 to 1260m/z (defined according to the protein charge envelope profile), 
signal to noise threshold around 10 (determined by a script present in Analyst software 
that is based in the ratio from the less intense peak used in calculation and the 
spectrum noise). A peak from the isotopic distribution of the deconvoluted spectrum 
was chosen to modeling the data and subsequently calculate the molecular weight of 
the protein. 
 
2.6. SIZE EXCLUSION-HPLC 
Size exclusion (SE) - High-performance liquid chromatography (HPLC) was 
performed using a Prominence Shimadszu system (Shimadzu Scientific Instruments) 
and a Superdex 200 5/150 GL column (GE Healthcare), and data were collected and 
analyzed by LC Solution Software (Shimadzu Scientific Instruments). The proteins were 
eluted using PBS with 10% glycerol (the same buffer in which the proteins were stored) 
at a flow rate of 0.4mL/min and monitoring absorbance at 214nm. Apparent molecular 
weights of eluted proteins were determined using a calibration curve established with 
the following standards: aprotinin (6.5kDa) (AppliChem), Ribonuclease A (13.7kDa), 
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Carbonic anhydrase (29kDa), Ovalbumin (44kDa), Conalbumin (75kDa), Aldolase 
(158kDa), Ferritin (440kDa), and Blue Dextran (≈2 000kDa) (all from GE Healthcare).  
 
2.7. CIRCULAR DICHROISM 
The secondary structure of DJ-1 wild-type and mutant proteins was evaluated 
by Circular Dichroism (CD) spectroscopy. The proteins were dissolved in PBS buffer 
containing 10% glycerol at concentrations around 2.0mg/mL as determined by 
ultraviolet (UV) absorbance measurements. Far UV CD spectra were acquired on an 
Olis DSM 20 circular dichroism spectropolarimeter continuously purged with nitrogen, 
equipped with a Quantum Northwest CD 150 temperature-controlled cuvette and 
controlled by the GlobalWorks software. Spectra were recorded at 37oC between 190 
and 260nm at 1 nm intervals using a 0.05mm pathlength cuvette. Two scans obtained 
with an integration time of 6 seconds were averaged and corrected by subtracting a 
baseline spectrum acquired under the same experimental conditions. The results are 
expressed as the mean residue molar ellipticity [Θ]MRW (deg cm2 dmol-1) defined as 
[Θ]MRW = Θobs × 100 × MW / (l × c × N), where Θobs is the observed ellipticity (mdeg), 
MW is the protein molecular weight (g mol-1), l is the cuvette pathlength (cm), c is the 
protein concentration (mg mL-1) and N is the number of aminoacid residues of the 
protein. The secondary structure contents were calculated with the GlobalWorks 
software using the CONTILL, CDSSTR and Selcon3 algorithms against the CLSTR 
reference basis set which contains soluble and denatured proteins with known 
secondary structure.  
 
2.8. THERMAL SHIFT 
Fluorescent dye Sypro orange (Sigma-Aldrich), an environmentally sensitive 
dye, was used to monitor protein unfolding. The unfolding process exposes the 
hydrophobic region of proteins and results in a large increase in ﬂuorescence that is 
used to monitor the protein-unfolding transition. The thermal shift assay was 
conducted in the 7500 Fast Real-time PCR system (Applied Biosystems), originally 
designed for PCR. The system contains a heating/cooling device for accurate 
temperature control and a charge-coupled device (CCD) detector for simultaneous 
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imaging of the ﬂuorescence changes in the wells of the microplate. To each well of the 
MicroAmp Optical 96-well reaction plate (Applied Biosystems) 5µL of 50x Sypro 
orange was added, the correspondent volume of protein to a final concentration of 
0.5mg/mL and 0.2mg/mL, and buffer (PBS with 10% glycerol) to the final volume of 
50µL. The plate was heated from 25 to 95oC with a heating rate of 1oC/min. The 
ﬂuorescence intensity was measured with excitation/emission wavelengths of 
490/580nm. 
 
2.9. DJ-1 AND DJ-1 MUTANTS MEDIATED NEUROPROTECTION 
2.9.1. CELL CULTURE 
Human neuroblastoma SH-SY5Y cells were cultured in Dulbecco's modified 
Eagle medium (DMEM) with Glutamax™ and low glucose (1g/L) (Gibco) supplemented 
with 10% fetal bovine serum (FBS) (Gibco), 1.25µg/mL of amphotericin B solution 
(Invitrogen) and 1% penicilin-streptomycin solution (Pen-Strep) (Cambrex). Dulbecco's 
phosphate buffered saline (DPBS) (Cambrex, Charles City, IA) was used to wash the 
cells and trypsin-EDTA (0.05% solution in phosphate buffered saline (PBS)) (Invitrogen) 
to detach for cell passage. Cells were maintained at 37oC and 95% air/ 5% CO2 
atmosphere in a humidified incubator (Shel Lab 3517-2) (Sheldon Manufacturing, Inc.). 
For the neuroprotection assays, SH-SY5Y cells were seeded at 30x103cells/cm2 
in DMEM with 10% FBS in 96 well plates (Corning) at 37oC, 5% CO2/95% air in a 
humidified incubator (Sheldon Manufacturing, Inc.) for 4h.  
 
2.9.2. OXIDATIVE STRESS STIMULI 
Four hours after plating, cells were stimulated with different concentrations (0, 
100 and 200µM) of hydrogen peroxide (Sigma-Aldrich) in DMEM with 0.1% of FBS in 
the presence or absence of recombinant His-tagged human DJ-1 protein (1μM), 
recombinant His-tagged human DJ-1 mutants (E163K, C106A or C106DD) or the 
corresponding vehicle (PBS with 10% of glycerol) for 24h. Change of the culture 
medium to DMEM with 0.1% of FBS was used as control condition. 
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2.9.3. CELL VIABILITY ASSESSMENT 
Cell viability was performed in white opaque 96-well plates (Corning) using the 
Cell Titer-Glo® Luminescent assay (Promega). The luminescent signal was detected by a 
LUMIstar Galaxy automated microplate luminescence reader (BMG Labtech), 
according to the manufacturer’s instructions. Briefly, this method determine the viable 
cell number based on bioluminescent quantitation of the ATP present in the sample, 
which indicates the presence of metabolically active cells.  
 
2.10. PULL-DOWN ASSAYS 
2.10.1. OXIDATIVE STIMULI 
SH-SY5Y cells were seeded at 75 000 cells/cm2 in DMEM medium with 10% FBS. 
After 24h, serum starvation was induced by changing the culture medium to DMEM 
medium with 0.1% FBS. The stimulus was performed 16h afterwards with the addition 
of 1mM of H2O2 in DMEM medium with 0.1% FBS to the cells for different time points: 
0, 15 and 40 minutes. Once stimulation time was over and to finish the stimulation, the 
cell culture medium was removed and PBS at room temperature was added to the 
cells.  
 
2.10.2. PROTEIN EXTRACTS 
After cell washing with PBS, cells were placed on ice and scraped with ice-cold 
Extraction Solution (ES) (IP (from Dynabeads co-immunoprecipitation kit, Invitrogen), 
100mM of NaCl, Complete Mini protease inhibitor mixture and Complete Mini 
phosphatase inhibitor mixture (Roche Diagnostics)), harvested to centrifuge tubes and 
incubated on ice for 15 minutes. After that time cells were centrifuged at 2 600g for 5 
minutes at 4oC. Later, the supernatant (protein extract) was collected to new tubes. A 
sample of the protein extract was collected to calculate the protein concentration 
using the BCA protein determination assay (Thermo Fisher Scientific) and the 
remaining extracts were frozen at -80°C until further use. 
 
56 | 
Experimental Procedures | 
2.10.3. PROTEIN QUANTIFICATION – BCA ASSAY 
The bicinchoninic acid (BCA) assay was used to determine the protein 
concentration in protein extracts. Bovine serum albumin (BSA) was used as standard 
and the assay was performed following the manufacturer protocol (Pierce as part of 
Thermo Fisher Scientific, Rockford, IL) for microwell plates. Shortly, the standards were 
prepared in IP buffer (IP and 100 mM of NaCl), then samples and standards were 
mixed with BCA Working Reagent in a 1:8 proportion and incubated for 30 minutes at 
37oC. After that time, samples´ absorvance was measured at 562nm on a Microplate 
Spectrophotometer (PowerWave XS, BioTek, Bad Friedrichshall, Germany). Using the 
results, the calibration curve was obtained and the protein extract concentration was 
interpolated from it.  
 
2.10.4. PULL-DOWN 
Initially the HisTrap resin (Ni Sepharose™ High Performance GE Healthcare) was 
resuspended in approximately 50 times the resin volume of PBS with 10% glycerol and 
40mM imidazole and centrifuged at 1 000g for 3 minutes. This process was repeated 
twice. After supernatant removal, enough volume of PBS and 40mM imidazole was 
added to the resin to allow distribution of 60µL of resin (Ni Sepharose™ High 
Performance HisTrap™ HP - GE Healthcare) into each tube. The resin was incubated 
with 5µg of recombinant DJ-1 wild-type or mutants (amount determine for resin 
saturation) for 2h at 1 100 rpm and 4oC in a thermomixer (Eppendorf). Following 
centrifugation at 1 000g for 3 minutes, the supernatant containing proteins that did 
not bind to HisTrap resin was collected to a clean tube. The resin was washed with 
500µL of PBS and 40mM imidazole, centrifuged at 1 000g for 3 minutes and the 
supernatant was recovered to a new tube. The previous procedure was repeated three 
times. Then, the resin was incubated with protein extracts (obtained under normal and 
oxidative stress conditions – section 2.10.2) for 16h at 4oC and 900 rpm. After that 
time, the tubes were centrifuged at 1 000g for 3 minutes and the supernatant was 
recovered. One milliliter of IP buffer was added to the resin, the tubes were 
centrifuged at 1 000g for 3 minutes and the supernatant recovered. This process was 
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repeated three times. Finally, the resin with the proteins attached was denatured with 
30µL of Laemmli Sample Buffer 2x (65.8mM Tris-HCl, pH 6.8, 2.1% SDS, 26.3% (w/v) 
glycerol, 0.01% bromophenol blue) (Bio-Rad) at 95oC for 15 minutes at 14 000 rpm in a 
thermomixer. The fractions of interest were electrophoretically separated using a 
polyacrylamide gel electrophoresis and other fractions and supernatants were stored 
at -20oC until further use. 
 
2.10.5. GEL SEPARATION, GEL BAND PROCESSING AND PEPTIDE EXTRACTION 
Pull-down samples, containing resin with DJ-1 WT, DJ-1 mutants and their 
interactors, were electrophoretically separated in a pre-cast 4-20% SDS-polyacrylamide 
gel (Bio-Rad)  using a Mini-PROTEAN Tetra Electrophoresis System (Bio-Rad) for 15min 
at 110V. Gel staining and processing was done as described in section 2.3 with 
modifications after sample evaporation and before trypsin addition. In this case, 50µL 
of DTT was added and incubated with agitation at 25oC, for 30min at 850rpm. Then the 
DTT was removed and the samples were evaporated for 30min to allow the addition of 
50µL of acrylamide and incubation with agitation at 25oC, for 30min at 850rpm. After 
that, the acrylamide was removed and samples were evaporated for 30min. Finally, 
200µL of water was added and removed to allow the hydration of the gel pieces and 
samples were dried on a Concentrador Plus (Eppendorf).  
 
2.10.6. PROTEIN IDENTIFICATION AND QUANTIFICATION 
Samples were analyzed on an AB Sciex 5600 TripleTOF in two phases: 
information-dependent acquisition (IDA) followed by SWATH (Sequential Windowed 
data independent Acquisition of the Total High-resolution Mass Spectra) acquisition, 
on the same sample. Peptides separation was performed using liquid chromatography 
(nanoLC Ultra 2D, Eksigent) on a Halo Fused-Core C18 reverse phase column (300µm ID 
× 15cm length, 2.7µm particles, 90Å pore size, Eksigent) at 5µL/min. Peptides were 
eluted into the mass spectrometer with an acetonitrile gradient in 0.1% FA (2% to 30%, 
in a linear gradient for 45 min),  using an electrospray ionization source (DuoSpray™ 
Source, ABSciex). Rolling collision was used with a collision energy spread of 5. One 
third of the volume of each sample was analyzed using classical shotgun data 
58 | 
Experimental Procedures | 
acquisition. The mass spectrometer was set for IDA scanning full spectra (350-
1250m/z) for 250ms, followed by up to 20 MS/MS scans (100–1500 m/z for 100ms 
each). Candidate ions with a charge state between +2 and +5 and counts above a 
minimum threshold of 70 counts per second were isolated for fragmentation and one 
MS/MS spectra was collected before adding those ions to the exclusion list for 15 
seconds (mass spectrometer operated by Analyst® TF 1.6, ABSciex). Two thirds of the 
volume of each sample were set for quantitative analysis by acquisition in SWATH 
mode. The SWATH setup was essentially performed as in Gillet et al [158], with the 
same chromatographic conditions used as in the IDA run described above. For SWATH-
MS–based experiments, the mass spectrometer was operated in a looped product ion 
mode. The instrument was specifically tuned to allow a quadrupole resolution of 25-
m/z mass selection. Using an isolation width of 26 m/z (containing 1 m/z for the 
window overlap), a set of 29 overlapping windows was constructed covering the 
precursor mass range of 350–1100 m/z. A 50 ms survey scan (350-1500 m/z) was 
acquired at the beginning of each cycle for instrument calibration and SWATH MS/MS 
spectra were collected from 100–1500 m/z for 100 ms resulting in a cycle time of 3.25s 
from the precursors ranging from 350 to 1100 m/z. The collision energy for each 
window was determined according to the calculation for a charge 2+ ion centered 
upon the window with a collision energy spread of 15.    
 
2.10.6.1. LIBRARY GENERATION AND SWATH DATA FILE PROCESSING 
A specific library of precursor masses and fragment ions was created for each 
recombinant protein used in the interactomic study – by combining all files from IDA 
experiments - and used for subsequent SWATH processing. Libraries were obtained 
using Protein Pilot software (v4.5, ABSciex) with the following search parameters: 
canonical SwissProt complete proteome database for human with DJ-1 mutants in 
study and iRTs peptides; trypsin digestion; acrylamide as cysteine alkylating reagent; 
thorough ID search effort, and 0.05 unused ProtScore (10% confidence score) as 
detected protein threshold. Data analysis was based on an independent False 
Discovery Rate (FDR) analysis using the target-decoy approach.  
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Prior to data processing, peptides were selected automatically from the library 
using the following criteria: (i) the unique peptides for a specific targeted protein were 
ranked by the intensity of the precursor ion from the IDA analysis as estimated by the 
ProteinPilot software, and (ii) Peptides that contained biological modifications and/or 
were shared between different protein entries/isoforms were excluded from selection. 
Up to 15 peptides were chosen per protein, and SWATH quantitation was attempted 
for all proteins in library files that were identified below 5% local FDR from ProteinPilot 
searches. In SWATH™ Acquisition data, peptides are confirmed by finding and scoring 
peak groups, which are a set of fragment ions for the peptide. 
Target fragment ions, up to 7, were automatically selected following the criteria 
described in Lambert et al [159]: (i) Fragment ions for a selected peptide were ranked 
according to ion intensity; (ii) ions higher in m/z than the y4 fragment ion for each 
selected peptide were ranked highest; (iii) ions within the SWATH isolation window 
were excluded from selection; (iv) if insufficient target ions were found, ions lower 
than y4 but outside of the SWATH window were chosen; (v) if there were still 
insufficient ions, then fragment ions from within the SWATH window region were 
chosen.  
Peak groups were scored following the criteria described in Lambert et al [159], 
briefly, each target fragment ion was scored based on the retention time adjustment, 
peak width overlap, peak intensity ratio, correct isotopic state, m/z error and MS/MS 
score. The individual peak group scores were combination of all subscores (scores from 
fragment ions) and the peak group with the best score was taken forward. Peak group 
confidence threshold was determined based on a FDR analysis using the target-decoy 
approach and 1% extraction FDR threshold was used for all the analyses. 
Peptide features (i.e., peptides in a given charge state) that met the 1% FDR 
threshold in all the experiments were retained, and the peak areas of the target 
fragment ions of those peptides were extracted across the experiments using a 
extracted-ion chromatogram (XIC) window of 5 minutes.   
Protein levels were estimated by summing all the transitions from all the 
peptides for a given protein (an adaptation of [160]). Protein levels were normalized 
for the levels of a peptide used as internal standard (the iRT peptide that 
demonstrated more stability (low %CV) across 4 analytical replicates). To identify the 
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true protein interactions, normalized data were compared between DJ-1 pull-down 
assays and resin (negative control). Only proteins which have twice or more the 
intensity in DJ-1 pull-down assays compared to resin were considered true 
interactions.  
For comparisons between DJ-1 purifications across the time course, abundances 
were normalized with respect to the four most abundant tryptic peptides from DJ-1. 
All comparisons were made to the control condition (0 min of hydrogen peroxide 
stimulus). 
 
2.11. BINDING PARTNERS QUALITATIVE ASSESSMENT  
Venn diagrams were used to compare the number of binding partners that are 
shared or unique among two or more conditions. The Venn diagram tool 
(http://bioinformatics.psb.ugent.be/webtools/Venn/) from Bioinformatics & 
Evolutionary Genomics was used. The lists containing the proteins from the desired 
conditions to be compared were uploaded and the selected output was symmetric 
Venn diagrams. The tool generates a Venn diagram of the inserted conditions and a 
“.txt” file containing the accession numbers of the analyzed proteins and the 
distribution of these proteins within the different conditions compared. Both diagrams 
and “.txt” files were downloaded and presented as results or used in further analysis. 
 
2.12. GENE ONTOLOGY (GO) ENRICHMENT ANALYSIS 
GO enrichment analysis was performed for each binding partners list, using the 
web-based application Gene Ontology enRIchment anaLysis and visuaLizAtion tool – 
GOrilla (http://cbl-gorilla.cs.technion.ac.il/) [161]. 
GOrilla helps to identify and visualize enriched GO terms in genes or proteins 
lists. The output of this analysis is visualized as a hierarchical structure, using a DAG 
(directed acyclic graph) graphical representation with color-coding that reflects the 
enrichment degree based on the p-value. Additionally, the nodes are clickable giving 
further information displayed on a table with information of the enriched GO terms 
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analyzed, their enrichment p-values and the relevant annotated genes/proteins used 
in the analysis. This data can be exported as an Excel file.  
All the analyses were done for the Homo sapiens species, in the single ranked 
list of genes running mode and based on biological process. Both diagram and excel file 
were exported and presented as results or used in further analysis.  
 
2.13. STATISTICAL ANALYSIS 
Statistical analysis of results from cell viability was performed using SPSS 
(Statistical Package for the Social Sciences) version 20.0 (IBM®). Statistical significance 
was considered relevant for *р < 0.05, **р < 0.01 and ***р < 0.001 using one-way 
ANOVA (Analysis Of Variance). Parametric assumptions (data normality and 
homoscedasticity) were tested using Shapiro-Wilk Test and Levene’s Test, respectively. 
Data presented as mean ± standard error of the mean (S.E.M.).  
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DJ-1 has been unequivocally linked to familial early onset Parkinson´s Disease 
[43, 81] and although its exact function has not been determined, this protein is widely 
recognized as involved in oxidative stress response, a main feature in preservation of 
neurons viability [2, 67]. Importantly, cysteine in position 106 is crucial in 
neuroprotection mediated by DJ-1 due to its essential role in DJ-1 acidic pI shift in 
oxidative stress conditions [80, 100]. 
DJ-1 mutations trigger loss of the protein neuroprotective function leading to 
the development of PD [75, 89]. PD-linked mutations associated to DJ-1 comprise 
natural and also engineered mutations developed to mimic and study the oxidative 
states of this protein [45, 101].  
Understanding the role and mechanisms of this protein can give insight into the 
pathogenesis of PD [94]. Therefore, in order to study the effect of DJ-1 mutations in 
neuronal cells under normal and stress conditions the project comprises the 
production, purification, structural characterization, viability and interactomic assays 
of DJ-1 wild-type and mutants E163K, C106A and C106DD. Specifically and following 
the project plan, the first step was confirmation of sequences mutation followed by 
production and purification of the proteins for further characterization by size 
exclusion chromatography, circular dichroism, thermal shift and mass spectrometry, 
study of the neuroprotective effect in a neuronal cell line and finally characterize the 
dynamic interactome of each protein. 
 
It is worth mentioning that DJ-1 WT was produced and purified by Matilde and 
kindly given to be used and studied in the project assays. Furthermore, in this project 
major emphasis will be given to the study of the mutants E163K, C106A and C106DD. 
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3.1. NUCLEOTIDE SEQUENCING 
In order to produce the DJ-1 mutants of interest, the first step was to construct 
plasmids containing each mutated DJ-1 gene, in this case the plasmid previously used 
to produce DJ-1 WT (see Experimental Procedures – 2.1). Before plasmids 
incorporation into competent cells, the sequence of DJ-1 gene needed to be confirmed 
for the presence of the correct mutated nucleotides. Thus, all plasmid DNA obtained 
was sequenced by Sanger DNA Sequencing method and the results from C106DD 
mutant showed the correct substitution (Figure 3.1). 
 
 
Figure 3.1 | DNA SEQUENCING RESULTS FOR THE DJ-1 MUTANT C106DD CODIFIYING SEQUENCE. 
Nucleotide sequence alignment of small fragments of DJ-1 mutant C106DD gene sequenced (A), its 
corresponding sequence in the C106DD designed plasmid (B) and in the DJ-1 WT designed plasmid (C). 
The codon containing the mutation is highlighted. The codon substitution was TGT to GAT GAT. 
  
Comparing to the DJ-1 WT gene it was verified the insertion of nucleotides as 
expected since this mutation implicates the substitution of one codon by two codons. 
Given this, it was confirmed the design of a plasmid DNA with the DJ-1 gene 
incorporating the C106DD mutation and it was possible to proceed to the production 
and purification of the mutated proteins. 
 Similar results were obtained for the sequencing of mutants C106A and E163K 
(Supplementary Figure 7.1). 
 
3.2. DJ-1 MUTANTS PRODUCTION AND PURIFICATION 
3.2.1. PRODUCTION AND PURIFICATION – AFFINITY AND SIZE EXCLUSION 
CHROMATOGRAPHIES 
The plasmids previously constructed and sequences verified were used for 
protein production followed by protein purification. The recombinant mutants E163K, 
C106A and C106DD, containing a His-tag, were expressed in E. coli XL1 blue competent 
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cells and purified by affinity chromatography using a HisTrap column followed by a 
size-exclusion chromatography using a Superdex 200 column. The HisTrap column was 
used to purify the recombinant DJ-1 and mutants from the culture medium, and to 
separate the homodimeric DJ-1 from DJ-1 oligomers the Superdex 200 column was 
used.  
The affinity chromatography (Figure 3.2) was performed using an imidazole 
step gradient (20mM sodium phosphate, 500mM NaCl, 20mM Imidazole, pH 7.2) and 
from the fractions recovered, only fraction 4 did not contained DJ-1. The highest value 
of optical density (OD) was observed in fraction 3, which suggests that this fraction 
contains a higher protein content. Therefore, and since in this elution step 300mM of 
imidazole were used, most of the proteins which do not contain the hexahistidine 
peptide have already been eluted, and this was the fraction chosen to load into the 
Superdex 200 column to perform a size exclusion chromatography. 
 
Figure 3.2 | AFFINITY CHROMATOGRAPHY PURIFICATION OF DJ-1 C106DD. The affinity 
chromatography was performed using a HisTrap column. Imidazole step gradient (50mM, 100mM, 
300mM and 500mM) is shown in dashed line. The grey bars correspond to the fractions that were 
collected from each elution step - fraction 1, 2, 3 and 4 eluted with 50, 100, 300 and 500mM of 
imidazole, respectively. 
  
 
The size exclusion chromatography allowed the recovery of two protein 
fractions (Figure 3.3) with the second one containing a higher protein content as 
shown by the highest OD at 280nm. Both fractions were collected and further analyzed 
with major interest in fraction 2. 
For the other mutants, similar results were obtained from affinity and size 
exclusion chromatography (Supplementary Figure 7.2 and Supplementary Figure 7.3). 
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Figure 3.3 | SIZE EXCLUSION CHROMATOGRAPHY PURIFICATION OF DJ-1 C106DD. Fraction 3 recovered 
from the affinity chromatography (Figure 3.2) was applied in an HiLoad 26-60 Superdex 200 column, 
using PBS as the mobile phase. The grey bars represent the fractions that were collected (fraction 1 and 
2). 
 
3.2.2. PROTEIN CONCENTRATION 
After the fractions of interest for each protein have been recovered, the 
protein concentration was determined by measuring the absorbance at 280nm 
(NanoDrop). The blank used in this procedure was the buffer in which the protein was 
and would be stored (PBS with 10% glycerol) and the result obtained was 2.19µg/µL 
for fraction 2 of the C106DD mutant. The protein concentration of the remaining 
mutants is shown in Supplementary Table 7.1. 
 
3.2.3. PROTEIN PURIFICATION ASSESSMENT 
The fractions recovered during the production and purification steps were 
resolved in a SDS-PAGE in order to evaluate the protein profile (Figure 3.4 and Figure 
3.5). In the case of protein expression the fractions recovered and analyzed were the 
BI (cellular extract obtained before induction of protein expression), AI I (insoluble 
protein fraction obtained from centrifugation after induction of protein expression) 
and AI S (soluble protein fraction obtained after induction of protein expression), and 
in protein purification using affinity chromatography the BL (cellular extract loaded on 
the HisTrap column), FT (flow-through obtained from HisTrap column), HT 1 (fraction 1 
eluted from the HisTrap column), HT 2 (fraction 2 eluted from the HisTrap column), HT 
3 (fraction 3 eluted from the HisTrap column) and HT 4 (fraction 4 eluted from the 
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HisTrap column (Figure 3.2)) (Figure 3.4). In the size exclusion chromatography the 
fractions were the Sx1 and Sx2, in protein concentration the BC Sx2, FT Sx2 and AC Sx2 
and the stored protein sample was the C106DD (Figure 3.5).  
 
 
Figure 3.4 | ANALYSIS OF DJ-1 C106DD EXPRESSION AND PURIFICATION BY SDS-PAGE. SDS-PAGE 
followed by Coomassie staining. MW – molecular weight marker: NZY Colour Protein Marker II 
(NZYTech); BI – cellular extract obtained before induction of protein expression; AI I – insoluble protein 
fraction obtained from centrifugation after induction of protein expression; AI S – soluble protein 
fraction obtained after induction of protein expression; BL – cellular extract loaded on the HisTrap 
column; FT – flow-through obtained from HisTrap column; HT 1 –fraction 1 eluted from the HisTrap 
column; HT 2 - fraction 2 eluted from the HisTrap column; HT 3 – fraction 3 eluted from the HisTrap 
column; HT 4 - fraction 4 eluted from the HisTrap column (Figure 3.2). The sample volume added to each 
well was 10µL. 
 
 
The results show that there isn´t any intense band at approximately 22 kDa, 
which is the molecular weight of DJ-1 monomer in the sample obtained before 
induction (BI). The same was observed in the insoluble sample recovered after 
induction of protein expression (AI I). On the other hand, in the soluble sample 
recovered after induction of protein expression (AI S) an intense band at 
approximately DJ-1 monomer molecular weight was observed that indicated that DJ-1 
was produced in a soluble form and not in inclusion bodies (AI I). In addition, from 
samples BI to AI it was observed enrichment in DJ-1, which means that after IPTG 
induction, the cells produced recombinant DJ-1. When a HisTrap column is used to 
purify the protein it can be seen the presence of the DJ-1 monomer band with high 
intensity in the sample loaded into the column (BL) that means that DJ-1 was loaded 
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into the column but there was also an intense band in the flow through (FT) recovered 
after sample loading into the column, which indicate that a large amount of DJ-1 was 
also lost. From all the fractions recovered from the protein elution of the HisTrap 
column, only fraction 4 did not contained an intense band around 22kDa.  
 
Figure 3.5 | ANALYSIS OF DJ-1 C106DD SIZE EXCLUSION CHROMATOGRAPHY BY SDS-PAGE. SDS-PAGE 
followed by Coomassie staining. MW – molecular weight marker: NZY Colour Protein Marker II 
(NZYTech); After loading the fraction HT 3 from the HisTrap elution on a HiLoad 26/60 Superdex 200 
prep grade fractions 1 (Sx 1) and 2 (Sx 2) were recovered; BC Sx 2 – sample containing fraction 2 
obtained from Superdex 200 before concentration; FT Sx 2 – flow-through obtained from concentration 
of fraction 2; AC Sx 2 - purified DJ-1 C106DD obtained after concentration of fraction 2; C106DD – 
sample AC Sx 2 stored in PBS with 10% glycerol at -80°C. The sample volume added to each well was 
10µL. 
 
The results obtained from the SDS-PAGE showed an intense band 
corresponding to DJ-1 (≈22kDa) in fraction 2 obtained from elution of the Superdex 
200 column (Sx 2), in the fraction that was concentrated (BC Sx 2), in the fraction 
obtained after protein concentration (AC Sx 2) and in sample stored (C106DD) (Figure 
3.5). In fraction 1 acquired after elution from the Superdex 200 column (Sx 1) this band 
is much less intense and in the flow through recovered after protein concentration (FT 
Sx 2) the band is almost undetectable.  
For the other proteins being used in this study (DJ-1 WT, C106A and E163K) 
similar results were obtained (Supplementary Figure 7.4 to 7.6). 
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3.3. SEQUENCE ANALYSIS BY LC-MS/MS 
The protein sequence of DJ-1 WT and mutants was confirmed by LC-MS/MS 
after protein digestion (see Experimental Procedures – 2.4). The C106DD mutant was 
identified with a Protein Pilot unused score of 141.28, a sequence coverage of 99.5% 
(the initial methionine was not identified) (Figure 3.6) and 115 peptides were 
identified with 95% or more confidence. The loss of the initial methionine is very 
common since a significant number of intracellular proteins produced in E. coli are 
post- or co-translational modified and the amino-terminal is removed enzymatically by 
the methionine aminopeptidase [162]. 
 
Figure 3.6 | SEQUENCE COVERAGE OF DJ-1 MUTANT C106DD. Green letters represent the residues 
identified in peptides with at least 95% confidence; grey letters represent the unidentified residues. 
Mutated residues are highlight in yellow.  
 
 Similar results were obtained for DJ-1 WT and mutants C106A and E163K 
(Supplementary Figure 7.7 to 7.9). 
 
3.4. PROTEIN CHARACTERIZATION 
After proteins production and purification, they were characterized to ensure 
protein structure and stability to use in further assays, including neuroprotection and 
interactomics. Thus, the secondary and quaternary structures of each protein were 
evaluated by circular dichroism and size exclusion (SE) - high-performance liquid 
chromatography (HPLC), respectively. The thermal stability was also assessed by 
thermal shift and the protein´s molecular weight was confirmed by LC-MS. Moreover, 
protein´s identification and contaminants identification were performed using LC-
MS/MS. 
 
3.4.1. SIZE EXCLUSION (SE) – HPLC 
Many studies report that the functional structure of DJ-1 is its homodimeric 
form [66, 69]. Moreover, it has been reported that the DJ-1 mutants in study (C106A, 
MGSSHHHHHHDYDIPTTENLYFQGHMASKRALVILAKGAEEMETVIPVDVMRRAGIKVTVAGLAGKDPVQC
SRDVVICPDASLEDAKKEGPYDVVVLPGGNLGAQNLSESAAVKEILKEQENRKGLIAAIDDAGPTALLAHEIGFG
SKVTTHPLAKDKMMNGGHYTYSENRVEKDGLILTSRGPGTSFEFALAIVEALNGKEVAAQVKAPLVLKD 
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C106DD and E163K) retain the homodimeric form despite the loss of protein function 
[90, 97, 99]. Given this, assessment of the quaternary structure of these proteins is 
essential and thus a SE - HPLC was performed in which the absorbance was measured 
at 214 nm over elution volume (Figure 3.7). 
 
Figure 3.7 | HPLC-SIZE EXCLUSION CHROMATOGRAMS OF PURIFIED DJ-1 WT AND MUTANTS C106A, 
C106DD AND E163K. Standards molecular weight (black dots) from left to right: Ferritin (440kDa); 
Aldolase (158kDa); Conalbumin (75kDa); Ovalbumin (44kDa); Carbonic Anhydrase (29kDa); Ribonuclease 
A (13.7kDa); Aprotinin (6.5kDa). The table shows the proteins´ legend as well as the elution volume at 
which the protein was retrieved and the corresponding molecular weight. El. Vol. – Elution volume; MW 
– molecular weight.  
 
With the obtained elution volume (2.07mL), and using the elution volumes of 
standards, it is possible to calculate the approximate molecular weight of the produced 
proteins (Supplementary Figure 7.10). The molecular weights obtained were around 
41kDa for the WT and C106A, approximately 37 and 45kDa for E163K and C106DD 
mutants, respectively. These values correspond to the molecular weight reported in 
the literature for the DJ-1 dimer [68]. The differences observed were considered small 
taking into account the wide range of the calibration curve (from 6.5kDa to 440kDa) 
and therefore even the E163K mutant was also considered to be present in the dimeric 
form. In addition, the results show that in the case of DJ-1 mutants E163K and C106DD 
there is another peak around 1.1mL and based on the value of molecular weight 
obtained for these peaks – 1 801kDa and 1 664kDa, respectively – the corresponding 
proteins seemed to be forming oligomers. This means that the purified proteins DJ-1 
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E163K and C106DD have not only the protein in the homodimeric form, considered the 
functional form, but also a small amount of protein in the oligomeric form, a 
nonfunctional form [69, 92, 163].  
 
3.4.2. LC-MS OF INTACT PROTEINS 
The LC-MS/MS analysis of the digested proteins shows that the protein 
sequence obtained was according with the expected from the vector, and that the 
initial methionine was not identified. However, this analysis does not indicate if the 
protein is present on its intact form, or if is a mixture of non-complete sequences. In 
order to elucidate if the protein has its correct molecular weight, an intact protein 
analysis was performed by LC-MS (Figure 3.8).  
A 
 
B 
 
Figure 3.8 | LC-MS ANALYSIS OF INTACT DJ-1 MUTANT C106DD. A - Average spectra of protein charge 
envelop of intact C106DD (in blue). Deconvoluted mass spectrum of protein charge envelop of intact 
C106DD (in red). B - Graphic of deconvoluted masses using BioAnalyst. 
22867.03
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From the graphic of the deconvoluted masses and using the BioAnalyst Software the 
value of the predicted molecular weight of the intact protein can be retrieved (Figure 
3.8 - B). For the mutant C106DD in study, the value obtained was 22 867.037 Da 
whereas the value calculated using the Mass Calculator tool, without the initial 
methionine, was 22 865.953 Da. The values are similar presenting a shift of 1.085 Da. 
 The same analysis was applied to the other mutants and DJ-1 WT and the 
values of average, predicted masses, and the mass shift observed were similar 
(Supplementary Table 7.2). 
 
3.4.3. THERMAL SHIFT 
The thermal shift concept is based on protein unfolding due to the increase in 
the temperature, which allows the exposure of its hydrophobic regions. During this 
process, the dye binds to these regions and the fluorescence signal increases with the 
exposure of more hydrophobic regions. A spectrum is obtained and the melting 
temperature can be determined and used to assess the thermal stability of the purified 
proteins. To assess if the mutants in study affect the stability of DJ-1, thermal 
denaturation experiments were performed where the ﬂuorescence intensity was 
monitored while temperature increased 1oC/min from 25oC to 95oC in a thermal shift 
assay (Figure 3.9). 
 
Figure 3.9 | FIRST DERIVATIVE CURVES OF DJ-1 WT AND MUTANTS C106A, C106DD AND E163K 
OBTAINED FROM THERMAL SHIFT ASSAY. The concentration of the recombinant DJ-1 WT and its 
mutants was 0.5mg/mL. The temperature at the peak is the melting temperature (Tm). The first 
derivative curves and melting temperatures were obtained by the normalized curves analysis and 
transformation as explained in Supplementary data 7.6. The table displays proteins´ legend as well as 
the Tm obtained for each protein. 
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The concentration of all the protein samples was adjusted to 0.5mg/mL and the 
results revealed that the folded structure of DJ-1 WT was relatively stable and protein 
unfolding was achieved for a melting temperature (Tm – temperature at which 50% of 
the protein is denatured) of 63.5oC. The mutant presenting the higher thermal stability 
was the mutation C106A with a Tm of 65.6oC. The most thermally unstable mutant was 
E163K exhibiting a Tm of 54.0oC and the mutant C106DD presented a Tm similar to the 
DJ-1 WT displaying a value of 61.4oC. Of note, the reduced signal amplitude of mutants 
E163K and C106DD compared to DJ-1 WT and mutant C106A. This fact could be 
associated with the protein concentration used in this assay, since only two different 
concentrations were tested (0.2 and 0.5mg/mL) and the results showed that the most 
adequate curves were the ones corresponding to 0.5mg/mL (data not shown). 
However, no other concentrations were tested due to the reduced amount of mutant 
proteins available for further studies. 
 
3.4.4. CIRCULAR DICHROISM 
In addition to the assessment of the primary and quaternary structure of a 
protein, the secondary structure was also evaluated. Thus, DJ-1 and DJ-1 mutants 
secondary structure was determined by circular dichroism (Figure 3.10).  
 
Figure 3.10 | FAR-ULTRAVIOLET CIRCULAR DICHROISM SPECTRA OF DJ-1 WT AND MUTANTS C106A, 
C106DD AND E163K. CD spectra were obtained under normal conditions at 37oC using a 0.05mm cell. 
The protein concentrations used were approximately 2.0mg/mL.  
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At physiologic pH and 37oC the far-UV CD spectra of the DJ-1 mutants showed 
high similarities in shape to the DJ-1 WT, but exhibited a decreased signal amplitude, 
with this effect being more pronounced for the E163K mutant. Despite this, all CD 
spectra displayed a broad negative ellipticity from 208 to 222 nm, consistent with a 
mixed α/β structure. The secondary structure content was similar for all the mutants, 
containing 20 to 30% of structure in α-helix, 20 to 30% of structure in β-sheet and 
approximately 50% without regular secondary structure. For DJ-1 WT, the secondary 
structure content was higher for the structure in α-helix, with approximately 40%, 20 
to 25% of structure in β-sheet and around 40 to 50% without regular secondary 
structure. These values were calculated by the GlobalWorks software (described in 
Experimental Procedures – 2.7). 
 
3.4.5. LC-MS/MS ANALYSIS OF DIGESTED SAMPLES 
An important feature that needs to be evaluated in the production of a 
recombinant protein before its use in further biological assays is the determination of 
contaminants in the proteins samples. In this way, an analysis by LC-MS/MS to the 
digested samples was performed to identify all the proteins present in each sample 
(Table 3.1). For this analysis both liquid and gel digestions were made and the results 
from both were combined.  
Table 3.1 | PROTEIN IDENTIFICATION BY LC-MS/MS ANALYSIS OF EACH PURIFIED PROTEIN.  
     WT C106A C106DD E163K 
Name Accession Number Species MW (Da) Function UP US UP US UP US UP US 
DJ-1 Q99497 HUMAN 19,891 Stress Response 113 165.4 96 183.2 129 193.5 112 165.3 
Superoxide dismutase 
[Cu-Zn]  Q96VL0 CLAPU 15,839 
Antioxidant; 
Oxidoreductase    2 3.64 2 4 2 1.16 
Alpha-S1-casein  P02662 BOVIN 24,529 Antioxidant      2 4 2 3.72 
Beta-casein  P02666 BOVIN 25,107 Antioxidant 
(protease activity)     1 2 1 2 
Glutaredoxin-1  P68688 ECOLI 9,685 
Oxidoreductase; 
cell redox 
homeostasis 
2 3.04 2 2.67 2 2.35 2 3.19 
Thioredoxin-1  P0AA25 ECOLI 11,807 
Oxidoreductase; 
cell redox 
homeostasis 
5 8.64 5 8.47 4 8.01 4 8.06 
Glutathione reductase  P06715 ECOLI 48,773 Oxidoreductase      3 5.74 2 2.65 
FMN-dependent NADH-
azoreductase  P41407 ECOLI 21,658 Oxidoreductase      2 4.09   
Cytochrome b  Q34945 LUMTE 42,882 Oxidoreductase    2 1.72       
Hydrogenase-1 small 
chain  P69739 ECOLI 40,681 Oxidoreductase      1 2   
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Probable hypoxanthine 
oxidase XdhD  Q46814 ECOLI 103,519 Oxidoreductase        1 2 
4-hydroxy-3-methylbut-
2-en-1-yl diphosphate 
synthase  
Q5GRK4 WOLTR 47,381 Oxidoreductase       1 2 
Aldehyde dehydrogenase 
5, mitochondrial  P40047 YEAST 56,693 
Oxidoreductase 
(catabolic process)   1 1.54   1 2 
Ketol-acid 
reductoisomerase  A4IRH9 GEOTN 37,666 Oxidoreductase      1 2   
Protochlorophyllide 
reductase B, 
chloroplastic  
Q42850 HORVU 42,148 Oxidoreductase 1 2 1 0.74     
Ferric uptake regulation 
protein  P0A9A9 ECOLI 16,795 
Transcription 
regulation 
(repressor) 
  2 4 2 4 5 10 
Transcriptional 
regulatory protein CusR  P0ACZ8 ECOLI 25,395 
Transcription 
regulator 
(activator) 
1 2       
50S ribosomal protein 
L28  P0A7M2 ECOLI 9,006 
Translation 
(Ribonucleo-
protein) 
    1 2     
50S ribosomal protein 
L11P  A3CSJ5 METMJ 16,317 
Translation   
(RNA binding) 1 2 1 2     
Beta-lactoglobulin  P02754 BOVIN 19,883 Transporter 
(retinol binding)         2 4.01 1 1.32 
Fatty acid-binding 
protein, epidermal  Q01469 HUMAN 15,164 Transporter              2 4 
Ferrous iron transport 
protein B  P33650 ECOLI 84,474 Transporter      2 4         
Farnesyl diphosphate 
synthase  P22939 ECOLI  32,160 Transferase     2 3.28 2 5.08 1 2 
Cyclomaltodextrin 
glucanotransferase  P31797 GEOSE 78,923 
Transferase 
(carbohydrate 
metabolic process) 
1 0.22 2 3.77         
Glycerol-3-phosphate 
acyltransferase  A6Q218 NITSB 22,430 
Transferase 
(Lipid biosynthesis 
and metabolism) 
1               
Serum albumin  P02769 BOVIN 69,293 
DNA binding 
(negative 
regulation of 
apoptotic process) 
            3 3.29 
Putative two-component 
response regulator-like 
APRR6  
Q9C9F6 ARATH 86,182 DNA binding 1 0.24             
Uncharacterized protein 
yffS  P76550 ECOLI 29,751 DNA binding             1 2 
Minor capsid protein 10B  P19727 BPT7 41,830 Caspsid Protein     1 2 1 2     
Filaggrin-2  Q5D862 HUMAN 248,073 
Structural 
molecule 
(calcium binding) 
        1 2     
Dermcidin P81605 HUMAN 11,284 Peptidase    1 0.61 2 3.92 2 3.66 
Lysozyme C  P61626 BOVIN 16,537 Hydrolase 
(lysozyme activity)         2 4 1 2 
High-molecular weight 
cobalt-containing nitrile 
hydratase subunit alpha  
P21219 RHORH 22,835 Lyase     1 0.52     1 0.91 
Putative lipocalin 1-like 
protein 1  Q5VSP4 HUMAN 17,918 Binding to lipids         1 2.01 1 0.78 
Uncharacterized protein 
yaiL  P51024 ECOLI 19,923 Unknown 1 2             
Putative molybdate 
metabolism regulator  P33345 ECOLI 140,939 Unknown             1 2 
UP – Unique peptides;  US – Unused score;  CLAPU - Claviceps purpurea; ECOLI - Escherichia coli; LUMTE - Lumbricus terrestris; 
WOLTR – Wolbachia subsp. Brugia malayi; GEOTN - Geobacillus thermodenitrificans; HORVU - Hordeum vulgare; METMJ - 
Methanoculleus marisnigri; GEOSE - Geobacillus stearothermophilus; NITSB – Nitratiruptor sp.; ARATH - Arabidopsis thaliana; 
BPT7 - Enterobacteria phage T7; RHORH - Rhodococcus rhodochrous. 
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 Proteins were grouped by function where the considered most relevant are 
presented on the top of the table (Table 3.1). The most significant proteins in the DJ-1 
WT sample are the ones that have similar DJ-1 functions, such as antioxidant and 
oxidoreductase activity. On the other hand, for the DJ-1 mutants the proteins of 
interest are the ones that have functions that could lead to cell dysfunction and 
neurodegeneration, like proteins that play a role in transcription and transport. Worth 
mentioning that most of the protein contaminants are bovin and E. coli proteins. The 
presence of bovin proteins is explained by the use of LB medium in bacterial culture 
and E. coli was the host selected for cloning and expression of the proteins in study 
therefore proteins from this species could be commonly identified. 
 
3.5. DJ-1 WT MEDIATED NEUROPROTECTION 
Previous reports have shown a protective effect of exogenous DJ-1 addition 
after cells exposure to hydrogen peroxide [164, 165]. To address this issue, the 
neuroprotective effect of DJ-1 WT and mutants was evaluated in the SH-SY5Y cell line 
using hydrogen peroxide as oxidative stress agent (Figure 3.11). 
The hydrogen peroxide concentrations used were chosen based on the dose-
response curve previously performed in SH-SY5Y cells, where a LD50 value of 247.4µM 
was obtained (data not shown). The results show no significant increase in cell viability 
in cells treated with hydrogen peroxide in the presence of DJ-1 WT (Figure 3.11). 
This indicates that DJ-1 WT was not protecting cells against H2O2-induced cell death. 
However, it is noteworthy that high values of cell viability were observed in the 
treatment with 100µM and 200µM of H2O2 (Figure 3.11) when comparing with 
previous results obtained in similar assays, where cell viability at 100µM and 200µM of 
H2O2 were around 50% and 30%, respectively (data not shown). Furthermore, the 
results indicate that cells treated with hydrogen peroxide and in the presence of the 
protein´s vehicle have an increase in cell viability similar to the effect of the protein, 
however this increase is not statistically significant (Figure 3.11). Additionally, the 
protection conferred to cells by DJ-1 WT could not be observed in a significant manner.  
Considering that in the current conditions there is a higher cell viability in the 
presence of H2O2, and the neuroprotection previously observed by DJ-1 was not  
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confirmed, the assays with the mutants were not performed. 
 
Figure 3.11 | PROTECTIVE EFFECT OF DJ-1 WT AGAINST HYDROGEN PEROXIDE-INDUCED OXIDATIVE 
STRESS. SH-SY5Y cells were plated and after 4h were treated with different concentrations of H2O2 (0, 
100 and 200µM) with the addition or not of DJ-1 WT (1µM) or vehicle. Cell viability was measured after 
24h and represented to the control (0µM of H2O2). Data represent the mean±SEM of three experiments, 
based on untreated cultures as 100% of viability. No significant results were obtained after statistical 
analysis using one-way ANOVA. 
  
3.6. DJ-1 WT AND MUTANTS INTERACTOME 
The mechanisms by which DJ-1 potentiate cell neuroprotection against 
oxidative stress are largely unknown. Given this, DJ-1 WT and mutants binding 
partners were identified after cell exposure to H2O2 for different periods (0, 15 and 
40min). This approach gives an overview of the dynamic interactome of DJ-1 WT and 
its mutants under different oxidative stress moments. 
A pull-down assay was performed to identify DJ-1 WT and mutants binding 
partners. For that, each recombinant protein was attached to the resin and the protein 
extracts recovered from cells exposed to H2O2 for different time points were placed in 
contact with the resin attached proteins. Recombinant DJ-1 proteins and their binding 
partners were recovered and protein identification was performed by LC-MS/MS. A list 
of proteins and peptides used in the identification of these proteins was obtained for 
each recombinant DJ-1 protein. Due to the extent list of results, the tables are shown 
in a supplementary file (“Proteins Identified by LC-MS_MS.pdf”).  
Due to the nature of this assay, a condition to assess the proteins that bind 
unspecifically to the resin (non-specific interactors) needed to be performed. This 
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comprised the execution of the experiment using the resin without any recombinant 
protein attached. In order to eliminate this non-specific interactors from further 
analysis, proteins were selected based on the relative peptide query (rPQ) [166], which 
is the number of peptides identified in each condition divided by the number of 
peptides identified in the control condition (resin). Proteins with rPQ of 2 or greater 
were considered as speciﬁcally co-purifying with DJ-1 WT and mutants. 
 To analyze the extensive lists of recombinant DJ-1 proteins´ binding partners 
obtained several tools were used, such as Venn Diagrams and Gene Ontology 
enRIchment anaLysis and visualization tool (GOrilla). 
 
3.6.1. BINDING PARTNERS QUALITATIVE ASSESSMENT 
Venn diagrams were used to help visualize the number of shared and unique 
proteins in each condition over the time and among different conditions (qualitative 
assessment) (see Experimental Procedures 2.11). With this intention, two main 
analyses were performed comparing the recombinant DJ-1 proteins in all and in each 
time point (Figure 3.12). Moreover, the number of shared and unique DJ-1 C106DD 
binding partners was evaluated over the different time points (0,15 and 40 minutes) 
(Figure 3.13). Similar analyses were performed for the other DJ-1 mutants 
(Supplementary Figure 7.18). 
The comparison between DJ-1 WT and mutants C106A, C106DD and E163K 
among all the time points revealed that 213 proteins were shared by all the 
recombinant proteins. Worth to mention that an overall decrease of the proteins 
identified for the C106A mutant was observed in almost every analyses. This fact is 
explained by the decreased number of proteins identified by LC-MS/MS (“Proteins 
Identified by LC-MS_MS.pdf”) in the analysis performed for this mutant. Regarding the 
analysis of all the recombinant proteins in each time point (0, 15 and 40min) it was 
shown that at 0min, 8 proteins were shared among all the recombinant proteins, at 
15min that number increased to 54 and at 40min, 25 proteins were shared. 
Considering the number of unique proteins identified, it should be noted the decrease 
in the unique proteins of the C106DD mutant (170, 9 and 38 at 0, 15 and 40min, 
respectively) and on the other hand, the increase in the unique proteins of DJ-1 WT 
(33, 74 and 126 at 0, 15 and 40min, respectively). 
80 | 
Results | 
Moreover, the C106DD mutant was reported to mimic DJ-1 WT in its oxidized 
form that commonly occurs under stress conditions. Therefore, a qualitative 
assessment of the binding partners identified for this mutant in each time point was 
performed (Figure 3.13).  
A 
 
B                       0 min 
 
C                      15 min 
 
D                     40 min 
 
Figure 3.12| VENN DIAGRAMS OF THE IDENTIFIED BINDING PARTNERS IN DJ-1 WT AND MUTANTS FOR 
ALL AND EACH TIME POINT. A- Venn diagram showing the distribution of shared and unique binding 
partners in all time points (0, 15 and 40min) of H2O2 stimulation in DJ-1 WT and mutants C106A, C106DD 
and E163K; with a combined protein number of 643. B- Venn diagram showing the distribution of shared 
and unique binding partners in the 0min condition. The combined protein number is 415. C - Venn 
diagram showing the distribution of shared and unique binding partners in the 15min of H2O2 
stimulation. The combined protein number is 494. D - Venn diagram showing the distribution of shared 
and unique binding partners in the 40min of H2O2 stimulation. The combined protein number is 403. 
 
 
Figure 3.13| VENN DIAGRAM ILLUSTRATING THE NUMBER OF SHARED OR UNIQUE C106DD MUTANT 
BINDING PARTNERS AMONG THE DIFFERENT TIME POINTS. There are 56 common binding partners of 
C106DD in all time points of H2O2 stimulation and the combined protein number is 409. 
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 The results obtained over the different conditions revealed that 56 proteins 
were commonly identified and a large variation in the unique proteins identified for 
the different time points was seen, with 199, 5 and 58 proteins identified for the 0, 15 
and 40min, respectively.  
 Further combinations, with more targeted analyses, were performed using 
Venn diagrams to facilitate the analysis of results obtained for each recombinant 
protein (Supplementary Figure 7.14 to 7.18). Additionally, the proteins identified for 
DJ-1 WT in the described pull-down assay were compared to the proteins identified in 
the immunoprecipitation performed in previous work (Supplementary Figure 7.19). 
 
3.6.2. GO ENRICHMENT ANALYSIS 
An important analysis was to evaluate whether the overall lists of binding 
partners obtained were significantly enriched in any particular GO terms based on 
biological processes. For that Gene Ontology enRIchment anaLysis and visuaLizAtion 
tool (GOrilla) was used (see Experimental Procedures 2.12), which provides a clear 
view of the relations between the enriched GO terms in the form of tree diagram.  
The GO enrichment analysis of the binding partners identified in all time points 
for DJ-1 WT, and C106DD, C106A and E163K mutants identified 100, 80, 59 and 78 
significant enriched GO terms, respectively (Figure 3.14). These GO terms were sorted 
into 6 to 8 major biological processes, usually common to all the recombinant proteins, 
and further into a larger number of subgroups. Several subgroups were considered 
relevant in this analysis, considering the enrichment values and variations among 
conditions, and thus 5 main groups of subgroups were formed for a simplified 
visualization of the results - “metabolic process and translation”, “protein localization 
and transport”, “RNA metabolic process”, “cellular component disassembly” and 
“interspecies interaction between organisms” (Figure 3.14 – colored boxes).  
As observed this type of analysis generates large amounts of results and 
information to be evaluated. So, the major groups were assessed taking into account 
the number of subgroups with higher GO terms enrichment and with the greater 
variations among recombinant proteins and time points. 
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Figure 3.14| GENE ONTOLOGY (GO) ENRICHMENT OF THE IDENTIFIED BINDING PARTNERS FOR EACH 
RECOMBINANT PROTEIN. The binding partners analyzed were those corresponding to all time points 
performed for each recombinant protein. The main groups of GO terms considered relevant were 
highlighted using colored boxes. A to D - GO enrichment of the identified binding partners for DJ-1 WT 
and C106DD, E163K and C106A mutants, respectively.  
 
 In this way, the group of “RNA metabolic processes” was selected for further 
analysis and discussion. Comparisons of this group between DJ- WT and mutants 
revealed a larger number of subgroups with a high degree of GO terms enrichment 
identified for DJ-1 WT (Figure 3.15). Therefore, a targeted GO enrichment analysis was 
performed for DJ-1 WT in the different time points (Figure 3.16). 
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A                                       WT 
 
B                                     C106DD 
 
C                                      E163K 
 
D                                    C106A 
 
Figure 3.15| GENE ONTOLOGY (GO) ENRICHMENT OF THE RNA METABOLIC PROCESS GROUP FOR 
EACH RECOMBINANT PROTEIN. A to D - Targeted view of the RNA metabolic process group highlighted 
by blue boxes in Figure 3.14 for DJ-1 WT, C106DD, E163K and C106A mutants, respectively. 
 
Examining the “RNA metabolic process” enrichment, it was observed an 
increase in the enrichment degree at 15 minutes of H2O2 stimulation when comparing 
with the control condition (0 min), followed by a decrease to 40 minutes after 
stimulation. 
 
Similar analyses among the different time points were performed for the DJ-1 
mutants (Supplementary Figure 7.20 to 7.22). 
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A                                                                                       0 min 
 
B                                                                                      15 min 
 
C                                                                                      40 min 
 
Figure 3.16| GENE ONTOLOGY (GO) ENRICHMENT OF THE IDENTIFIED BINDING PARTNERS FOR DJ-1 
WT IN EACH TIME POINT. The main groups of GO terms considered relevant were highlighted using 
colored boxes. A to C - GO enrichment of the identified binding partners for DJ-1 WT at 0, 15 and 40 
min, respectively. 
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3.6.3. QUANTITATIVE ANALYSIS BY SWATH 
Focus was given to DJ-1 WT binding partners and a list of identified interactors 
in the RNA metabolic process group was obtained (supplementary file available in 
digital support – “DJ-1 WT binding partners _RNA Metabolic Process.pdf”). In this list 
83 proteins were identified and an analysis was performed to determine which 
proteins from this list could be quantified by SWATH–MS. Briefly, this approach 
generates a complete recording of the fragment ion spectra of all the analytes in a 
sample within a determined m/z window and then acquired data from the 
chromatographic peak of each peptide is further used to determine the relative 
quantity of a certain protein.  
The 42 DJ-1 WT binding partners that were quantifiable by SWATH are shown in 
Table 3.2 along with the fold increase values represented in log scale and normalized 
for the control condition (normal condition – 0 minutes). Additionally, a visual 
representation of these results is presented in Figure 3.17. 
 
Table 3.2 | QUANTITATIVE ANALYSIS OF DJ-1 BINDING PARTNERS BY SWATH-MS. 
Protein name Accession 15 min 
(log10) 
40 min 
(log10) 
U5 small nuclear ribonucleoprotein 200 kDa helicase  O75643|U520_HUMAN -0.16 0.11 
ATP-dependent RNA helicase DDX3X  O00571|DDX3X_HUMAN -0.15 0.01 
Splicing factor U2AF 65 kDa subunit  P26368|U2AF2_HUMAN -0.08 -0.11 
40S ribosomal protein S4, X isoform  P62701|RS4X_HUMAN 0.05 -0.05 
Asparagine--tRNA ligase, cytoplasmic  O43776|SYNC_HUMAN 0.05 0.02 
Small nuclear ribonucleoprotein Sm D2  P62316|SMD2_HUMAN 0.06 -0.02 
Histone-binding protein RBBP4  Q09028|RBBP4_HUMAN 0.10 0.08 
40S ribosomal protein S3  P23396|RS3_HUMAN 0.12 0.09 
Small nuclear ribonucleoprotein-associated protein N  P63162|RSMN_HUMAN 0.12 -0.01 
Heterogeneous nuclear ribonucleoprotein H  P31943|HNRH1_HUMAN 0.15 0.03 
40S ribosomal protein S3a  P61247|RS3A_HUMAN 0.16 0.04 
General transcription factor II-I  P78347|GTF2I_HUMAN 0.17 0.28 
Heterogeneous nuclear ribonucleoprotein D0  Q14103|HNRPD_HUMAN 0.19 0.08 
40S ribosomal protein S27  P42677|RS27_HUMAN 0.19 0.06 
Polypyrimidine tract-binding protein 1  P26599|PTBP1_HUMAN 0.19 0.13 
40S ribosomal protein SA  P08865|RSSA_HUMAN 0.21 0.12 
Aspartate--tRNA ligase, cytoplasmic  P14868|SYDC_HUMAN 0.22 0.03 
40S ribosomal protein S2  P15880|RS2_HUMAN 0.22 0.09 
Heat shock cognate 71 kDa protein  P11142|HSP7C_HUMAN 0.23 0.30 
60S ribosomal protein L9  P32969|RL9_HUMAN 0.23 0.04 
40S ribosomal protein S15a  P62244|RS15A_HUMAN 0.23 0.08 
Poly(rC)-binding protein 2  Q15366|PCBP2_HUMAN 0.24 0.10 
Arginine--tRNA ligase, cytoplasmic  P54136|SYRC_HUMAN 0.24 0.14 
Poly(rC)-binding protein 1  Q15365|PCBP1_HUMAN 0.25 0.11 
40S ribosomal protein S6  P62753|RS6_HUMAN 0.26 0.02 
40S ribosomal protein S24  P62847|RS24_HUMAN 0.28 0.15 
Heterogeneous nuclear ribonucleoproteins A2/B1  P22626|ROA2_HUMAN 0.29 0.11 
40S ribosomal protein S5  P46782|RS5_HUMAN 0.29 0.26 
60S ribosomal protein L23a  P62750|RL23A_HUMAN 0.30 0.07 
40S ribosomal protein S10  P46783|RS10_HUMAN 0.31 0.22 
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60S ribosomal protein L7  P18124|RL7_HUMAN 0.32 0.06 
Heterogeneous nuclear ribonucleoprotein F  P52597|HNRPF_HUMAN 0.32 0.25 
60S ribosomal protein L7a  P62424|RL7A_HUMAN 0.33 0.08 
40S ribosomal protein S16  P62249|RS16_HUMAN 0.34 0.27 
40S ribosomal protein S13  P62277|RS13_HUMAN 0.34 0.12 
40S ribosomal protein S7  P62081|RS7_HUMAN 0.34 0.24 
60S ribosomal protein L4  P36578|RL4_HUMAN 0.36 0.18 
60S ribosomal protein L14  P50914|RL14_HUMAN 0.36 0.08 
60S ribosomal protein L11  P62913|RL11_HUMAN 0.36 0.19 
60S ribosomal protein L6  Q02878|RL6_HUMAN 0.37 0.12 
40S ribosomal protein S23  P62266|RS23_HUMAN 0.38 0.20 
40S ribosomal protein S18  P62269|RS18_HUMAN 0.42 0.26 
 
 
Analyzing the results obtained in Figure 3.17, two main groups of proteins are 
very distinctive. One of them is represented by three proteins - the U5 small nuclear 
ribonucleoprotein 200 kDa helicase, the ATP-dependent RNA helicase DDX3X and the 
splicing factor U2AF 65 kDa subunit – where it was seen lower quantities at 15 minutes 
of stimulus compared to the control condition (0min of stimulus). Another 
characteristic group comprises the large set of proteins mainly containing 40S and 60S 
ribosomal proteins, which were presented in a significant amount at 15min with more 
than two-fold increase in comparison to the control.  
  
 
Figure 3.17 | FOLD-INCREASE OF DJ-1 WT BINDING PARTNERS IN OXIDATIVE STRESS CONDITIONS. The 
relative quantitative binding at 15 and 40 minutes of oxidative stress stimulus are presented in a log 
scale and were normalized for the control (normal conditions – 0 min). The dashed line represents the 2 
fold-increase (0.301 in the log scale). 
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Parkinson´s disease is a progressive neurodegenerative disorder that can be 
sporadic or familial [8, 9]. However, the etiology and pathology of this disorder is 
largely unknown [2, 10]. The study of the mechanisms of monogenic forms of PD has 
provided insight into the pathophysiology of this disease. Among these genes, DJ-1 has 
been associated with PD due to the variety of functions related to neuroprotection 
[44]. This protein participates in the response to oxidative stress acting as an oxidative 
stress sensor in which the cysteine residue 106 plays an essential role [80]. Mutations 
associated to DJ-1 lead to loss of protein function and ultimately development of PD 
[94]. Given all of the previous facts, the main goals of this study were to evaluate the 
neuroprotective effect of the DJ-1 mutations E163K (natural mutation), C106A and 
C106DD (engineered mutations) and to characterize the dynamic interactome of these 
mutants and DJ-1 WT. 
DJ-1 WT and mutants were produced and characterized to be used in further 
studies of neuroprotection against hydrogen peroxide-induced cell death and dynamic 
interactome. The coding DNA sequence of DJ-1 and its mutants was sequenced by 
Sanger DNA sequencing and all the mutations were confirmed. The molecular weight 
of all the mutants was approximately 43kDa (Figure 3.4, Figure 3.5, Figure 3.7, 
Supplementary Figure 7.4 to 7.6) corresponding to the dimeric form, which is an 
important feature of these proteins  [69, 90, 97, 99] and the molecular weight of the 
monomers of all the proteins (Figure 3.8 and Supplementary Table 7.2) was in 
accordance with the described (approximately 22kDa) [6]. Also, the results from the 
intact protein analysis showed the presence of other peaks in addition to the peak 
corresponding to the intact protein (Figure 3.8 - B and Supplementary Figure 7.11 - B). 
Some of these peaks can be explained by modifications in the intact protein, like 
oxidations or even addition of amino acid residues, such as methionine. For instance, 
for the C106DD mutant the peak with a MW of 23 043.54Da (mass shift of 178 Da 
comparing to the MW of the intact protein) could be due to the occurrence of three 
oxidations in the intact protein in addition to the initial non-cleaved residue of 
methionine. A similar peak with a mass shift of 178 Da comparing to the MW of the 
intact protein (at 22 885.32Da) was obtained for the C106A mutant (Supplementary 
Figure 7.11 - B) and the same explanation could be applied. For the E163K mutant, the 
presence of three additional peaks in the graphic of deconvoluted masses at 22 
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770.90Da, 22 786.45Da and 22 915.82Da (mass shift of 33, 49 and 178Da comparing to 
the MW of the intact protein, respectively) (Supplementary Figure 7.11 - D) could be 
explained by two and three oxidations in the intact protein, and three oxidations in 
addition to one more residue of methionine, respectively. Furthermore, the amino-
acid sequence of the purified proteins was confirmed, in which only the initial 
methionine was not identified due to a natural post-translational modification that 
occurs in E. coli, the host used in protein production (Figure 3.6 and Supplementary 
Figure 7.7 to 7.9).  
The CD spectrum of DJ-1 WT revealed a well folded polypeptide with a 
considerable amount in α-helix content of approximately 40%, 20 to 25% structure in 
β-sheet and around 40 to 50% without regular secondary structure (Figure 3.10), 
results that are in accordance with previous reports from CD analysis and also from 
crystallographic analysis [69, 90, 92, 103, 163]. The secondary structure content of DJ-1 
mutants in study was similar and in accordance with previous reports [90, 92, 167], 
with 20 to 30% of structure in α-helix, 20 to 30% of structure in β-sheet and 
approximately 50% without regular secondary structure (Figure 3.10). Furthermore, 
the decrease in signal amplitude observed for the mutants could result from a minor 
perturbation in the structure of each one of the mutants. Given this, the results 
suggest that none of the DJ-1 mutants in study significantly alters the secondary 
structure of DJ-1 in solution. 
The thermal stability of DJ-1 mutants was not significantly altered, except for 
the E163K mutant, compared to the DJ-1 WT with all the purified proteins presenting 
similar melting temperatures (Figure 3.9), which means that the mutations impact on 
DJ-1 structure are not very significant, as expected [45, 99], at least for the analyzed 
parameters. Noteworthy the overall reduced signal amplitude for the E163K mutant 
curve that could be due to the concentration used, since this parameter is considered 
a fundamental variable to improve data quality [168, 169]. Therefore, other 
concentration values, preferably higher, should be tested to improve the signal 
amplitude and thereby obtain a more accurate melting temperature value.  
The final purified proteins samples have some contaminants in their 
composition, mainly derived from the LB medium and E. coli used in bacterial culture 
and as a host, respectively, during protein production (Table 3.1). Moreover, some 
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proteins were identified as human proteins. These proteins could be identified as 
human, by the software (ProteinPilot), based on the peptides confidence and 
sequence coverage, but in this case, it is more likely that they are derived from a 
similar organism, such as bovin, since bovin and not human proteins were used in 
proteins´ production and purification experiments. 
Protein contaminants with similar DJ-1 WT functions were identified that could 
influence DJ-1 function in cells and its effect in neuroprotection. However, it should be 
considered the low level of identification on these proteins. Given this, the proteins 
with similar antioxidant function and with similar molecular weight (Alpha-S1-casein 
and Beta-casein) were identified with only two and one peptide, respectively, in the 
C106DD and E163K mutants (Table 3.1). In contrast, DJ-1 mutants were identified with 
129 and 112 peptides, clearly showing a large enrichment in comparison to these 
contaminants. Moreover, the contaminants are barely seen on the SDS-PAGE gel 
(Figure 3.5 – lane C106DD, Supplementary Figure 7.5 – lane C106A and Supplementary 
Figure 7.6 – lane E163K). In DJ-1 WT, two proteins with similar oxidoreductase and cell 
redox homeostasis functions (Glutaredoxin-1 and Thioredoxin-1) were identified, with 
2 and 5 peptides, respectively. However, bands with small molecular weight that could 
correspond to these contaminants did not appear on the SDS-PAGE gel (data not 
shown) and DJ-1 WT was identified with 113 peptides, showing a strong enrichment of 
DJ-1 compared to the contaminants. 
Previous work was done by our research group to evaluate DJ-1-mediated 
neuroprotection in SH-SY5Y cells treated with different concentrations of hydrogen 
peroxide (0, 25, 50, 100 and 200µM). In these experiments, exogenous addition of 
recombinant DJ-1 had a protective effect on H2O2-induced cell death. Taking these 
results into account, one of the goals of this project was to assess DJ-1 WT and 
mutants C106A, C106DD and E163K neuroprotection in SH-SY5Y treated with H2O2. 
However, in DJ-1 mediated neuroprotection assays it was not observed a protective 
effect by DJ-1 in cells stimulated with hydrogen peroxide. This result could be 
associated with the low level of cell death that makes difficult to observe a significant 
increase in cell viability when DJ-1 is present. Moreover, an increment in cell viability 
was observed in cells in the presence of the vehicle (PBS with 10% glycerol), which 
could be explained by the already reported hydroxyl radical scavenger function of 
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glycerol in cells [170, 171]. This fact could be also affecting the correct assessment of 
DJ-1 neuroprotective effect, since the neuroprotection that was observed in some 
cases could be resulting from the protein´s buffer and not from DJ-1 itself. Besides 
protein´s buffer, DJ-1 WT was produced in its function form (dimer) (Figure 3.7), with 
the desired thermal stability (Figure 3.9) and secondary structure (Figure 3.10) and by 
the analysis of the contaminants´ function these should not negatively influence DJ-1 
neuroprotective function (Table 3.1). A proposed solution could be to produce and 
store the proteins in a buffer that does not affect cell viability and research is being 
made to this end. Furthermore, in order to understand the high values of cell viability 
observed, a new hydrogen peroxide was tested but the results remained very similar. 
Therefore, another explanation for these values was the cell line quality and 
development that could be impaired somehow. Nonetheless, further work is being 
done involving the research for a new and suitable buffer to store the protein and 
improvements in cell line development and quality, in which the acquisition of a new 
cell line could be a possibility.  
DJ-1 has been reported as a multifunctional protein [43, 45, 67] and it has been 
demonstrated that interactions between proteins are essential in the biological 
processes in cells [134]. Thus, the study of the interactome, defined as a group of 
protein-to-protein interactions that occurs in a cell under a specified condition and 
time point, is considered important in the translation of molecular mechanisms into 
cellular functions [132, 134]. Given this, DJ-1 WT and mutants interactome under 
normal and stress conditions in different time points - dynamic interactome – was 
evaluated through pull-down assays of each one of the recombinant proteins with 
protein extracts recovered from cells not subjected to oxidative stimulus (0 minutes 
condition), and upon H2O2 stimulus after 15 and 40 minutes.  
The qualitative assessment of the binding partners identified for DJ-1 WT and 
mutants C106DD, E163K and C106A performed by Veen diagrams revealed that the 
majority of binding partners identified are shared among DJ-1 WT and mutants 
demonstrating that these binding partners are constant in DJ-1 WT and mutants, not 
suffering possible interferences caused by DJ-1 mutations. This also reveals that the 
analysis of primary, secondary and quaternary structure, which indicated minor 
differences, is in accordance with a high degree of shared binding partners. They do 
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not suffer interference from the mutations in the interaction with DJ-1 (Figure 3.12 - 
A). Analyzing each time point separately, an increase in proteins binding to DJ-1 WT, 
C106A and E163K mutants was observed after 15min of stimulus, suggesting that this 
state of oxidation promotes unique protein interactions in these recombinant proteins 
(Figure 3.12 – B to D). For the C106DD mutant a decrease in unique interactors was 
seen for 15 and 40min (oxidative stress conditions) in comparison to the 0min (normal 
conditions). Since C106DD mutant seems to mimic DJ-1 WT active form in cells, this 
could mean that when DJ-1 WT is in its active form promotes interactions with 
proteins similar to the ones present in cells under normal conditions rather than the 
ones present under stress conditions (Figure 3.12 – B to D). This fact was confirmed by 
the time course evaluation of C106DD binding partners (Figure 3.13), showing that a 
higher number of interactors was identified under normal conditions. Additionally, this 
analysis showed that the lowest number of unique interactors of C106DD was at 15 
minutes of oxidative stress. This suggests that for this mutant an interaction with 
proteins under increased oxidative stress conditions was promoted over lower 
oxidative stress conditions. It is worth to mention that the number of total proteins 
identified for each recombinant protein influences this type of analysis, as seen for the 
C106A mutant analysis. 
 A GO term enrichment analysis is a common tool used in large lists of genes or 
proteins, allowing the visualization and identification of the major biological processes 
to which the binding partners identified are associated. In this respect, from the major 
groups identified, the RNA metabolic process emerged as an interesting target in this 
study. This was because the enrichment GO terms values among DJ-1 proteins was 
higher for DJ-1 WT, which revealed that this group in DJ-1 WT would have unique 
proteins associated with this processes in comparison to the other mutants (Figure 
3.15). In addition, RNA metabolic processes comprise cellular chemical reactions and 
pathways associated with RNA, namely transcription and translation processes and DJ-
1 have been associated with the regulation of RNA metabolism [172]. Evaluating the 
enrichment degree in this group for DJ-1 WT among the different times, it was seen a 
significant increase in enrichment after 15min of oxidative stimulus in comparison with 
normal (0 min) and higher oxidative stress (40 min) conditions (Figure 3.16). This 
suggests that after 15min of stimulus more proteins involved in RNA metabolic 
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processes bound to DJ-1 WT and after 40min of stimulus this number decreased in 
comparison to the 15min condition, presenting a similar GO enrichment pattern to the 
normal conditions (0min). 
 Using a SWATH analysis it was possible to quantify some of the DJ-1 WT binding 
partners identified for the RNA metabolic processes in the different oxidative stress 
conditions. Among these proteins there are several 40 and 60S ribosomal proteins and 
specifically the U5 small nuclear ribonucleoprotein 200 kDa helicase that have already 
been identified in the IP previously performed by our research group, and are present 
in the shared proteins identified both in the IP and PD procedures (Supplementary 
Figure 7.19). Interestingly, the SWATH analysis revealed a large set of 40S and 60S 
ribosomal proteins being identified with a two-fold increase or higher at 15 minutes of 
oxidative stimulus (Figure 3.17). Worth mention that the 15 and 40 minutes of 
stimulus were chosen in order to represent an initial and a more extended state of 
oxidation, respectively. This means that DJ-1 WT in initial oxidative stress conditions 
greatly binds to these ribosomal proteins, which are involved in translational 
processes. A previous study demonstrated that under oxidative stress conditions the 
formation of aggregate between proteins and RNA in ribosomes was promoted [173]. 
Being these proteins structural elements of the ribosome, DJ-1 WT binding could 
directly stabilize the ribosome structure preventing the formation of protein 
aggregates with RNA in the ribosomes and promote the interaction with the RNA 
leading to a proper translation process. This ribosome stabilization could be associated 
with a chaperone like function previously reported that helps other proteins or 
complexes to maintain their structure under oxidative stress conditions. For these set 
of ribosomal proteins after 40 minutes of stimulus the amount of binding protein to 
DJ-1 WT was reduced in comparison to the 15 minutes condition. This suggests that 
the proposed function for DJ-1 WT is more important in an initial state of oxidation 
probably because it directly disturbs translation with immediately consequences in 
protein production as response to oxidative stress. Therefore, due to the importance 
of this process DJ-1 WT needs to act in early states of oxidative stress conditions.  
Another protein identified in the IP assay and quantified in this study was the 
U5 small nuclear ribonucleoprotein 200 kDa helicase, also known as BRR2. In contrast 
to the observed for the 40 and 60S ribosomal proteins, a lower quantity of this 
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interactor was observed after 15 minutes of stimulus (Figure 3.17). This protein is a 
member of the DExH/Dbox helicase family and plays a key role in the activation of the 
spliceosome, which is involved in pre-mRNA splicing [174]. BRR2 unwinds the U4/U6 
snRNA duplices promoting the formation of the spliceosome catalytic center [175]. In 
this way, the observed decrease in DJ-1 WT interaction with U5 small nuclear 
ribonucleoprotein 200 kDa helicase at an initial state of oxidative stress conditions can 
be explained as DJ-1 WT releasing the BRR2 protein, and promoting its location at the 
spliceosome to interact with the U4 snRNA to displace it from the U6 snRNA, a 
essential step to create the active site for splicing catalysis [176]. In a more extended 
state of oxidative stress conditions (40 min) the amount of BRR2 protein binding to DJ-
1 WT increases in comparison to the control condition. It has been reported that 
DExH/Dbox helicases, like BRR2, are also involved in remodeling RNA–protein 
complexes formed in the spliceosome and ribosome, for instance [177, 178]. Given 
this, at this level of oxidation DJ-1 WT could promote the interaction with BRR2 protein 
in order to modulate its function and act in remodeling the interactions between RNA 
and proteins for a long term effect in oxidative stress regulation. 
In addition, a new and interesting DJ-1 WT interactor, not identified in the IP 
assay previously mentioned, and involved in apoptotic processes was identified and 
quantified in this study - ATP-dependent RNA helicase DDX3X. It was seen that after 15 
minutes of stimulus a lower amount of this protein was interacting with DJ-1 WT 
(Figure 3.17). As a member of the DEAD-box RNA helicase family, functions correlated 
with RNA processing, transport and also translation processes have been reported for 
this protein [179]. More interesting was the described function as antiapoptotic 
protein, negatively regulating the apoptotic processes via death domain receptors 
[180]. It was shown that DDX3X protein form a death antagonizing signaling complex 
with other antiapoptotic proteins at death receptors to inhibit apoptotic signals and 
therefore ensuring the maintenance of unstimulated death receptors in a quiescent 
state. In this line of thought, the observed decrease in DJ-1 WT interaction with ATP-
dependent RNA helicase DDX3X at an initial state of oxidative stress conditions can be 
explained as DJ-1 WT release of DDX3X protein promoting its interaction with death 
receptors and as a result inhibit the activation of apoptotic signaling pathways. In a 
more extended state of oxidative stress conditions (40 min) the amount of DDX3X 
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protein binding to DJ-1 WT returns to values near the ones observed under normal 
conditions. At this point, DJ-1 WT may adjust its form of action in response to the 
oxidative stress events that are occurring in cells promoted by this extended level of 
oxidation. In this way, DJ-1 WT could redirect its functions like chaperone, antioxidant 
and ROS scavenger activities, which represent more directed forms of response to 
oxidative stress.  
In summary, two proteins were confirmed to be DJ-1 WT interactors by two 
different assays with further quantification of these proteins accomplished in this 
study. A new DJ-1 WT interactor was identified, the ATP-dependent RNA helicase 
DDX3X. For this protein, the quantification by SWATH was important and provided a 
more accurate binding rate profile for this protein, since based on the number of 
peptides identified no modifications seemed to occur among the different time points 
when in fact a decrease in the binding rate to DJ-1 WT at 15 minutes of oxidative stress 
was observed (supplementary file - “Proteins Identified by LC-MS_MS.pdf”). 
Nonetheless, a higher number of SWATH analysis should be performed in order to 
increase the confidence in the results obtained and improve the number of proteins 
that could be quantified using this method. In addition, the identified interactors 
should be validated and further research should be performed to confirm and obtain 
more insights into these suggested DJ-1 molecular mechanisms of action against 
oxidative stress. 
Noteworthy that one of the main goals of this project was to characterize the 
dynamic interactome and quantify the binding partners of DJ-1 WT and mutants 
E163K, C106A and C106D. Through the identification of the differences between DJ-1 
WT and mutants binding partners obtain insight into the molecular mechanisms by 
which DJ-1 exerts its neuroprotective function and which functions are impaired in DJ-
1 mutants. However, due to some problems in the samples processing this goal was 
somehow compromised and these analyses will be repeated. Furthermore, to take into 
account the losses through the sample processing steps, an internal standard will be 
added to the samples, such as GFP. In this way, a thorough analysis will be made giving 
a more accurate understanding on the loss of DJ-1 mutants binding partners and 
furthermore elucidations into DJ-1 WT functions that were impaired by these 
mutations would be obtained. 
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The main goal of this study was to obtain insight into of DJ-1 WT function in 
cells through the characterization of the dynamic interactome of DJ-1 WT and mutants 
E163K, C106A and C106DD, under normal and stress conditions. A focus was given to a 
natural mutation and two engineered mutations, specifically at the C106 residue due 
to its importance in DJ-1 functions against oxidative stress. To accomplish this, DJ-1 WT 
and mutants were produced for further use in SH-SY5Y cells to assess their 
neuroprotective effect and evaluate the changes in their interactome under stress 
conditions. 
The previously mentioned DJ-1 mutations were successfully accomplished and 
proteins´ characterization revealed that these proteins were in the dimeric form, had 
similar secondary structures contents and identical thermal stabilities, as previously 
described. Furthermore, no significant contaminants were identified in the purified 
proteins that could greatly influence these proteins´ functions in cells. The 
characterization steps are particularly relevant when the protein will be used for 
biological assays, such as survival and interactomics assays, where not only the primary 
sequence is important, but mainly the maintenance of the structure that will be 
recognized by the biological system. 
Contrarily to what was previously observed, DJ-1 WT-mediated 
neuroprotection was not confirmed in cells stimulated with hydrogen peroxide.  
Through the dynamic interactomic analysis, several new putative binding 
partners for DJ-1 WT and mutants E163K, C106DD and C106A were identified, which 
can contribute with insight in revealing DJ-1 WT functions against oxidative stress. 
However, validation of these interactors is required as well as further assessment of 
these interactors’ function and influence in the regulation of DJ-1 functions. 
Furthermore, a recent developed label-free method to quantify proteins 
allowed a better characterization of the continuously changing protein-protein 
interactions that occurs in the dynamic interactome, significantly contributing to the 
insight previously obtained. Thus, further elucidations can be obtained into Parkinson’s 
Disease pathology and potential new targets for PD prevention and therapy could have 
been identified.  
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7. SUPPLEMENTARY DATA 
  
 
  
 
Supplementary Data | 
7.1. SEQUENCING 
As shown for the results obtained for the C106DD mutant, the sequencing 
confirmed the acquisition of plasmid DNA with the DJ-1 C106A and E163K mutated 
genes to use for further production and purification of the respective mutated 
proteins. This was confirmed by comparison of the different plasmids constructs of 
these mutants (Supplementary Figure 7.1) where the codon substitution was 
confirmed (highlighted nucleotides in the figures). Codon substitutions for all the 
mutants are described in Experimental Procedures - 2.1. 
 
I 
 
II 
 
Supplementary Figure 7.1| DNA SEQUENCING RESULTS OF DJ-1 MUTANTS C106A (I) AND E163K (II) 
CODIFIYING SEQUENCES. Nucleotide sequence alignment of small fragments of DJ-1 mutant C106A (or 
E163K) gene sequenced (A), its corresponding sequence in the C106A (or E163K) designed plasmid (B) 
and in the DJ-1 WT designed plasmid (C). The codon containing the mutation is highlighted. The codon 
substitution was TGT to GCG for the C106A mutation and GAA to AAA in the E163K mutation.  
 
7.2. DJ-1 WT AND MUTANTS PRODUCTION AND PURIFICATION 
7.2.1. PRODUCTION AND PURIFICATION – AFFINITY AND SIZE EXCLUSION 
CHROMATOGRAPHIES 
As mentioned above, after sequencing the mutated genes, the proteins were 
produced and purified. In the purification step two columns were used, the HisTrap 
and the Superdex 200, and the chromatograms obtained for the mutants C106A and 
E163K are shown below (Supplementary Figure 7.2).  
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Supplementary Figure 7.2 | AFFINITY CHROMATOGRAPHY PURIFICATION OF DJ-1 C106A (A) AND 
E163K (B). The affinity chromatography was performed using a HisTrap column. Imidazole step gradient 
(50mM, 100mM, 300mM and 500mM) is shown in dashed line. The grey bars correspond to the fractions 
that were collected from each elution step - fraction 1, 2, 3 and 4 eluted with 50, 100, 300 and 500mM of 
imidazole, respectively. 
 
 From each affinity purification four fractions were recovered and in both cases, 
the fraction 3 eluted with 300mM of imidazole was collected and loaded into the 
Superdex 200 column by the same reasons mentioned in section 3.2. Fraction 4 from 
the C106A chromatogram (Supplementary Figure 7.2 – A) did not contain protein but 
the same fraction from E163K chromatogram contains a low amount of protein as it 
can be observed by the small peak obtained. 
 
From the purification of mutants C106A and E163K two and one fraction were 
recovered, respectively (Supplementary Figure 7.3). In the purification of E163K a 
problem occurred and the first peak could not be recovered. However, based in the 
low values of volume in which this peak appeared the protein present in this fraction 
would not be in the homodimeric form, but instead in oligomeric forms. Therefore, 
this would not be the fraction of interest to use. The fractions of interest were the 
ones recovered around 210mL, which were fraction 2 from C106A chromatogram and 
fraction 1 from E163K chromatogram. 
Furthermore, analysis of fraction 1 from C106A mutant purification by HPLC 
showed the presence of protein in the form of oligomers (data not shown). Given the 
above mentioned, the fractions stored for further analysis were fraction 2 from C106A 
purification and fraction 1 from E163K size exclusion chromatographies. 
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A 
 
B 
 
Supplementary Figure 7.3 | SIZE EXCLUSION CHROMATOGRAPHY PURIFICATION OF DJ-1 C106A (A) 
AND E163K (B). Fraction 3 recovered from the affinity chromatography of C106A and E163K 
(Supplementary Figure 7.2 – A and B, respectively) was applied in an HiLoad 26-60 Superdex 200 
column. The mobile phase used was PBS. The grey bars represent the fractions that were collected  
(fraction 1 and 2 (A) and fraction 1 (B)). 
 
7.2.2. PROTEIN PURIFICATION ASSESSMENT 
 The following figures show the protein profile obtained for samples recovered 
from protein expression (BI, AI I and AI S) and protein purification using affinity 
chromatography (BL, FT, HT 1, HT 2, HT 3, HT 4) – Supplementary Figure 7.4 – and 
samples recovered from size exclusion chromatography (Sx1 and Sx2), from protein 
concentration (BC Sx2, FT Sx2 and AC Sx2) and the stored protein sample (C106A) – 
Supplementary Figure 7.5. 
Analyzing the results it can be seen that the samples obtained before induction 
(BI) and insoluble protein fraction obtained after induction of protein expression (AI I) 
have a band around the molecular weight of DJ-1 with very low intensity 
(Supplementary Figure 7.4). This suggests that DJ-1 was not present in the medium 
before protein expression induced with IPTG and neither in the insoluble protein 
fraction recovered after induction of protein expression. On the contrary, an intense 
band around 24kDa was observed in the soluble protein fraction after induction of 
protein expression (AI S) which indicates that DJ-1 was produced in a soluble form and 
present in the soluble proteins fraction. 
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Supplementary Figure 7.4 | ANALYSIS OF DJ-1 C106A EXPRESSION AND PURIFICATION BY SDS-PAGE. 
SDS-PAGE followed by Coomassie staining. MW – molecular weight marker: NZY Colour Protein Marker 
II (NZYTech); BI – cellular extract obtained before induction of protein expression; AI I – insoluble 
protein fraction obtained from centrifugation after induction of protein expression; AI S – soluble 
protein fraction obtained after induction of protein expression; BL – cellular extract loaded on the 
HisTrap column; FT – flow-through obtained from the HisTrap column; HT 1 –fraction 1 eluted from the 
HisTrap column; HT 2 - fraction 2 eluted from the HisTrap column; HT 3 - fraction 3 eluted from the 
HisTrap column; HT 4 - fraction 4 eluted from the HisTrap column (Supplementary Figure 7.2 - A). The 
sample volume added to each well was 10µL. 
  
Regarding protein purification using an HisTrap column it could be observed the 
presence of a DJ-1 band in all fractions except fraction 4. This means, in the case of 
fraction recovered before column loading (BI) and fraction recovered from the flow 
through after column loading (FT), that DJ-1 was effectively loaded into the column but 
also that a large quantity of DJ-1 did not bind to the resin and therefore was lost. The 
presence of DJ-1 in fractions 1 to 3 (HT 1 to 3) and absence from fraction 4 (HT 4) was 
expected through the analysis of the affinity purification chromatogram. Noteworthy 
that in fractions 1 to 3 more bands are present besides DJ-1´s band and that the 
intensity of these bands is lower in fraction 3, which suggests that this fraction has a 
lower amount of contaminants. Therefore, this fraction was chosen to be purified by 
size exclusion chromatography.  
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Supplementary Figure 7.5 | ANALYSIS OF DJ-1 C106A SIZE EXCLUSION CHROMATOGRAPHY BY SDS-
PAGE. SDS-PAGE followed by Coomassie staining. MW – molecular weight marker: NZY Colour Protein 
Marker II (NZYTech); After loading the fraction HT 3 from the HisTrap elution on a HiLoad 26/60 
Superdex 200 prep grade fractions 1 (Sx 1) and 2 (Sx 2) were recovered; BC Sx 2 – sample containing 
fraction 2 obtained from Superdex 200 before concentration; FT Sx 2 – flow-through obtained from 
concentration of fraction 2; AC Sx 2 - purified DJ-1 C106A obtained after concentration of fraction 2; 
C106A – sample AC Sx 2 stored in PBS with 10% glycerol at -80°C. The sample volume added to each well 
was 10µL. 
 
 The two fractions recovered from size exclusion chromatography (Sx 1 and Sx 
2), after loading fraction 3 (HT 3), both contained a band corresponding to DJ-1 
(≈22kDa) being the Sx 2 band more intense (Supplementary Figure 7.5). Additionally, 
the sample containing fraction 1 also presented another band around 48 kDa that 
could correspond to oligomers, also supported by the size exclusion chromatogram 
analysis. Thereby, fraction 2 (Sx 2) was selected to storage and use in further assays. 
Before storage, this fraction was concentrated and in the sample retrieved before 
concentration (BC Sx 2) the presence of DJ-1 in the sample was confirmed by the band 
shown at approximately 22 kDa. Due to the very low intensity of DJ-1 band in the 
sample obtained from the flow through of the concentration (FT Sx 2) it can be 
concluded that almost no protein was lost during this process. This is confirmed by the 
very intense DJ-1 band in the sample recovered after protein concentration (AC Sx 2). 
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In this sample, there are other bands present, which suggested that these 
contaminants were also concentrated. The concentrated sample was stored in PBS 
with 10% glycerol (C106A) and the SDS-PAGE showed only an intense band at DJ-1 
molecular weight compared to the sample obtained after concentration. This fact 
could be explained by the dilution performed in  PBS with 10% glycerol to store the 
protein. 
 Samples recovered during protein expression (BI, AI I, AI S), protein purification 
using a HisTrap column (HT 3) followed by Superdex 200 column (Sx 1) from E163K 
were resolved by SDS-PAGE (Supplementary Figure 7.6). To evaluate the protein profile 
of this protein only one SDS-PAGE gel was performed and some fractions were not 
recovered. 
 
 
Supplementary Figure 7.6 | ANALYSIS OF DJ-1 E163K EXPRESSION AND PURIFICATION BY SDS-PAGE. 
SDS-PAGE followed by Coomassie staining. MW – molecular weight marker: NZY Colour Protein Marker 
II (NZYTech); BI – cellular extract obtained before induction of protein expression; AI I – insoluble 
protein fraction obtained from centrifugation after induction of protein expression; AI S – soluble 
protein fraction obtained after induction of protein expression; HT 3 – fraction 3 eluted from the HisTrap 
column; Sx 1 – fraction 1 eluted after loading sample HT 3 on a HiLoad 26/60 Superdex 200 prep grade; 
E163K – sample Sx F1 stored in PBS with 10% glycerol at -80°C. The sample volume added to each well 
was 10µL. 
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The results show that there was no band at DJ-1 molecular weight before 
protein expression induction (BI), which means that DJ-1 was not present in the 
medium before protein expression induced with IPTG. After protein expression 
induction DJ-1 was present in large amount in the soluble fraction (AI S) and in a 
smaller amount in the insoluble fraction (AI I). This means that DJ-1 was mostly 
produced in a soluble form and present in the soluble protein fraction. Fraction 3 (HT 
3) recovered from the HisTrap column, corresponds to protein elution at 300mM of 
imidazole with an intense DJ-1 band along with other bands with very low intensity. 
After protein elution from the HisTrap, fraction 3 was loaded into the Superdex 200 
column and one fraction was recovered from this elution (Sx 1). In this fraction an 
intense band for DJ-1 was present again which suggests the presence of DJ-1 in large 
amounts in this sample. Therefore, the sample Sx 1 was diluted in PBS with 10% 
glycerol and stored at -80oC (E163K). 
 
7.2.3. PROTEIN CONCENTRATION 
Protein samples obtained for each mutant were analyzed by absorbance at 
280nm (NanoDrop) to determine the protein concentration before storage. As 
mentioned above, the blank used in this procedure was the same buffer in which the 
protein was stored (PBS with 10% glycerol) and the results are shown in 
Supplementary Table 7.1. 
 
Supplementary Table 7.1 | PROTEIN CONCENTRATION OF FINAL SAMPLES CONTAINING THE 
MUTANTS IN STUDY. 
 
Protein 
Concentration   
(µg/µL) 
Wild-type 1.97 
C106A 2.46 
C106DD 2.19 
E163K 2.05 
 
 
The desired concentration in the sample to store was around 2.0mg/mL. As 
observed in Supplementary Table 7.1 all the concentrations are around this value with 
the exception of mutant C106A with a higher concentration. 
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7.3. SEQUENCE ANALYSIS BY LC-MS/MS 
The C106A mutant was identified with an unused protein score of 134.34, a 
sequence coverage of 99.5% and 107 peptides were identified with 95% or more 
confidence. The results indicated that the initial methionine was not identified which is 
represented by a sequence coverage of 99.5% (Supplementary Figure 7.7). 
 
Supplementary Figure 7.7 | SEQUENCE COVERAGE OF DJ-1 MUTANT C106A. Green letters represent 
the residues identified in peptides with at least 95% confidence; grey letters represent the unidentified 
residues. Mutated residue is highlight in yellow.  
 
The E163K mutant was identified with an unused protein score of 127.55, a 
sequence coverage of 100% and 96 peptides were identified with 95% or more 
confidence. Unlike the results obtained for the other proteins, for this mutant the 
initial methionine was identified but with low confidence (Supplementary Figure 7.8).  
 
 
Supplementary Figure 7.8 | SEQUENCE COVERAGE OF DJ-1 MUTANT E163K. Green letters represent 
the residues identified in peptides with at least 95% confidence; grey letters represent the unidentified 
residues; red letters represent the residues identified in peptides with low confidence. Mutated residue 
is highlight in yellow.  
 
This fact justifies the sequence coverage value of 100%. Probably for this protein the 
cleavage of the initial methionine was inefficient and that allowed the identification of 
this residue even though with low confidence. 
DJ-1 WT was identified with an unused protein score of 152.33, a sequence 
coverage of 99.5% and 116 peptides were identified with 95% or more confidence. The 
results indicated that the initial methionine was not identified contributing to a value 
of 99.5% for sequence coverage (Supplementary Figure 7.9). 
MGSSHHHHHHDYDIPTTENLYFQGHMASKRALVILAKGAEEMETVIPVDVMRRAGIKVTVAGLAGKDPVQC
SRDVVICPDASLEDAKKEGPYDVVVLPGGNLGAQNLSESAAVKEILKEQENRKGLIAAIAAGPTALLAHEIGFGS
KVTTHPLAKDKMMNGGHYTYSENRVEKDGLILTSRGPGTSFEFALAIVEALNGKEVAAQVKAPLVLKD 
 
MGSSHHHHHHDYDIPTTENLYFQGHMASKRALVILAKGAEEMETVIPVDVMRRAGIKVTVAGLAGKDPVQC
SRDVVICPDASLEDAKKEGPYDVVVLPGGNLGAQNLSESAAVKEILKEQENRKGLIAAICAGPTALLAHEIGFGS
KVTTHPLAKDKMMNGGHYTYSENRVEKDGLILTSRGPGTSFKFALAIVEALNGKEVAAQVKAPLVLKD 
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Supplementary Figure 7.9 | SEQUENCE COVERAGE OF DJ-1 WT. Green letters represent the residues 
identified in peptides with at least 95% confidence; grey letters represent the unidentified residues. 
 
7.4. SIZE EXCLUSION– HPLC 
To evaluate if the proteins were in a homodimeric form, a size exclusion – HPLC 
was performed. In this technique, the molecular weight of each protein was 
determined using a calibration curve obtained by the retention time of certain 
standards – Supplementary Figure 7.10.  
 The molecular weight of DJ-1 and its mutants was calculated using the 
retention time of each sample. Firstly, the retention time was converted to elution 
volume (Ve) using the column flow rate value. With elution volume and the values of 
column void volume (V0) – blue dextran elution volume - and geometric column 
volume (Vc), the partition coefficient (Kav) was calculated using the following formula: 
𝑲𝒂𝒗 =  𝑽𝒆−𝑽𝟎𝑽𝒄−𝑽𝟎  .  
 The calibration curve was represented by the partition coefficient (Kav) versus 
the logarithm of molecular weight (log (MW)) as shown in Supplementary Figure 7.10.  
 
Supplementary Figure 7.10 | HPLC-SIZE EXCLUSION CHROMATOGRAPHY CALIBRATION CURVE. 
Molecular weight of standards (dots) from right to left: Ferritin (440 kDa); Aldolase (158 kDa); 
Conalbumin (75 kDa); Ovalbumin (44 kDa); Carbonic Anhydrase (29 kDa); Ribonuclease A (13.7 kDa); 
Aprotinin (6.5 kDa). The mobile phase was PBS with 10% glycerol (buffer used to store the proteins). Kav 
– partition coefficient, log (MW) - logarithm of molecular weight. 
MGSSHHHHHHDYDIPTTENLYFQGHMASKRALVILAKGAEEMETVIPVDVMRRAGIKVTVAGLAGKDPVQC
SRDVVICPDASLEDAKKEGPYDVVVLPGGNLGAQNLSESAAVKEILKEQENRKGLIAAICAGPTALLAHEIGFGS
KVTTHPLAKDKMMNGGHYTYSENRVEKDGLILTSRGPGTSFEFALAIVEALNGKEVAAQVKAPLVLKD 
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Therefore, using the calculated value of Kav of the protein, the log (MW) can be 
retrieved and finally the molecular weight can be inferred. 
 
7.5. LC-MS OF INTACT PROTEINS 
The following results represent the deconvoluted mass spectrum and graphic of 
deconvoluted masses for the mutants C106A and E163K (Supplementary Figure 7.11).  
 
 
 
Supplementary Figure 7.11 | LC-MS ANALYSIS OF INTACT DJ-1 MUTANTS C106A AND E163K. A and C - 
Average spectra of protein charge envelop of intact C106A and E163K, respectively (in blue). 
Deconvoluted mass spectrum of protein charge envelop of intact C106A and E163K, respectively (in 
red). B and D - Graphic of deconvoluted masses of C106A and E163K, respectively, using BioAnalyst. 
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 In the same way as explained in the section 3.4.2 from results, the values from 
the average and predicted masses were obtained for DJ-1 WT and mutants C106A and 
E163K – Supplementary Table 7.2. 
 
Supplementary Table 7.2 | PROTEINS´ MASSES OBTAINED WITH BIOANALYST AND PREDICTED FROM 
THE SEQUENCE. Average and predicted masses were obtained using BioAnalyst and Mass Calculator 
tool, respectively. The predicted masses were calculated without the initial methionine. The shift 
between the two mass values is also shown. 
 
Protein 
Average Mass 
(Da) 
Predicted Mass 
(Da) 
Shift (Da) 
WT 22739.998 22738.899 1.099 
E163K 22739.057 22737.908 1.149 
C106A 22707.938 22707.407 0.531 
C106DD 22867.037 22865.953 1.085 
 
 In a general way, similar results for predicted and average mass were obtained 
giving low shift values. All the values were very close to 22.7 kDa as expected since this 
is the approximate molecular weight of DJ-1 WT monomer. 
 
7.6. THERMAL SHIFT – NORMALIZED CURVES 
The results obtained from the thermal shift assay were represented by 
normalized curves (normalized fluorescence intensity versus temperature) 
(Supplementary Figure 7.12). To simplify the acquisition of the melting temperature of 
each protein – temperature at the inflection point of the normalized curves slope – 
derivative curves were obtained from the normalized curves, where the Tm is the 
temperature value of the peak obtained in these curves (Figure 3.9). 
The normalized curves indicated that mutants E163K and C106DD presented 
higher fluorescence for initial values of temperature. Based on the concept of thermal 
shift this means that the structure of these proteins have more hydrophobic regions 
initially exposed allowing the dye to bind to more protein regions and promoting the 
increase in fluorescence signal. Due to this fact inferior Tm values were obtained for 
these proteins compared to the DJ-1 WT and mutant C106A. Since these proteins had 
127 | 
| Supplementary Data 
already more hydrophobic regions exposed, the temperature necessary to denature 
50% of the protein structure was lower. 
 
Supplementary Figure 7.12 | NORMALISED CURVES OF DJ-1 WT AND MUTANTS C106A, C106DD AND 
E163K OBTAINED FROM THERMAL SHIFT ASSAY. The concentration of the recombinant DJ-1 WT and its 
mutants was 0.5mg/mL. The melting temperature (Tm) was determined using the first derivative of the 
normalized curve for each protein (Figure 3.9).  
 
7.7. CIRCULAR DICHROISM 
Initially, the analysis of CD was performed at 25oC (Supplementary Figure 7.13), 
a commonly used temperature to determine the secondary structure content of 
proteins. However, the assays in which the proteins would be used were performed at 
 
Supplementary Figure 7.13 | FAR-ULTRAVIOLET CIRCULAR DICHROISM SPECTRA OF DJ-1 WT AND 
MUTANTS C106A, C106DD AND E163K. CD spectra were obtained under normal conditions at 25oC 
using a 0.05mm cell. The protein concentrations used were approximately 2.0mg/mL.  
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37oC and thereby the CD analysis was repeated and performed at 37oC (Figure 3.10). 
At physiologic pH and 25oC the circular dichroism (CD) spectral analysis showed 
that DJ-1 mutants C106A, C106DD and E163K have essentially the same structure as 
DJ-1 WT with a decrease in signal amplitude for mutants spectra. However, all CD 
spectra displayed a broad negative ellipticity from 208 to 222 nm, consistent with a 
mixed α/β structure. Despite these differences, the secondary structure content was 
similar for all proteins containing 20 to 30% of structure in α-helix, 20 to 30% of 
structure in β-sheet and approximately 50% without regular secondary structure, as 
calculated by the GlobalWorks (described in Experimental Procedures – 2.7).  
Overall, these results are similar to the results obtained for 37oC, with the 
exception of the DJ-1 WT that showed a higher content of structure in α-helix, 
approximately 40%, compared to the 20 to 30% obtained at 25oC. 
 
7.8. BINDING PARTNERS QUALITATIVE ASSESSMENT 
A general Venn diagram previously shown illustrates the shared and unique 
proteins among DJ-1 WT and mutants (Figure 3.12). However, due to the elevated 
number of conditions to be compared, the comparison between only two conditions 
can be time consuming and visually confusing. In this way, the following figures 
(Supplementary Figure 7.14 to 7.18) provide a more targeted comparison between 
each recombinant protein and C106DD mutant, as an example. More and similar 
combinations were performed for each recombinant protein (data not shown). 
 
A 
 
B 
 
C 
 
Supplementary Figure 7.14| VENN DIAGRAMS OF THE IDENTIFIED BINDING PARTNERS IN DJ-1 WT AND 
MUTANTS C106A AND E163K. A- Venn diagram showing the distribution of shared binding partners for all 
time points among DJ-1 C106DD and DJ-1 WT. The combined protein number is 566. B - Venn diagram 
showing the distribution of shared binding partners for all time points among DJ-1 C106A and C106DD. 
The combined protein number is 481. C - Venn diagram showing the distribution of shared binding 
partners for all time points among DJ-1 C106DD and E163K. The combined protein number is 541.  
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A                     0 min 
 
B                     15 min 
 
C                     40 min 
 
Supplementary Figure 7.15| VENN DIAGRAMS OF THE IDENTIFIED BINDING PARTNERS IN DJ-1 
MUTANTS C106DD AND E163K FOR EACH TIME POINT. A- Venn diagram showing the distribution of 
shared and unique binding partners in the 0min condition. The combined protein number is 378. B - 
Venn diagram showing the distribution of shared and unique binding partners in the 15min condition. 
The combined protein number is 351. C - Venn diagram showing the distribution of shared and unique 
binding partners in the 40min condition. The combined protein number is 273. 
 
A                     0 min 
 
B                     15 min 
 
C                     40 min 
 
Supplementary Figure 7.16| VENN DIAGRAMS OF THE IDENTIFIED BINDING PARTNERS IN DJ-1 
MUTANTS C106DD AND C106A FOR EACH TIME POINT. A- Venn diagram showing the distribution of 
shared and unique binding partners in the 0min condition. The combined protein number is 346. B - 
Venn diagram showing the distribution of shared and unique binding partners in the 15min condition. 
The combined protein number is 248. C - Venn diagram showing the distribution of shared and unique 
binding partners in the 40min condition. The combined protein number is 193. 
 
A                     0 min 
 
B                     15 min 
 
C                     40 min 
 
Supplementary Figure 7.17| VENN DIAGRAMS OF THE IDENTIFIED BINDING PARTNERS IN DJ-1 WT 
AND C106DD MUTANT FOR EACH TIME POINT. A- Venn diagram showing the distribution of shared and 
unique binding partners in the 0min condition. The combined protein number is 384. B - Venn diagram 
showing the distribution of shared and unique binding partners in the 15min condition. The combined 
protein number is 355. C - Venn diagram showing the distribution of shared and unique binding partners 
in the 40min condition. The combined protein number is 442. 
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A                       WT 
 
B                    C106A 
 
C                     E163K 
 
Supplementary Figure 7.18| VENN DIAGRAMS ILLUSTRATING THE NUMBER OF SHARED OR UNIQUE 
BINDING PARTNERS OF DJ-1 WT AND MUTANTS C106A AND E163K AMONG THE DIFFERENT TIME 
POINTS. A- There are 91 common binding partners in all time points for DJ-1 WT and the combined 
protein number is 445. B- There are 5 common binding partners in all time points for DJ-1 C106A and 
the combined protein number is 234. C- There are 84 common binding partners in all time points for DJ-
1 E163K and the combined protein number is 406. 
 
 As mentioned above, a comparison was made between the binding partners 
identified in the pull-down assay (PD) performed in this project and in the 
immunoprecipitation (IP) performed in previous work (Supplementary Figure 7.19). 
The results show that 171 binding partners were identified in both assays, and 332 and 
387 are unique binding partners for the PD and IP assay, respectively. 
 
Supplementary Figure 7.19| VENN DIAGRAM ILLUSTRATING THE NUMBER OF SHARED OR UNIQUE 
BINDING PARTNERS AMONG THE INTERACTOMIC ASSAYS FOR DJ-1 WT PERFORMED BY 
IMUNNOPRECIPITATION AND PULL-DOWN. There are 171 common binding partners between the IP 
assay previously performed (data not shown) and the PD assay performed in this project. The combined 
protein number is 890. IP – Immunoprecipitation; PD – Pull-down. 
 
7.9. GO ENRICHMENT ANALYSIS 
Similarly to the analysis presented for DJ-1 WT, a GO term enrichment analysis 
was performed for each DJ-1 mutant in the different time points (Supplementary 
Figure 7.20 to 7.22). 
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A                                                                                       0 min 
 
 
B                                                                                      15 min 
 
C                                                                                      40 min 
 
Supplementary Figure 7.20| GENE ONTOLOGY (GO) ENRICHMENT OF THE IDENTIFIED BINDING 
PARTNERS FOR C106DD MUTANT IN EACH TIME POINT. The main groups of GO terms considered 
relevant were highlighted using colored boxes. A to C - GO enrichment of the identified binding partners 
for C106DD mutant at 0, 15 and 40 min, respectively. 
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A                                                                                      0 min 
 
 
B                                                                                      15 min 
 
C                                                                                      40 min 
 
Supplementary Figure 7.21| GENE ONTOLOGY (GO) ENRICHMENT OF THE IDENTIFIED BINDING 
PARTNERS FOR E163K MUTANT IN EACH TIME POINT. The main groups of GO terms considered 
relevant were highlighted using colored boxes. A to C - GO enrichment of the identified binding partners 
for E163K mutant at 0, 15 and 40 min, respectively. 
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A                                                                                       15 min 
 
 
B                                                                                      40 min 
                                                            
Supplementary Figure 7.22| GENE ONTOLOGY (GO) ENRICHMENT OF THE IDENTIFIED BINDING 
PARTNERS FOR C106A MUTANT IN EACH TIME POINT. The main groups of GO terms considered 
relevant were highlighted using colored boxes. A and B - GO enrichment of the identified binding 
partners for C106A mutant at 15 and 40 min, respectively. 
 
 Due to the low number of identified proteins for the C106A mutant at 0 
minutes condition it was not possible to perform a GO term enrichment analysis. This 
was only possible for the 15 and 40 minutes conditions and in the later also a reduced 
number of proteins were identified, which conditioned the results obtained in this 
analysis leading to the establishment of fewer groups and with smaller GO term 
enrichment (Supplementary Figure 7.22). 
 
NOTE: The tree diagrams obtained from GO term enrichment analysis are available at 
high resolution in PNG files (folder “Gorilla - Tree Diagrams”). 
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